CN110066351A - Alkylated cyclodextrin composition and its preparation and application - Google Patents
Alkylated cyclodextrin composition and its preparation and application Download PDFInfo
- Publication number
- CN110066351A CN110066351A CN201910279005.5A CN201910279005A CN110066351A CN 110066351 A CN110066351 A CN 110066351A CN 201910279005 A CN201910279005 A CN 201910279005A CN 110066351 A CN110066351 A CN 110066351A
- Authority
- CN
- China
- Prior art keywords
- alkylated cyclodextrin
- cyclodextrin composition
- composition
- less
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/30—Active carbon
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/30—Active carbon
- C01B32/354—After-treatment
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/30—Active carbon
- C01B32/354—After-treatment
- C01B32/378—Purification
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Abstract
The present invention relates to alkylated cyclodextrin composition and its preparation and application.Specifically, the method of alkylated cyclodextrin composition the present invention relates to preparation comprising alkylated cyclodextrin, comprising: (a) makes cyclodextrin and alkylating agent be mixed to form the reaction environment comprising alkylated cyclodextrin, one or more undesirable components and one or more drug degradation impurity；(b) one or more separation are carried out to remove one or more undesirable components from the reaction environment, to form the partially purified solution for including the alkylated cyclodextrin and one or more drug degradation impurity, wherein one or more separation are ultrafiltration, diafiltration, centrifugation, extraction, solvent deposition or dialysis；(c) it is partially purified solution described in the not phosphatic activated carbon treatment of 10 μ S or lower with residual conduction rate and generates the alkylated cyclodextrin；And (d) measure the chloride level of the alkylated cyclodextrin composition；Wherein the chloride level is 0.07% (w/w) or lower.
Description
The application, which is to submit on 2 27th, 2013, entitled " alkylated cyclodextrin composition and its preparation and to make
With method " Chinese patent application 201380022316.4 divisional application.
Related application
This application claims in the priority of 2 months the 61/604th, No. 504 U.S. Provisional Applications submitted for 28th in 2012, it is somebody's turn to do
Application is whole to quote addition herein (including any attached drawing).
Technical field
The present invention relates to compositions and its preparation and application comprising subchloride alkylated cyclodextrin composition.
Background technique
The hydrophobic, hydrophilic, polymerization of cyclodextrin, ionization, non-ionized derivative and many other are developed
Derivative, and established its purposes in a variety of industry.In general, cyclodextrin derivatization is by replacing cyclodextrin with substituent group
The reaction of-OH group on the position 2-, 3- and/or 6- of amylose ring and carry out.Substituent group includes neutrality, anion
And/or the functional group of cation.
Known cyclodextrine derivatives such as alkylated cyclodextrin includes but is not limited to sulfoalkyl ether cyclodextrin, alkyl ether ring paste
Smart (for example, methyl, ethyl and propyl ether cyclodextrin), hydroxyalkyl cyclodextrin, sulfanyl ether ring dextrin, carboxylation cyclodextrin (such as
Succinyl group-beta-cyclodextrin etc.), sulfated cyclodextrin etc..The alkylated cyclodextrin of functional group with more than one type
Be it is known, such as sulfoalkyl ether-alkyl ether-cyclodextrin (see, for example, WO 2005/042584 and US 2009/0012042,
Respectively whole quote is added herein for it).Particularly, it has been found that the alkylation with 2- hydroxypropyl and/or sulfoalkyl ether group
Purposes of the cyclodextrin in pharmaceutical preparation.
CyDex Pharmaceuticals, Inc. withWithThe commercially available beta-cyclodextrin of form
Sulfobutyl ether derivative (" SBE- β-CD ").Anion sulfobutyl ether substituent group improves the water solubility and peace of parent P-cyclodextrin
Quan Xing reversibly can form complex compound with active agents, thus increase the solubility of active agents, and in some cases
In, increase the stability of active agents in aqueous solution.Chemical structure with Formula X:
Wherein R is (- H)21-nOr ((- CH2)4-SO3 -Na+)n, and n is 6 to 7.1.
Sulfoalkyl ether derivatized cyclodextrin (such as) it is using such as the 5,134,127th, 5,376,645
With discontinuous method (batch method) preparation described in No. 6,153,746 United States Patent (USP)s (respectively whole quote is added herein)
's.
Sulfoalkyl ether cyclodextrin and other derivatized cyclodextrins can also pass through institute in following patent and disclosed patent application
Prepared by method described in the method and following non-patent publications stated, the patent and disclosed patent application are as follows: US
3,426,011、US 3,453,257、US 3,453,259、US 3,459,731、US 4,638,058、US 4,727,06、US
5,019,562、US 5,173,481、US 5,183,809、US 5,241,059、US 5,536,826、US 5,594,125、US
5,658,894、US 5,710,268、US 5,756,484、US 5,760,015、US 5,846,954、US 6,407,079、US
7,625,878, US 7,629,331, US 7,635,773, US2009/0012042, JP 05001102 and WO 01/40316；
The non-patent publications are as follows: Lammers et al., Recl.Trav.Chim.Pays-Bas 91:733 (1972)；Staerke
23:167 (1971), Adam et al., J.Med.Chem.45:1806 (2002), Qu et al., J.Inclusion
Phenom.Macrocyclic Chem.43:213 (2002), Tarver et al., Bioorg.Med.Chem.10:1819
(2002), Fromming et al., Cyclodextrins in Pharmacy (Kluwer Academic Publishing,
Dordrecht,1994),Modified Cyclodextrins:Scaffolds and Templates for
Supramolecular Chemistry (C.J.Easton et al. editor, Imperial College Press, London, UK,
1999), New Trends in Cyclodextrins and Derivatives (Dominique Duchene is edited,
Editions de Santé,Paris,FR,1991),Comprehensive Supramolecular Chemistry 3
(Elsevier Science Inc., Tarrytown, NY), the entire disclosure quote addition herein.
The impurity present in alkylated cyclodextrin composition can reduce shelf-life and the effect of bioactive agent composition.It can pass through
(such as mixed) activated carbon is exposed to remove impurity from alkylated cyclodextrin composition.Known activated carbon treatment contains
There are the aqueous solution and suspension of cyclodextrin.See, for example, the 4,738,923rd, 5,393,880 and No. 5,569,756 United States Patent (USP).
However, still needing the alkylated cyclodextrin composition of high-purity.
Summary of the invention
The method of alkylated cyclodextrin composition the present invention provides preparation comprising alkylated cyclodextrin, the method packet
It includes: being mixed to form cyclodextrin and alkylating agent comprising alkylated cyclodextrin, one or more undesirable compounds and one
The reaction environment (milieu) of kind or a variety of drug degradation impurity；(b) one or more separation are carried out with from the reaction environment
One or more undesirable components are removed, so that being formed includes the alkylated cyclodextrin and one or more medicines
The partially purified solution of object degradation impurity, wherein one or more separation are that ultrafiltration, diafiltration, centrifugation, extraction, solvent are heavy
It forms sediment or dialyses；It and (c) with residual conduction rate (residual conductivity) is 10 μ S or lower not phosphate-containing
(phosphate-free) partially purified solution described in activated carbon treatment simultaneously generates the alkylated cyclodextrin.
In some embodiments, the alkylated cyclodextrin composition also includes the phosphate less than 500ppm.One
In a little embodiments, the alkylated cyclodextrin composition also includes the phosphate less than 125ppm.
In some embodiments, the residual conduction rate of the not phosphatic activated carbon is 9 μ S or lower.Some
In embodiment, the residual conduction rate of the not phosphatic activated carbon is 8 μ S or lower.
In some embodiments, the alkylated cyclodextrin composition also includes less than the chloride of 0.5% (w/w).
In some embodiments, the alkylated cyclodextrin composition also includes less than the chloride of 0.1% (w/w).In some realities
It applies in scheme, the alkylated cyclodextrin composition also includes less than the chloride of 0.05% (w/w).
In some embodiments, the average substitution degree of the alkylated cyclodextrin composition is 2 to 9.In some implementations
In scheme, the average substitution degree of the alkylated cyclodextrin composition is 4.5 to 7.5.In some embodiments, the alkyl
The average substitution degree for changing cyclodextrin composite is 6 to 7.5.
In some embodiments, the alkylated cyclodextrin composition be absorbed as be less than 1A.U., it is such as long in 1cm journey
Cuvette (cell) in containing alkylated cyclodextrin composition/mL solution aqueous solution described in 300mg 245nm extremely
It is measured under 270nm wavelength by UV/ Vis Spectrophotometry.In some embodiments, described to be less than 1A.U.
Absorption be attributed to drug degradation agent.
In some embodiments, the alkylated cyclodextrin composition be absorbed as be less than 0.5A.U., such as in 1cm journey
In long cuvette containing alkylated cyclodextrin composition/mL solution aqueous solution described in 300mg in 245nm to 270nm wave
It is measured under long by UV/ Vis Spectrophotometry.In some embodiments, the suction less than 0.5A.U.
It receives and is attributed to drug degradation agent.
In some embodiments, the absorption is to combine in the long cuvette of 1cm journey to containing 500mg SAE-CD
What object/mL solution aqueous solution was measured at 245nm to 270nm wavelength by UV/ Vis Spectrophotometry.
In some embodiments, the alkylated cyclodextrin composition be absorbed as be less than 1A.U., it is such as long in 1cm journey
Cuvette in containing alkylated cyclodextrin composition/mL solution aqueous solution described in 300mg in 320nm to 350nm wavelength
It is measured by UV/ Vis Spectrophotometry down.In some embodiments, the absorption less than 1A.U. is returned
Because in colour coupler.
In some embodiments, the alkylated cyclodextrin composition be absorbed as be less than 0.5A.U., such as in 1cm journey
In long cuvette containing alkylated cyclodextrin composition/mL solution aqueous solution described in 300mg in 320nm to 350nm wave
It is measured under long by UV/ Vis Spectrophotometry.In some embodiments, the suction less than 0.5A.U.
It receives and is attributed to colour coupler.
In some embodiments, the absorption is in the long cuvette of 1cm journey containing being alkylated ring described in 500mg
Dextrin composition/mL solution aqueous solution is surveyed at 320nm to 350nm wavelength by UV/ Vis Spectrophotometry
Fixed.
In some embodiments, the not phosphatic activated carbon is cleaned with solvent, until the solvent of elution has reached
To the residual conduction rate in (c).In some embodiments, the not phosphatic activated carbon is washed with water, until
The water of elution has reached the residual conduction rate in (c).
In some embodiments, the alkylated cyclodextrin is the sulfoalkyl ether cyclodextrin of formula (II):
Wherein p is 4,5 or 6, and R1At each occurrence independently selected from-OH or-O- (C2-C6Alkylidene)-SO3 -- T,
Wherein for T at each occurrence independently selected from pharmaceutically acceptable cation, condition is at least one R1Be-OH and at least one
R1It is O- (C2-C6Alkylidene)-SO3 --T.In some embodiments, R1At each occurrence independently selected from-OH or-O- (C4
Alkylidene)-SO3 -- T, and-T is Na at each occurrence+。
In some embodiments, by the alkylated cyclodextrin composition and one or more excipient compositions.
In some embodiments, it combines the alkylated cyclodextrin composition with activating agent.
The invention further relates to the products prepared by method described herein.
Other embodiments of the invention, feature and advantage, and a variety of implementations of the present invention are described in detail with reference to the accompanying drawings
The composition of scheme, structurally and operationally.
Detailed description of the invention
It is included herein and the attached drawing for forming specification a part instantiates one or more embodiments of the invention,
The attached drawing is also used to illustrate the principle of the present invention together with explanation and those skilled in the relevant arts is enabled to manufacture and use this
Invention.Following drawings only provides by way of illustration, therefore is not intended to be limited to the scope of the present invention.
Fig. 1 provides after the processing of single carbon that (190nm is extremely for the UV/ Vis scan of the solution containing SAE-CD composition
Diagram 400nm), wherein sulfoalkyl ether cyclodextrin concentration is changed to 60 weight % from 1 weight %.
Fig. 2 provides the UV/ Vis scan (190nm of the solution containing SAE-CD composition after second of carbon is handled
To the diagram of 400nm), wherein sulfoalkyl ether cyclodextrin concentration is changed to 60 weight % from 1 weight %.
Fig. 3 provides the at a temperature of thermal degradation and causticity degradation (caustic degradation) 0 hour, 24 at 60 DEG C
SBE after hour, 72 hours, 96 hours and 168 hours6.6(190nm is to 400nm's) for the UV/ Vis scan of-β-CD solution
Diagram, thus prove beta-cyclodextrin degradation and drug degradation impurity (having absorption under the wavelength of 245nm to 270nm) and/
Or the formation of colour coupler (having absorption under the wavelength of 320nm to 350nm).
Fig. 4 provide be exposed to 70 DEG C of 48 hours periods of temperature and then with different amounts of activated carbon treatment it
Afterwards, the UV of the solution of-CD of β containing SAE- scans the (diagram of 190nm to 400nm).
Fig. 5 provides SBE6.6The diagram of influence of the initial UV/ visible absorption of-β-CD solution to API stability.
Fig. 6 provides preparation SBE6.6The diagram of the impurity level of the method for-β-CD, wherein being detected using charged aerosol
Device measures impurity.
Fig. 7 provides preparation SBE6.6The diagram of chloride (chloride) concentration level of the method for-β-CD, wherein making
Chloride concentration is measured with charged aerosol detector.
Fig. 8 provides the two batches SBE using charged aerosol detectors measure6.6- β-CD during ultra-filtration, at ultrafiltration
At the end of reason, 5 minutes, 10 minutes and 20 minutes after being added to the first carbon column, be added to the second carbon column it
The diagram of 5 minutes afterwards, 10 minutes and 20 minutes chloride concentration levels.
Fig. 9 is provided after (a) first carbon column (labeled as small) and (is labeled as in (b) second carbon column
It is big) after residual chloride horizontal (being measured using the chromatography of ions) relative to final SBE6.6- β-CD product it is residual
Remaining conductivity level (being labeled as ZIC pHILIC%Cl-) (using the ZIC pHILIC column using charged aerosol detector into
Row measurement) diagram (lot number 17CX01.HQ00056-17CX01.HQ00064).
Figure 10 is provided using ion chromatography measurement in (a) activated carbon treatment period (lot number
17CX01.HQ00001-17CX001.HQ00003,17CX01.HQ00004.02 and 17CX01.HQ00005-
17CX01.HQ00034) and after (b) two activated carbon treatment periods (lot number 17CX01.HQ00035-7CX01.HQ00079)
SBE6.6The diagram of the sodium chloride concentration (w/w) of-β-CD sample.The detection of the chromatography of ions is limited to the chloride of 0.05 weight %.
Specific embodiment
The present invention includes the combination and sub-portfolio of many aspects and embodiment disclosed herein.In addition, when for implementing
When scheme describes specific feature, structure or characteristic, it should be understood that such feature, knot in those skilled in the art's cognitive range
Structure or characteristic can act other embodiments, regardless of whether specifically describing.With reference to as detailed below, embodiment, right
It is required that and after attached drawing, these and other aspects of the invention can be apparent.
As used herein, percentage refers to " weight % " and/or " w/w " (w/w concentration), unless otherwise noted.
The all of spatial description are referred to (for example, "upper", "lower", " upward ", " downward ", " top ", " bottom " herein
Deng) be only used for describing and illustrating purpose, and should be interpreted that process, equipment, composition and the product to any method of the present invention
There is no limit can in any direction or mode carries out space arrangement.
Alkylated cyclodextrin
" alkylated cyclodextrin composition " is the alkane comprising degree of substitution or average substitution degree (ADS) with specified substituent
The composition of base cyclodextrin.Alkylated cyclodextrin composition includes (the specific substitution of each substance of alkylated cyclodextrin substance
The individual degree of substitution of base is different) distribution, wherein the specified substituent of each substance is identical.As used herein, " alkane
Base cyclodextrin composite " is the composition (that is, the composition for not including forms of pharmacologically active agents) of basic pharmaceutical inert.For example, ring
Dextrin composition may include the ring of the cyclodextrin of at least 90% (w/w), the cyclodextrin of at least 95% (w/w), at least 97% (w/w)
Dextrin, the cyclodextrin of at least 99% (w/w), the cyclodextrin of at least 99.9% (w/w) or at least 99.99% (w/w) cyclodextrin.
Alkylated cyclodextrin can be water soluble allcylbenzene cyclodextrin, be that the parent ring of its corresponding underivatized is pasted
Essence is compared to the water solubility for showing enhancing and with any alkylation ring of the molecular structure based on α-, β-or gamma-cyclodextrin
Dextrin.In some embodiments, derivatized cyclodextrin prepared by the method for the present invention has 100mg/mL or higher
Water solubility, or the water solubility less than 100mg/mL.
It can be derivative in the neutral, anion in the position C2, C3 or C6 for forming each sugar of cyclodextrin ring or cationic substituent
Change cyclodextrin.This document describes suitable water soluble allcylbenzene cyclodextrin.The alkylated cyclodextrin can also be water-insoluble
The mother body cyclodextrin of alkylated cyclodextrin or its corresponding underivatized compares the alkylation with lower water solubility
Cyclodextrin.
As used herein, " replace based precursor " or " alkylating agent " is to refer to react with-OH group present on cyclodextrin
Compound, reagent, part or substance.In some embodiments, derivatized cyclodextrin includes substituent group, such as sulfoalkyl ether
Base, ether, alkylether radicals, alkenyl ether, hydroxyalkyl ether, hydroxyalkenyl group ether, sulfanyl ether, aminoalkylether, mercapto
Base, amino, alkyl amino, carboxyl, ester group, nitro, halo groups, aldehyde radical, 2,3- glycidyl and combinations thereof.In some implementations
In scheme, alkylating agent includes alkyl sultone (sultone) (such as Isosorbide-5-Nitrae-butane sultone, 1,5- pentane sultone, 1,3- penta
Alkane sultone etc.).Alkylated cyclodextrin is the cyclodextrin that wherein one or more-OH groups are substituted by-O-R group, wherein R packet
Include moieties.For example,-O-R group can be alkyl ether or sulfoalkyl ether.
In some embodiments, such as alkylated cyclodextrin of compound ether alkylated cyclodextrin includes under (passing through illustration)
Table 1 those of is listed.
Table 1.
After reaction, purifying and/or isolation (isolation), alkylated cyclodextrin composition of the invention be can wrap
It includes a small amount of (for example, 1 weight % or less, 0.5 weight % or less, 0.1 weight % or less, 0.05 weight % or less, 0.001 weight
Measure % or less, 0.0005 weight % or less or 0.0001 weight % or less) cyclodextrin raw material (for example, the parent of underivatized
Cyclodextrin).
Alkylated cyclodextrin can exist with high-purity forms.Referring to No. 7,635,773 United States Patent (USP).In some embodiment party
In case, alkylated cyclodextrin be with it is knownCommercial lots, which are compared, has reduced drug degradation agent (drug-
Degrading agent) amount high-purity SAE-CD composition.The composition with it is knownCommercially available batch
Secondary compare optionally has the phosphatic amount reduced or completely not comprising phosphate.The composition with it is knownCommercial lots are compared to also optionally with the amount of lower colour coupler.The SAE-CD composition with it is knownCommercial lots compare the amount that can also have -1 sulfonic acid of 1,4- butane sultone and 4- hydroxy-butan of reduction.
Alkylated cyclodextrin composition of the invention is provided relative to the relevant alkylated cyclodextrin composition of other structures
Unexpected advantage." structure related " for example refers to the substituent group of the alkylated cyclodextrin in composition and compares
The substituent group of other alkylated cyclodextrins is essentially identical.Exemplary advantage may include increased purity, reduction pyrogen content,
The content, and/or drop of the quality agent content of reduced drug degradation agent content, reduction, the unreacted substitution based precursor of reduction
The content of low unreacted cyclodextrin raw material.Exemplary advantage further includes reduced chloride content.
Water soluble allcylbenzene cyclodextrin composite may include sulfoalkyl ether cyclodextrin (SAE-CD) compound or chemical combination of Formulas I
The mixture of object:
Wherein n is 4,5 or 6；Wherein R1、R2、R3、R4、R5、R6、R7、R8And R9It independently is-H, linear chain or branched chain C1-C8-
(alkylidene)-SO3 -Group or the linear chain or branched chain C optionally replaced1-C6Group；Wherein R1、R2、R3、R4、R5、R6、R7、R8And R9
In at least one be linear chain or branched chain C1-C8(alkylidene)-SO3 -Group.
In some embodiments, SAE-CD composition includes the water soluble allcylbenzene cyclodextrin of Formula II:
Wherein: p is 4,5 or 6；
R1At each occurrence independently selected from-OH or-SAE-T；
- SAE- is-O- (C2-C6Alkylidene)-SO3 -Group, wherein at least one SAE independently are-O- (C2-C6Alkylene
Base)-SO3 -Group ,-O- (CH2)gSO3 -Group, the wherein g (such as-OCH that is 2 to 6 or 2 to 42CH2CH2SO3 -Or-
OCH2CH2CH2CH2SO3 -)；And-T is at each occurrence independently selected from pharmaceutically acceptable cation, including such as H+, alkali
Metal is (for example, Li+、Na+、K+), alkaline-earth metal is (for example, Ca+2、Mg+2), ammonium ion and amine cation such as (C1-C6)-alkyl
Amine, piperidines, pyrazine, (C1-C6)-alkanolamine, ethylenediamine and (C4-C8The cation of)-cycloalkanes hydramine etc.；Condition is at least one R1
It is hydroxylic moiety and at least one R1It is-SAE-T.
As at least one R of derivatized cyclodextrin molecule1When being-SAE-T, the degree of substitution for the part-SAE-T should be managed
Solution is at least one (1).When term-SAE- is for when indicating sulfoalkyl-(alkyl sulfonic acid)-ether moiety, it should be understood that-SAE- is wrapped part
Cationic (- T) is included, unless specified otherwise herein.Therefore, term " SAE " and "-SAE-T " can take the circumstances into consideration to be used interchangeably herein.
Because SAE-CD is polyanion cyclodextrin, salt form that can be different is provided.Suitable counter ion counterionsl gegenions
Including cationic organic atoms or molecule and cationic inorganic atoms or molecule.SAE-CD may include single type contend with from
The mixture of son or different counter ion counterionsl gegenions.The property of SAE-CD can be changed by changing the characteristic of existing counter ion counterionsl gegenions.
For example, the first salt form of SAE-CD composition can have bigger infiltration compared with the second different salt forms of identical SAE-CD
The water activity of saturating gesture or bigger reduces ability.
In some embodiments, sulfoalkyl ether cyclodextrin and it is one or more it is selected from the following it is pharmaceutically acceptable sun from
Son complexing: for example, H+；Alkali metal is (for example, Li+、Na+、K+)；Alkaline-earth metal is (for example, Ca+2、Mg+2)；Ammonium ion；With amine sun from
Son, such as (C1-C6)-alkylamine, piperidines, pyrazine, (C1-C6)-alkanolamine, ethylenediamine and (C4-C8The cation of)-cycloalkanes hydramine
Deng；And combinations thereof.
Other exemplary sulfoalkyl ether (SAE)-CD derivatives include:
Table 2.
| SAEx-α-CD | SAEx-β-CD | SAEx-γ-CD |
| (sulfoethyl ether)x-α-CD | (sulfoethyl ether)x-β-CD | (sulfoethyl ether)x-γ-CD |
| (sulfopropyl ether)x-α-CD | (sulfopropyl ether)x-β-CD | (sulfopropyl ether)x-γ-CD |
| (sulfobutyl ether)x-α-CD | (sulfobutyl ether)x-β-CD | (sulfobutyl ether)x-γ-CD |
| (sulphur amyl ether)x-α-CD | (sulphur amyl ether)x-β-CD | (sulphur amyl ether)x-γ-CD |
| (sulphur hexyl ether)x-α-CD | (sulphur hexyl ether)x-β-CD | (sulphur hexyl ether)x-γ-CD |
Wherein x indicates average substitution degree.In some embodiments, alkylated cyclodextrin is formed in the form of salts.
The various embodiments of sulfoalkyl ether cyclodextrin are pasted including 20-O- (methyl)-6G-O- (4- sulphur butyl)-β-ring
Essence, seven-O- (sulphur methyl)-ten four-O- (3- sulfopropyl)-beta-cyclodextrin, seven-O- [(1,1- dimethyl ethyl) dimethyl methyl silicon
Alkyl]-ten four-O- (3- sulfopropyl)-beta-cyclodextrin, seven-O- (sulphur methyl)-ten four-O- (3- sulfopropyl)-beta-cyclodextrin, with
And seven-O- [(1,1- dimethyl ethyl) dimetylsilyl]-ten four-O- (sulphur methyl)-beta-cyclodextrin.Other known packet
The alkylated cyclodextrin of the part containing sulfoalkyl includes that sulfoalkyl is thio and sulfoalkyl sulfanyl ether derivant, such as eight-(S- sulphurs third
Base)-eight thio-y-cvclodextrins, eight-O- [3- [(2- sulfoethyl) is thio] propyl]-beta-cyclodextrin] and eight-S- (2- sulphur second
Base)-eight thio-y-cvclodextrins.
In some embodiments, it is 2 to 9,4 to 8,4 to 7.5,4 that alkylated cyclodextrin composition of the invention, which is ADS,
To 7,4 to 6.5,4.5 to 8,4.5 to 7.5,4.5 to 7,5 to 8,5 to 7.5,5 to 7,5.5 to 8,5.5 to 7.5,5.5 to 7,5.5
To sulfoalkyl ether-β-ring of 6.5,6 to 8,6 to 7.5,6 to 7.1,6.5 to 7.1,6.2 to 6.9 or 6.5/ alkylated cyclodextrin
Dextrin composition, and remaining substituent group is-H.
In some embodiments, alkylated cyclodextrin is the compound of formula III:
Wherein n is 4,5 or 6, wherein R1、R2、R3、R4、R5、R6、R7、R8And R9Independently selected from :-H, linear chain or branched chain C1-
C8(alkylidene)-SO3 -Group and the linear chain or branched chain C optionally replaced1-C6Group.
Water soluble allcylbenzene cyclodextrin composite may include alkyl ether (the AE)-cyclodextrin compound or compound of formula IV
Mixture:
Wherein: m is 4,5 or 6；R is at each occurrence independently selected from-OH and AE；And AE is-O- (C1-C6Alkane
Base)；Condition is that at least one R is-OH；And there are at least one AE.
Other exemplary AE-CD derivatives include:
Table 3.
Wherein ME indicates that methyl ether, EE indicate that ethylether, PE indicate that propyl ether, BE indicate that butyl ether, PtE indicate amyl
Ether, HE indicates hexyl ether, and y indicates average substitution degree.
Water soluble allcylbenzene cyclodextrin composite may include the HAE- cyclodextrin compound of Formula V or the mixture of compound:
Wherein: " v " is 4,5 or 6；" Q " is at each occurrence independently selected from-OH and-HAE；And HAE is HO (C1-
C6Alkyl)-O-, condition is that there are at least one parts-HAE.
Other exemplary hydroxyalkyl ether (HAE)-CD derivatives include:
Table 4.
| (HAE)z-α-CD | (HAE)z-β-CD | (HAE)z-γ-CD |
| HMEz-α-CD | HMEz-β-CD | HMEz-γ-CD |
| HEEz-α-CD | HEEz-β-CD | HEEz-γ-CD |
| HPEz-α-CD | HPEz-β-CD | HPEz-γ-CD |
| HBEz-α-CD | HBEz-β-CD | HBEz-γ-CD |
| HPtEz-α-CD | HPtEz-β-CD | HPtEz-γ-CD |
| HHEz-α-CD | HHEz-β-CD | HHEz-γ-CD |
Wherein HME indicates that hydroxymethyl ether, HEE indicate that hydroxyethyl ether, HPE indicate that hydroxypropyl ether, HBE indicate hydroxyl butyl ether,
HPtE indicates hydroxyl amyl ether, and HHE indicates hydroxyl hexyl ether, and z indicates average substitution degree.
Water soluble allcylbenzene cyclodextrin composite may include the SAE-AE-CD compound of Formula IV or the mixture of compound:
Wherein: " v " is 4,5 or 6；" A " is at each occurrence independently selected from-OH ,-SAET and-AE；X is the part SAET
Degree of substitution and be 1 to 3v+5；Y is the degree of substitution of the part AE and is 1 to 3v+5；- SAE is-O- (C2-C6Alkylidene)-
SO3 -；T independently is cation at each occurrence；And AE is-O (C1-C3Alkyl)；Condition is that there are at least one-SAET
Part and at least one part-AE；And x, the sum of-OH group sum is 3v+6 in y and alkylated cyclodextrin.
The specific embodiment of derivative of the invention includes such embodiment: 1) alkylene moiety of SAE has
Carbon number identical with the moieties of AE；2) alkylene moiety of SAE has the carbon number different from the moieties of AE；3) alkyl
With alkylene moiety independently selected from linear chain or branched chain part；4) alkyl and alkylene moiety are independently selected from saturation or unsaturation
Part；5) ADS of SAE group is greater than or is similar to the ADS of AE group；Or 6) ADS of SAE group is less than the ADS of AE group.
Water soluble allcylbenzene cyclodextrin composite may include SAE-HAE-CD compound or the mixing of compound of Formula VII
Object:
Wherein: " v " is 4,5 or 6；" X " is at each occurrence independently selected from-OH, SAET and HAE；X is the part SAET
Degree of substitution and be 1 to 3w+5；Y is the degree of substitution of the part HAE and is 1 to 3w+5；- SAE is-O- (C2-C6Alkylidene)-
SO3 -；T independently is cation at each occurrence；And HAE is-HO (C1-C6Alkyl)-O-；Condition is that have at least one
A part-SAET and at least one part-HAE；And x, the sum of-OH group sum is 3w+6 in y and alkylated cyclodextrin.
Alkylated cyclodextrin may include SAE-CD, HAE-CD, SAE-HAE-CD, HANE-CD, HAE-AE-CD, HAE-SAE-
CD, AE-CD, SAE-AE-CD, neutral cyclodextrins, anionic cyclodextrin, cationic cyclodextrin, halogen-derived cyclodextrin, amino
Derivatized cyclodextrin, nitrile derivatized cyclodextrin, aldehyde derivatized cyclodextrin, carboxylate derivatized cyclodextrin, sulfuric ester derivatization ring
Dextrin, sulfonate derivatized cyclodextrin, sulfydryl derivatized cyclodextrin, alkylamino derivatized cyclodextrin or succinyl group derivatization ring
Dextrin.
In given alkylated cyclodextrin composition, the substituent group of one or more alkylated cyclodextrin can it is identical or
It is different.For example, the part SAE or HAE can have same type or inhomogeneity when coming across alkylated cyclodextrin composition every time
Alkylidene (alkyl) group of type.In such embodiments, the alkylidene group of the part SAE or HAE is coming across every time
It can be ethyl, propyl, butyl, amyl or hexyl when in alkylated cyclodextrin composition.
Alkylated cyclodextrin may differ in its functional group's degree of substitution, the carbon number in functional group, its molecular weight,
It is used to form the glucopyranose units number in the matrix cyclodextrin of derivatized cyclodextrin included and/or its substitution mode.In addition,
With controlled but non-precision mode functional group's derivatized cyclodextrin.In this regard, degree of substitution really indicates functional group/cyclodextrin
The number of average is (for example, SBE7- β-CD has average 7 substitutions/cyclodextrin).Therefore, there is the average substitution degree for 7
("ADS").In addition, the substituted regional chemistry of the hydroxyl group of cyclodextrin relative to the specific hydroxyl of hexose ring substitution and become
Change.In this regard, during the substitution of different hydroxyl groups is likely to occur in manufacture derivatized cyclodextrin, and specific derivatized cyclodextrin
There can be the substitution mode of preferential (but non-exclusive or specific).In view of the foregoing, point of specific derivatized cyclodextrin composition
Son amount can change with batch.
In single parent cyclodextrin molecule, it is available for 3v+6 hydroxylic moiety of derivatization.In v=4 (α-ring paste
Essence) in the case where, the degree of substitution " y " of the part can be 1 to 18 value.In the case where v=5 (beta-cyclodextrin), the part
Degree of substitution " y " can be 1 to 21 value.In the case where v=6 (gamma-cyclodextrin), the degree of substitution " y " of the part can be 1 to 24
Value.Generally, " y " is also 1 to 3v+g value, the value that wherein g is 0 to 5.In some embodiments, " y " is 1 to 2v+g or 1
To 1v+g.
The degree of substitution (" DS ") of specific part (such as SAE, HAE or AE) is the SAE (HAE connecting with each cyclodextrin molecular
Or AE) in other words the measurement of substituent group quantity is the molal quantity of the substituent group of every mole of cyclodextrin.Therefore, for each alkylation
Cyclodextrin substance, each substituent group have the DS of its own.The average substitution degree (" ADS ") of substituent group is for alkane of the invention
The measurement of substituent group sum present in each cyclodextrin molecular that alkylated cyclodextrin is distributed in base cyclodextrin composite.Cause
This, SAE4The ADS (each CD molecule) that-CD has for 4.
Some embodiments of the invention include such embodiment: 1) alkylated cyclodextrin is more than the hydroxyl of half
Part is derivatized；2) half of alkylated cyclodextrin or the hydroxylic moiety lower than half are derivatized；3) alkylated cyclodextrin
Substituent group it is identical at each occurrence；4) substituent group of alkylated cyclodextrin includes at least two different substituent groups；Or
Person 5) alkylated cyclodextrin substituent group include it is one or more selected from unsubstituted alkyl, replace alkyl, halide (halogenated), halogen
Substituted alkyl, amine (amino), aminoalkyl, aldehyde, carbonylic alkyl, nitrile, cyanoalkyl, sulfoalkyl, hydroxyalkyl, carboxyalkyl, sulfanyl,
Unsubstituting alkylidene, substituted alkylene, aryl, aryl alkyl, heteroaryl and heteroaryl alkyl substituent group.
Alkylated cyclodextrin composition may include the different multiple individual alkylated cyclodextrin substances of individual degree of substitution, thus
As described herein, average substitution degree is calculated by the individual degree of substitution of the substance.More specifically, SAE-CD derivative group
Closing object may include multiple SAE-CD substances respectively for SAE substituent group with particular individual degree of substitution.Therefore, SAE-CD is derivative
The ADS of the SAE of object indicates the average value of the IDS value of the group of individual molecular in composition.For example, SAE5.2- CD composition includes
Multiple SAExThe distribution of-CD molecule, wherein " x " (DS of SAE group) can be 1 to 10-11 for individual cyclodextrin molecular；So
And the group of SAE- cyclodextrin molecular makes the average value 5.2 of " x " (ADS of SAE group).
Alkylated cyclodextrin composition can have in up to low ADS.Alkylated cyclodextrin composition can also have width
Or narrow " span ", it is the quantity of the individual DS substance in alkylated cyclodextrin composition.For example, comprising with single regulation
It is 1 that the alkylated cyclodextrin composition of the single alkylated cyclodextrin substance of individual DS, which is considered span, and the alkylation ring
The individual DS of dextrin is equal to the ADS of its alkylated cyclodextrin composition.For example, the electrophoretogram for the alkylated cyclodextrin that span is 1
Should only have a kind of alkylated cyclodextrin substance for DS.The alkylated cyclodextrin composition that span is 2 is included in its individual
Different two kinds individual alkylated cyclodextrin substances in terms of DS, and its electrophoretogram can for example show different in terms of DS two kinds
Different alkylated cyclodextrin substances.Similarly, the span for the alkylated cyclodextrin composition that span is 3 is included in the individual side DS
Three kinds of different individual alkylated cyclodextrin substances of face.The span of alkylated cyclodextrin composition is usually 5 to 15 or 7 to 12,
Or 8 to 11.
Mother body cyclodextrin include formed cyclodextrin glucopyranose residues the position C-2 and C-3 on secondary hydroxyl group with
Primary hydroxyl group on the position C-6 of the glucopyranose residues.Before each of these hydroxylic moieties can be for use by substituent group
Body performs the derivatization.According to synthetic method used, substituent part can at random or be distributed in slightly orderly mode can
In hydroxy position.It can also optionally change the regional isomerism of the derivatization carried out by substituent group.It is selected independently every
The regional isomerism of one composition.For example, existing major part substituent group can be located at the primary hydroxyl group group of mother body cyclodextrin, or
Positioned at one or two of the secondary hydroxyl group group of mother body cyclodextrin.In some embodiments, main substituent groups, which are distributed, is
C-3 > C-2 > C-6, and in other embodiments, main substituent groups distribution is C-2 > C-3 > C-6.Some embodiment party of the invention
Case includes alkylated cyclodextrin molecule, and wherein fraction substituent part is located at C-6, and most of substituent part is located at C-
2 and/or C-3.Other embodiments of the invention include alkylated cyclodextrin molecule, and wherein substituent part is substantially homogeneously
It is distributed in C-2, C-3 and C-6.
Alkylated cyclodextrin composition includes the distribution of multiple individual alkylated cyclodextrin substances, and each substance has individual
Degree of substitution (" IDS ").Capillary Electrophoresis can be used to quantify the content of each cyclodextrin substance in particular composition.Analysis method
(Capillary Electrophoresis, such as electrically charged alkylated cyclodextrin) delicately distinguishes a kind of only alkyl containing only 5% enough
Change cyclodextrin and 95% another alkylated cyclodextrin composition with comprising originate alkylated cyclodextrin composition.
Above-mentioned variation between the individual substance of alkylated cyclodextrin in distribution can lead to Ion binding constant K1:1Change
Change, this transfers the required molar ratio that will affect derivatized cyclodextrin and activating agent.The equilibrium constant can also change with temperature and slightly,
And the tolerance of the ratio is needed so that substance is in the temperature fluctuation that may occur during manufacture, storage, transport and use
Dissolution is kept in journey.The equilibrium constant can also change with pH, and can need the tolerance of the ratio so that substance may made
Make, store, transporting and use during keep dissolution in the pH wave process that occurs.The equilibrium constant can also be since there are other figurations
Agent (for example, buffer, preservative, antioxidant) and change.Therefore, the ratio of derivatized cyclodextrin and activating agent may differ from
Ratio as described herein, to compensate above-mentioned variable.
Manufactured alkylated cyclodextrin can be used for composition, preparation, method and system according to the method for the present invention, such as with
Lower those disclosed: the 5,134,127th, 5,376,645,5,914,122,5,874,418,6,046,177,6,133,248,6,
153,746,6,407,079,6,869,939,7,034,013,7,625,878,7,629,331 and No. 7,635,773 U.S. are special
Benefit；2005/0164986th, 2005/0186267,2005/0250738,2006/0258537,2007/0020196,2007/
0020298、2007/0020299、2007/0175472、2007/0202054、2008/0194519、2009/0011037、
2009/0012042, No. 2009/0123540 U.S. Publication；12/404,174th, 12/407,734,61/050,918,61/
177,718 and No. 61/182,560 U. S. applications；And PCT/US06/62346, PCT/US07/71758, PCT/US07/
71748、PCT/US07/72387、PCT/US07/72442、PCT/US07/78465、PCT/US08/61697、PCT/US08/
61698, PCT/US08/70969 and PCT/US08/82730 PCT international application, the entire disclosure quote addition herein.
The alkylation with same functional group of other known grades is also acted as according to alkylated cyclodextrin prepared by methods herein
The suitable substituent group of cyclodextrin.
In some embodiments, alkylated cyclodextrin is combined with alkylated cyclodextrin of the invention is used to prepare accordingly
The cyclodextrin of object, which is compared, has bigger water solubility.For example, in some embodiments, underivatized cyclodextrin is used as original
Material, such as available commercially from such as WACKER BIOCHEM CORP(Adrian, MI) and the α-in other sources, β-or gamma-cyclodextrin.Not
Derivatized cyclodextrin has limited water solubility compared with alkylated cyclodextrin of the invention.For example, underivatized α-CD, β-
CD, γ-CD are respectively provided with the water solubility of about 145g/L, 18.5g/L and 232g/L at saturation condition.
The processing of water soluble allcylbenzene cyclodextrin composite is optionally removed to the underivatized of most of (such as > 50%)
Cyclodextrin or other pollutants.
The term as used herein " alkylidene " and " alkyl " (such as in-O- (C2-C6Alkylidene) SO3 -In group or in alkane
In base amine cation) respectively include straight chain, ring-type and branch saturation and unsaturation (i.e. comprising one or more double bonds) two
Valence alkylidene and univalent alkyl.For example, the part SAE or HAE can have phase when coming across alkylated cyclodextrin composition every time
Same type or different types of alkylidene (alkyl) group.In such embodiments, the alkylidene of the part SAE or HAE exists
It can be ethyl, propyl, butyl, amyl or hexyl when coming across in alkylated cyclodextrin composition every time.
Equally, term herein " alkanol " includes the straight chain of triacontanol group, the saturation of ring-type and branch and unsaturated alkane
Base component, wherein hydroxyl can be located at any available position on moieties.Term " cyclic alkanol " includes unsubstituted or substituted (example
Such as replaced by methyl or ethyl) cyclic alcohol.
In some embodiments, the present invention provides alkyl ether cyclodextrin (AE-CD) composition, it includes average substitutions
Alkyl ether cyclodextrin, the phosphate less than 500ppm and the chloride for being less than 0.5% (w/w) that degree is 2 to 9, wherein the AE-
CD composition is absorbed as being less than 1A.U., to containing 300mg AE-CD composition/mL solution such as in the long cuvette of 1cm journey
Aqueous solution measured at 245nm to 270nm wavelength by UV/ Vis Spectrophotometry.In some embodiment party
In case, the absorption less than 1A.U. is attributed to drug degradation agent.In some embodiments, the alkyl ether cyclodextrin group
Closing object is not sulfobutyl ether cyclodextrins composition.In some embodiments, the alkyl ether cyclodextrin is not sulfobutyl ether β-
Cyclodextrin.In some embodiments, the AE-CD composition is absorbed as 0.5A.U. or lower, such as long in 1cm journey ratio
Pass through UV/ visible light at 245nm to 270nm wavelength to containing 300mg AE-CD composition/mL solution aqueous solution in color ware
What spectrophotometry was measured.In some embodiments, the 0.5A.U. or lower, which absorbs, is attributed to drug degradation
Agent.In some embodiments, the AE-CD composition is absorbed as 0.2A.U. or lower, such as long in 1cm journey cuvette
In to containing 300mg AE-CD composition/mL solution aqueous solution at 245nm to 270nm wavelength pass through UV/ visible light light-splitting
What photometry was measured.In some embodiments, the 0.2A.U. or lower, which absorbs, is attributed to drug degradation agent.
In some embodiments, the absorption of the AE-CD composition is in the long cuvette of 1cm journey to containing 500mg AE-CD
What composition/mL solution aqueous solution was measured at 245nm to 270nm wavelength by UV/ Vis Spectrophotometry.
In some embodiments, the present invention provides alkyl ether cyclodextrin (AE-CD) composition, it includes average substitutions
Alkyl ether cyclodextrin, the phosphate less than 500ppm and the chloride for being less than 0.5% (w/w) that degree is 2 to 9, wherein the AE-
CD composition is absorbed as being less than 1A.U., to containing 300mg AE-CD composition/mL solution such as in the long cuvette of 1cm journey
Aqueous solution measured at 320nm to 350nm wavelength by UV/ Vis Spectrophotometry.In some embodiment party
In case, the absorption less than 1A.U. is attributed to colour coupler.In some embodiments, the alkyl ether cyclodextrin composite
It is not sulfobutyl ether cyclodextrins composition.In some embodiments, the alkyl ether cyclodextrin is not sulfobutyl ether β-ring paste
Essence.In some embodiments, the AE-CD composition is absorbed as 0.5A.U. or lower, such as long in 1cm journey cuvette
In to containing 300mg SAE-CD composition/mL solution aqueous solution at 320nm to 350nm wavelength by UV/ visible light point
Light photometry is measured.In some embodiments, the 0.5A.U. or lower, which absorbs, is attributed to colour coupler.?
In some embodiments, the AE-CD composition is absorbed as 0.2A.U. or lower, to containing such as in the long cuvette of 1cm journey
There is 300mg AE-CD composition/mL solution aqueous solution to survey at 245nm to 270nm wavelength by UV/ visible light light-splitting luminosity
What the method for determining was measured.In some embodiments, the 0.2A.U. or lower, which absorbs, is attributed to colour coupler.In some implementations
In scheme, the absorption of the AE-CD composition is in the long cuvette of 1cm journey to containing 500mg SAE-CD composition/mL
What the aqueous solution of solution was measured at 320nm to 350nm wavelength by UV/ Vis Spectrophotometry.
In some embodiments, the average substitution degree of AE-CD is 4.5 to 7.5.In some embodiments, AE-CD
Average substitution degree is 6 to 7.5.In some embodiments, the average substitution degree of AE-CD is 6.2 to 6.9.
In some embodiments, the present invention provides the compositions comprising AE-CD composition and activating agent.
In some embodiments, the present invention provides sulfoalkyl ether cyclodextrin (SAE-CD) compositions, and it includes average
Sulfoalkyl ether cyclodextrin, the phosphate less than 500ppm and the chloride for being less than 0.5% (w/w) that degree of substitution is 2 to 9, wherein
The SAE-CD composition is absorbed as being less than 1A.U., such as combines in the long cuvette of 1cm journey to containing 300mg SAE-CD
What object/mL solution aqueous solution was measured at 245nm to 270nm wavelength by UV/ Vis Spectrophotometry.One
In a little embodiments, the absorption less than 1A.U. is attributed to drug degradation agent.In some embodiments, the sulfoalkyl
Ether cyclodextrin composite is not sulfobutyl ether cyclodextrins composition.In some embodiments, the sulfoalkyl ether cyclodextrin is not
It is sulfobutyl ether beta-cyclodextrin.In some embodiments, the SAE-CD composition is absorbed as 0.5A.U. or lower, such as
In the long cuvette of 1cm journey to containing 300mg SAE-CD composition/mL solution aqueous solution in 245nm to 270nm wavelength
It is measured by UV/ Vis Spectrophotometry down.In some embodiments, the 0.5A.U. or lower suction
It receives and is attributed to drug degradation agent.In some embodiments, the SAE-CD composition is absorbed as 0.2A.U. or lower, such as
In the long cuvette of 1cm journey to containing 300mg SAE-CD composition/mL solution aqueous solution in 245nm to 270nm wavelength
It is measured by UV/ Vis Spectrophotometry down.In some embodiments, the 0.2A.U. or lower suction
It receives and is attributed to drug degradation agent.In some embodiments, the absorption of the SAE-CD composition is the cuvette long in 1cm journey
In to containing 500mg SAE-CD composition/mL solution aqueous solution at 245nm to 270nm wavelength by UV/ visible light point
Light photometry is measured.
In some embodiments, the sulfoalkyl cyclodextrin is the compound of Formula II:
Wherein p is 4,5 or 6, and R1At each occurrence independently selected from-OH or-O- (C2-C6Alkylidene)-SO3 -- T,
Wherein for T at each occurrence independently selected from pharmaceutically acceptable cation, condition is at least one R1Be-OH and at least one
R1It is O- (C2-C6Alkylidene)-SO3 --T.In some embodiments, R1At each occurrence independently selected from-OH or-O- (C4
Alkylidene)-SO3 -- T, and-T is Na at each occurrence+。
In some embodiments, the present invention provides sulfoalkyl ether cyclodextrin (SAE-CD) compositions, and it includes average
Sulfoalkyl ether cyclodextrin, the phosphate less than 500ppm and the chloride for being less than 0.5% (w/w) that degree of substitution is 2 to 9, wherein
The SAE-CD composition is absorbed as 1A.U. or lower, to containing 300mg SAE-CD group such as in the long cuvette of 1cm journey
Close what object/mL solution aqueous solution was measured at 320nm to 350nm wavelength by UV/ Vis Spectrophotometry.?
In some embodiments, the 1A.U. or lower, which absorbs, is attributed to colour coupler.In some embodiments, the sulfoalkyl
Ether cyclodextrin composite is not sulfobutyl ether cyclodextrins composition.In some embodiments, the sulfoalkyl ether cyclodextrin is not
It is sulfobutyl ether beta-cyclodextrin.In some embodiments, the SAE-CD composition is absorbed as 0.5A.U. or lower, such as
In the long cuvette of 1cm journey to containing 300mg SAE-CD composition/mL solution aqueous solution in 320nm to 350nm wavelength
It is measured by UV/ Vis Spectrophotometry down.In some embodiments, the 0.5A.U. or lower suction
It receives and is attributed to colour coupler.In some embodiments, the SAE-CD composition is absorbed as 0.2A.U. or lower, such as in 1cm
Pass through at 245nm to 270nm wavelength in the long cuvette of journey to containing 300mg SAE-CD composition/mL solution aqueous solution
UV/ Vis Spectrophotometry is measured.In some embodiments, the 0.2A.U. or lower absorption attribution
In colour coupler.In some embodiments, the absorption of the SAE-CD composition is in the long cuvette of 1cm journey to containing
500mg SAE-CD composition/mL solution aqueous solution is surveyed at 320nm to 350nm wavelength by UV/ visible light light-splitting luminosity
What the method for determining was measured.
In some embodiments, the average substitution degree of SAE-CD is 4.5 to 7.5.In some embodiments, SAE-CD
Average substitution degree be 6 to 7.5.In some embodiments, the average substitution degree of SAE-CD is 6.2 to 6.9.
In some embodiments, the present invention provides the compositions comprising SAE-CD composition and activating agent.
The invention further relates to for making surfactant stabilized method, the method includes providing comprising alkylation ring paste
The alkylated cyclodextrin composition of essence, the phosphate less than 500ppm and the chloride less than 0.5%, wherein the alkylation ring
Being absorbed as of dextrin composition is less than 1A.U., as in the long cuvette of 1cm journey as described in containing 300mg alkylated cyclodextrin
What composition/mL solution aqueous solution was measured at 245nm to 270nm wavelength by UV/ Vis Spectrophotometry；
And it combines the alkylated cyclodextrin composition with activating agent.In some embodiments, the absorption less than 1A.U.
It is attributed to drug degradation agent.
The invention further relates to for making surfactant stabilized method, the method includes providing comprising alkylation ring paste
The alkylated cyclodextrin composition of essence, the phosphate less than 500ppm and the chloride less than 0.5%, wherein the alkylation ring
Being absorbed as of dextrin composition is less than 1A.U., as in the long cuvette of 1cm journey as described in containing 300mg alkylated cyclodextrin
What composition/mL solution aqueous solution was measured at 245nm to 270nm wavelength by UV/ Vis Spectrophotometry；
And it combines the alkylated cyclodextrin composition with activating agent.In some embodiments, the absorption less than 1A.U.
It is attributed to colour coupler.
The present invention also provides the methods for preparing alkylated cyclodextrin composition, which comprises
(a) cyclodextrin and alkylating agent are mixed to form comprising alkylated cyclodextrin, Yi Zhonghuo
The reaction environment of a variety of undesirable components and one or more drug degradation impurity；
(b) progress is one or more separates to remove one or more undesirable components from the reaction environment,
To form the partially purified solution for including the alkylated cyclodextrin and one or more drug degradation impurity, wherein
One or more separation are ultrafiltration, diafiltration, centrifugation, extraction, solvent deposition or dialysis；
(c) it is partially purified solution described in the not phosphatic activated carbon treatment of 10 μ S or lower with conductivity and produces
The raw alkylated cyclodextrin.
The term as used herein " batch " or " criticizing " refer to since processing operation start to handle end of run it is discontinuous
(discrete) manufacture or processing operation.In some embodiments, being more than batch of the present invention provides preparation includes alkane
The method of the alkylated cyclodextrin composition of base cyclodextrin, which comprises (a) mixes cyclodextrin with shape with alkylating agent
At the reaction ring comprising alkylated cyclodextrin, one or more undesirable compounds and one or more drug degradation impurity
Border；(b) one or more separation are carried out to remove one or more undesirable components from the reaction environment, to form packet
Partially purified solution containing the alkylated cyclodextrin and one or more drug degradation impurity, wherein it is described a kind of or
A variety of separation are ultrafiltration, diafiltration, centrifugation, extraction, solvent deposition or dialysis；And (c) with residual conduction rate be 10 μ S or lower
Not phosphatic activated carbon treatment described in partially purified solution and generate the alkylated cyclodextrin；And it (d) repeats
(a) to (c) to obtain another batch of alkylated cyclodextrin composition.
In some embodiments, described more than batch of alkylated cyclodextrin composition is at least 4 batches, at least 5 batches, extremely
Few 6 batches, at least 7 batches, at least 8 batches, at least 9 batches, at least 10 batches, at least 11 batches, at least 12 batches, at least 13 batches, at least 14 batches, extremely
Few 15 batches, at least 16 batches, at least 17 batches, at least 18 batches, at least 19 batches, at least 20 batches, at least 30 batches, at least 40 batches, at least 50
It criticizes, at least 60 batches, at least 70 batches, at least 80 batches, at least 90 batches or at least 100 batches.In some embodiments, described to be more than
Batch of alkylated cyclodextrin composition is 4 to 100 batches, 10 to 100 batches, 20 to 100 batches, 30 to 100 batches, 40 to 100 batches, 50
To 100 batches, 10 to 20 batches, 10 to 30 batches, 10 to 40 batches or 10 to 50 batches.
In some embodiments, the alkylated cyclodextrin composition of 50% or more batch has less than 0.1% (w/w)
Chloride level, the alkylated cyclodextrin composition of 65% or more batch has the chloride water less than 0.1% (w/w)
Flat, the alkylated cyclodextrin composition of 75% or more batch has a chloride level less than 0.1% (w/w), and 80% or more
Multiple batches of alkylated cyclodextrin composition has the chloride level less than 0.1% (w/w), the alkyl of 85% or more batch
Change cyclodextrin composite with the chloride level less than 0.1% (w/w), the alkylated cyclodextrin combination of 90% or more batch
Object has the chloride level less than 0.1% (w/w), and the alkylated cyclodextrin composition of 95% or more batch, which has, to be less than
The alkylated cyclodextrin composition of the chloride level of 0.1% (w/w), 98% or more batch has less than 0.1% (w/w's)
Chloride level, the alkylated cyclodextrin composition of 50% or more batch have the chloride level less than 0.08% (w/w),
The alkylated cyclodextrin composition of 65% or more batch has a chloride level less than 0.08% (w/w), and 75% or more
The alkylated cyclodextrin composition of batch has the chloride level less than 0.08% (w/w), the alkyl of 80% or more batch
Change cyclodextrin composite with the chloride level less than 0.08% (w/w), the alkylated cyclodextrin group of 85% or more batch
Object is closed with the chloride level less than 0.08% (w/w), the alkylated cyclodextrin composition of 90% or more batch has small
Have in the alkylated cyclodextrin composition of the chloride level of 0.08% (w/w), 95% or more batch less than 0.08% (w/
W) chloride level, the alkylated cyclodextrin composition of 98% or more batch have the chloride less than 0.08% (w/w)
Level, the alkylated cyclodextrin composition of 50% or more batch have a chloride level less than 0.05% (w/w), 65% or
More multiple batches of alkylated cyclodextrin composition has the chloride level less than 0.05% (w/w), 75% or more batch
Alkylated cyclodextrin composition has the chloride level less than 0.05% (w/w), the alkylation ring paste of 80% or more batch
Smart composition has the chloride level less than 0.05% (w/w), the alkylated cyclodextrin composition tool of 85% or more batch
There is the chloride level less than 0.05% (w/w), the alkylated cyclodextrin composition of 90% or more batch, which has, to be less than
The alkylated cyclodextrin composition of the chloride level of 0.05% (w/w), 95% or more batch has less than 0.05% (w/w)
The alkylated cyclodextrin composition of chloride level or 98% or more batch there is the chlorination less than 0.05% (w/w)
Object is horizontal.
In some embodiments, the batch of alkylated cyclodextrin composition is sequentially prepared.
The preparation of alkylated cyclodextrin composition
The present invention describes a variety of methods for preparing alkylated cyclodextrin composition.In general, will be in neutrality to alkaline aqueous
Underivatized cyclodextrin raw material in medium is exposed to substitution based precursor.The substitution based precursor can be added incrementally or primary fast
Speed addition (as a bolus), and can be before cyclodextrin raw material to be exposed to the alkaline aqueous medium being optionally present, period
Or addition replaces based precursor later.To add additional basic matterial or padded coaming visually to keep in the desired range pH
It is interior.Reaction can be performed the derivatization under environment temperature or raised temperature.Once derivatization has progressed to desired degree, then appoint
Selection of land adds acid to make reaction terminating.Be further processed reaction environment (for example, solvent deposition, filtering, centrifugation, evaporation, concentration,
Drying, chromatography, dialysis and/or ultrafiltration) to remove undesirable material and form target composition.Last processing it
Afterwards, composition can be in solid, liquid, semisolid, gel, syrup, paste, powder, aggregation, particle (granule), microballoon
(pellet), compression material, the solid that can be redissolved, suspension, vitreum, crystalline material, amorphous substance, particle
(particulate), the form of globule (bead), lotion or wet substance.
Alkylated cyclodextrin the present invention provides preparation comprising the alkylated cyclodextrin optionally with predetermined degree of substitution
Composition, which comprises in the presence of an alkali metal hydroxide, make unsubstituted cyclodextrin raw material be enough to realize it is pre-
Determine the alkylating agent combination of the amount of degree of substitution；The alkylation of the cyclodextrin is carried out at 9 to 11 pH, until remaining unreacted
Cyclodextrin be less than 0.5 weight % or less than 0.1 weight %；Addition is enough to realize the additional hydroxide of the amount of the degree of substitution
Object simultaneously carries out alkylation until completing；And additional hydroxide is added to destroy the alkylating agent of any remnants.
A certain amount of hydroxide can be used and under certain condition (that is, amount, the temperature of the additional hydroxide of addition
Degree, the duration for carrying out alkylating agent hydrolysis) the additional hydroxide of addition, so that the level of alkylating agent remaining in aqueous crude product
It is reduced to less than 20ppm or less than 2ppm.
It is possible that reaction environment or partial purification aqueous solution can include unreacted alkylating agent.It can be additional by adding
Alkylating agent or by will include the substance solution heat come ira situ degradation alkylating agent.After mixing in reaction environment
There are the excessive alkylating agents that in the case where the alkylating agent of unacceptable amount, needs to degrade.It can be by adding additional alkylating agent
Or by will include the solution heating of the substance come ira situ degradation alkylating agent.
It can be degraded by following: reaction environment is exposed at least 60 DEG C, at least 65 DEG C or 60 DEG C to 85 DEG C, 60
DEG C to 80 DEG C or 60 DEG C to 95 DEG C of raised temperature, continue at least 6 hours, at least 8 hours, 8 hours to 12 hours, 6 hours
To 72 hours or 48 hours to 72 hours, thus ira situ degradation alkylating agent and the amount or elimination of alkylating agent in waterborne liquid are reduced
Alkylating agent in waterborne liquid.
After being reacted as described herein, the aqueous medium comprising alkylated cyclodextrin, which is neutralized to pH, is
7, to make reaction terminating.Then, the solution is diluted with water to reduce viscosity, the case where to be especially further purified
Under.It can be used and be further purified, the diafiltration including but not limited on ultra-filtering element is to remove such as salt (for example, in hydroxide
Sodium be used as alkali in the case where NaCl) byproduct of reaction and other low molecular weight by-products solution.Can by ultrafiltration into
One step enriched product.Then with activated carbon treatment reaction mixture to improve its color, reduce biological load amount and removal one substantially
Kind or a variety of drug degradation impurity.It can (such as freeze-drying, spray drying or vacuum rotary drum be dry by suitable dry technology
It is dry) isolate product.
It can be by unsubstituted α-, β-or gamma-cyclodextrin dissolution of raw material in alkali (usually such as lithium hydroxide, sodium hydroxide
Or the hydroxide of potassium hydroxide) aqueous solution in.Alkali is deposited with catalytic amount (that is, the molar ratio relative to cyclodextrin is less than 1:1)
To realize scheduled or desired degree of substitution.That is, the amount of alkali, which is less than in cyclodextrin molecular, is intended to each of derivatization
One molar equivalent of hydroxyl.Because cyclodextrin becomes dissolved in aqueous solution as the temperature rises and gradually, should will include
The aqueous reaction mixture of alkali and cyclodextrin is increased to 50 DEG C of temperature to ensure to be completely dissolved.During entire alkylated reaction
Generally use stirring.
After dissolution is completed, alkylating agent is added to start alkylated reaction.The alkylating agent added during entire reaction
Total amount usually with relative to the amount of cyclodextrin complete reaction needed for stoichiometry compared be it is excessive, because of some alkylating agents
It is hydrolyzed during reaction and/or is destroyed/degrades, so that it be made to be not useable for alkylated reaction.For desired degree of substitution
The precise volume of alkylating agent can be measured by using trial operation.Whole needed for completing reaction can be added before initiation reaction
The alkylating agent of amount.Because system be it is aqueous, reaction usually 50 DEG C to 100 DEG C at a temperature of carry out.Reaction can be small
It is carried out at a temperature of 100 DEG C, without dedicated press device.In general, 65 DEG C to 95 DEG C of temperature is appropriate.
In the initial stage (herein referred as pH controls the stage) of reaction, it should carefully monitor pH and remain at least alkali
Property, or be maintained in 8 to 11 pH.The monitoring of pH can be routinely realized by using standard pH meter.It can be by adding hydrogen
Oxide water solution such as 10-15% solution realizes the adjusting of pH.The stage is controlled in initial pH, reacts unreacted cyclodextrin
To following degree, that is, the remaining unreacted cyclodextrin for being less than 0.5 weight % or less than 0.1 weight % in the solution.Therefore logical
It crosses part and replaces the journey for reacting the cyclodextrin of substantially all initial load (charge), but being less than desired predetermined degree of substitution
Degree.Residual cyclodextrin for example can be monitored by HPLC as described below in the entire initial stage, until having realized few
In the expectation terminal of 0.5% or less than 0.1% residual cyclodextrin raw material.It can be by continuously adding the hydrogen of concentration to reaction medium
Oxide or the concentration hydroxide that discrete amount (discrete amount) is added in the form of little increment, to keep and/or rise
High pH.Addition in the form of little increment is specially suitable.
Once it is normalized or optimize alkylation operation, so that known generating desired degree of substitution and low remaining ring
The reactant of specific quantity is combined in the operation of dextrin, then it can be at the end (rather than in entire initial pH control or in initial pH
Control period) simply check the operation, so that it is guaranteed that the cyclodextrin raw material for having been realized in low remaining (unreacted) is horizontal.Following table
Relationship between the amount for the butane sultone being loaded into reactor and the average substitution degree of resulting SAE-CD is shown.
It should be noted that the initial p H of reaction medium can be higher than 11, such as in the cyclodextrin raw material and alkali group for making initial load
After conjunction but before adding alkylating agent.However, pH rapid decrease needs to add after addition alkylating agent and reaction start
Alkali is to maintain the alkaline pHs of about 8 to about 11.
Once the level of remaining unreacted cyclodextrin has reached desired level, such as less than within the pH control stage
0.5 weight % then can make pH be increased above the 11, level for example higher than 12, thus drive response by adding additional alkali
It completes.PH can be at least 12, to make reaction with the progress of reasonable rate, but the rate does not make unreacted alkylating agent up to
Fast hydrolyzing rather than reacted with cyclodextrin.In the latter half of reaction, the additional substitution of cyclodextrin molecular is realized, until obtaining
Obtain scheduled degree of substitution.Amount needed for the total amount of the hydroxide added during entire reaction is generally approximate stoichiometry adds
The molar excess (amount relative to alkylating agent used) of upper 10-20%.Excess of the addition more than 10-20% is also feasible.
As described above, reaction end can be detected by HPLC.Suitable temperature is 65 DEG C to 95 DEG C.HPLC system, which generallys use, to be had
The anion exchange analytical column of Pulse amperometric detection (PAD).Elution can be by using the gradient of two solvent systems, such as solvent A
It is the sodium hydrate aqueous solution of 25mM (mM), and solvent B is the 1M sodium nitrate in 250mM sodium hydroxide.
Once complete alkylated reaction and have reached low residual cyclodextrin terminal, then can add additional hydroxide with
Destroy and/or degrade the alkylating agent of any remnants.Additional hydroxide usually with relative to 0.5 molar equivalent of cyclodextrin extremely
The amount of 3 molar equivalents is added, and makes reaction medium in 65 DEG C to 95 DEG C continuous heatings, is typically lasted for 6 hours to 72 hours.
After the destruction of remaining alkylating agent, the lower-molecular-weight component of such as salt can be reduced or removed by diluting, being percolated
Product, concentration, carbon processing and dry extraly to handle resulting crude product, to generate final product.
Initial monitor pH keeps pH for 8 to 11 to ensure the progress with alkyl derivatized reaction.In the initial stage,
Addition for promoting alkylated hydroxide can be stage or substep.The pH of monitoring reaction is ensured and can be controlled
The reaction so that whole initial feed fundamental reactions of cyclodextrin raw material to following degree, that is, realize that each cyclodextrin molecular is flat
At least one equal alkyl-substituted degree.Therefore, entire cyclodextrin reactant is consumed when this method starts, so that in crude product
The level of cyclodextrin of remnants (unreacted) be low, the spy of the method compared with the crude product generated by following methods
Sign is initially to merge to make to react with cyclodextrin and alkylating agent group by entire stoichiometry or excessive alkali to carry out uncontrolledly.Whole
After the cyclodextrin raw material of a useful load partially reacts, remaining hydroxide can be added, thus by with scheduled expectation
Degree of substitution is completed alkyl and is replaced to drive reaction to be completed.Consumed in the first pH control stage initial load cyclodextrin it
Afterwards, hydroxide adding rate is not crucial.Therefore, hydroxide (example can be added continuously or in the form of the discrete steps
As in the form of a solution).In addition, the pH of reaction medium should be maintained above about 12, so that reaction rate is commercially available.
The reduction and removal of impurity in cyclodextrin composite
Initial pH control provides the means that certain by-products are reduced from reaction mixture.For example, being generated by alkylation
Acid, and the pH of reaction mixture tends to reduce (that is, becoming more Plus acidic) as reaction carries out.On the one hand, it will react
Alkalinity is remained, because if reaction medium becomes acidity, then reacting can significantly slow or stop.It therefore, should be according to need
Hydroxide aqueous solution is added, so that the pH of reaction medium to be remained at least 8 level.On the other hand, if keeping pH super
Certain level is crossed, such as pH is greater than 12, then there may be high-caliber by-product such as 4- hydroxy alkyl sulfonic acid esters and double sulphurs for reaction
Alkyl ether, to consume alkylating agent raw material.By monitor reaction solution pH and pH is remained into 8 to 12 or 8 to 11, react into
Row, and the by-product of low relative levels is generated simultaneously, and provides the relative clean of the aforementioned by-product comprising low relative levels
Reaction mixture.
Amount mentioned above with " stoichiometry is sufficient " etc., which provides reactant, is spread out completely relative to by the cyclodextrin of concern
The amount of reactant needed for biochemistry to desired degree of substitution.As used herein, " alkali metal hydroxide " refer to LiOH, NaOH,
KOH etc..If it is desire to generating the product for being suitable for parenteral administration, NaOH may be used.
According to whether it is expected lower or higher degree of substitution, it can be by using the amount of lower accordingly or higher alkylating agent
To control degree of substitution.In general, achievable degree of substitution is 4.5 to 7.5,5.5 to 7.5 or 6 to 7.1 average value.
The crude product (that is, the product obtained after the destruction of remaining alkylating agent) of methods herein is comprising level than with single
The horizontal lower residual cyclodextrin of the residual cyclodextrin that the method that useful load initially adds alkali generates, and be another spy of the invention
Sign.The crude product generated by means of the present invention is generally comprised to be pasted less than the remaining ring of 0.5 weight % or less than 0.1 weight %
Essence.As described below, the advantage of the crude product also resides in that it includes low-down remaining alkylating agent is horizontal.
In general, pure by ultrafiltration (i.e. crude product contacted with semipermeable membrane (film for passing through low molecular weight impurities) method)
Change the cyclodextrin crude product aqueous solution obtained after remaining alkylating agent destroys.The film is depended on by the molecular weight of the impurity of the film
Molecular cut off.For the present invention, the film that molecular cut off is 1,000 dalton (" Da ") is generallyd use.Retention can be used
Molecular weight is 500Da to 2,000Da, 500Da to 1,500Da, 750Da to 1,250Da or 900Da to 1,100Da or about 1,
The filter membrane of 000Da come carry out diafiltration and/or ultrafiltration.Then it is further processed the desired product in retentate with activated carbon,
To remove drug degradation impurity substantially.Cyclodextrin crude product aqueous solution is (i.e. after the destruction of remaining alkylating agent but in purifying
The solution of preceding acquisition) advantage be its based on solution weight include less than 2ppm, less than the remnants of 1ppm or less than 250ppb
Alkylating agent.Crude solution also contains substantially no remaining alkylating agent.
At this point, then water can be evaporated (for example, by distillation, spray drying, freeze-drying for example, by being filtered to remove activated carbon
Deng) isolate final commercial product.The final product that the present invention generates advantageously comprises low-down alkylating agent residual level,
Such as the final product based on drying (i.e. comprising water) less than 10 weight %, less than 2ppm, less than 1ppm, less than 250ppb's
Remaining alkylating agent, or contain substantially no remaining alkylating agent.Therefore the final product comprising the alkylating agent less than 250ppb is this
Another feature of invention.After completing alkylation to desired degree of substitution, is handled by basic hydrolysis above-mentioned and reduce alkanisation
Agent, that is, by be enough to reduce the amount of alkylating agent unreacted in desciccate to less than 2ppm, less than 1ppm or less than
The amount and condition of the aspiration level of 250ppb adds additional hydroxide solution.
The activated carbon for being suitable for the invention method can be not phosphatic, and can be powder or particle, or
The suspension or slurries that person is generated by it.In general, not phosphatic activated carbon is that phosphoric acid or not otherwise is not used
The carbon for being exposed to phosphoric acid and activating.
Various active carbon is available.For example, Norit-Americas has been commercialized more than 150 kinds of different brackets and type
Activated carbon, trade name is for example WithThe carbon the difference is that partial size, using,
Activation method and practicability.For example, some activated carbon are optimal for decoloration and/or taste removal.Other activated carbon are for removal
Albumen, minerals and/or amino acid moiety are optimal for making solution clarification.
Being suitable for the invention activated carbon includes but is not limited to:4x12,12x20 or 20x40 particle, are originated from
Lignite, steam activation (Norit Americas, Inc., Amersfoort, NE)；S 51HF (is originated from lignite, steams
Vapour activation, powder)；AndDC-32 is powdered or graininess carbon, is originated from timber, zinc chloride activation (Takeda
Chemical Industries,Ltd.,Osaka,JP)。
If the prior art is to used in purification of alkyl ether ring dextrin, this hair is generally unsuitable for using the carbon of phosphoric acid activation
It is bright comprisingKB-G、KB-B andKB-WJ, andCASP andCN1。
In some embodiments, the phosphate level in alkylated cyclodextrin composition is less than 200ppm, is less than
150ppm, less than 125ppm, less than 100ppm, less than 95ppm, less than 90ppm, less than 85ppm, less than 80ppm, be less than
75ppm, be less than 70ppm, be less than 65ppm, be less than 60ppm, be less than 55ppm, be less than 50ppm, be less than 45ppm, be less than 40ppm,
Less than 35ppm, be less than 30ppm, be less than 25ppm, be less than 20ppm, be less than 15ppm, be less than 10ppm or be less than 5ppm.Some
In embodiment, the phosphate level in alkylated cyclodextrin composition is 200ppm to 5ppm, 150ppm to 5ppm, 125ppm
To 5ppm, 100ppm to 5ppm, 75ppm to 5ppm, 50ppm to 5ppm, 150ppm to 10ppm, 125ppm to 10ppm,
100ppm to 10ppm or 75ppm to 10ppm.
The load ratio (loading ratio) of activated carbon ultimately depends on alkylated cyclodextrin in solution, colour coupler and medicine
The amount or concentration of object degradation impurity and the physical property of activated carbon used.In general, the period per treatment is by weight, ring paste
Essence and the weight ratio of activated carbon be 5:1 to 10:1,6:1 to 9:1,7:1 to 9:1,8:1 to 9:1,8.3:1 to 8.5:1,8.4:1 extremely
8.5:1 or 8.44:1.
As used herein, " process cycle " is the activated carbon contacts for instigating the cyclodextrin composite and predetermined amount of predetermined amount.
Process cycle can be carried out in the form of single treatment or with multiple (recycling) by (pass-through) processing form.
Embodiment provided herein is detailed for evaluating and comparing different brackets, batch, source and the activated carbon of type
During removal is present in SAE-CD (in-process) one of environment or solution or a variety of drug degradation components and
The operation of efficiency in terms of one or more coupler components.In general, with environment during activated carbon treatment or solution & stir
120 minutes.If using loose, particle or the activated carbon of powder type, can by include via filter media should
The liquid of carbon removes it, to provide clear solution.
Filter membrane may include nylon,PVDF or other compatibility materials.Can according to including SAE-CD
Solution in SAE-CD separation substance partial size or molecular weight optionally change the aperture of filter membrane.
Embodiment provided herein detail for aqueous reaction environment of the invention carry out one or more separation and/
Or the operation of purifying.Reaction solution is diluted with aqueous solution, and is percolated, the volume of retentate is made to keep base during diafiltration
This is constant.It can be percolated on the filter of 1,000Da, so that one or more undesirable components pass through filter, but
The most of alkyl ether being present in alkylated cyclodextrin composition is retained in retentate, rather than is passed through with filtrate.So
Afterwards, ultrafiltration is carried out by reducing the volume of retentate, retentate is thus concentrated.Molecular cut off is the mistake of about 1,000Da
Filter can also be used for ultrafiltration.Retentate includes alkylated cyclodextrin, then can use activated carbon treatment, as described herein.
One or more undesirable components include but is not limited to: low molecular weight impurities (that is, molecular weight be about 500Da or
Lower impurity), water-soluble and/or water-insoluble ion (that is, salt), the alkylating agent through hydrolyzing, 5- (methylol) -2- furfural,
Unreacted cyclodextrin raw material, degradation cyclodextrin substance (for example, by unreacted cyclodextrin, part reaction cyclodextrin and/
Or SAE-CD formed degradation material and/or open loop substance), unreacted alkylating agent (for example, Isosorbide-5-Nitrae-butane sultone), and its
Combination.
In some embodiments, composition of the invention is substantially free of one or more drug degradation agent.Can especially it lead to
UV/ visible light (" UV/vis ") spectrophotometry is crossed to measure the presence of one or more drug degradation agent.Such as this paper institute
With " drug degradation agent " or " drug degradation impurity " refers to substance, the part etc. of certain active components in degradation aqueous solution.Ying Li
Solve drug degradation agent can with it is non-degradable it is all can with the drug of alkylated cyclodextrin combination of compositions, this depend on drug chemistry
Structure and its degradation pathway.In some embodiments, drug degradation substance has in the visible light region UV/ of spectrum and inhales
It receives, such as has absorption maximum value under the wavelength of 245nm to 270nm.
Drug degradation agent can be measured in alkylated cyclodextrin group by the UV/ visible light in terms of absorbance unit (A.U.)
Close the presence in object.In some embodiments, alkylated cyclodextrin composition be absorbed as be less than 1A.U., be less than
0.9A.U., be less than 0.8A.U., be less than 0.7A.U., be less than 0.6A.U., 0.5A.U., be less than 0.4A.U., be less than 0.3A.U.,
Less than 0.2A.U. or it is less than 0.1A.U..
The absorbance of solution is linear with concentration according to the following formula:
A=ε lc
Wherein
A=absorbance
ε=extinction coefficient
L=journey is long
C=molar concentration.
The cuvette that can be used 1cm journey long is surveyed under 245 to 270nm wavelength using UV/ Vis Spectrophotometry
Measure presence of the drug degradation agent in alkylated cyclodextrin composition.In some embodiments, alkylated cyclodextrin composition
Be absorbed as it is following: for containing 200mg alkylated cyclodextrin composition/mL solution aqueous solution, in 245nm to 270nm wave
It is long lower for less than 1A.U.；For containing 300mg alkylated cyclodextrin composition/mL solution aqueous solution, in 245nm to 270nm
For less than 1A.U. under wavelength；For contain 400mg alkylated cyclodextrin composition/mL solution aqueous solution, 245nm extremely
For less than 1A.U. under 270nm wavelength；For containing 500mg alkylated cyclodextrin composition/mL solution aqueous solution, in 245nm
For less than 1A.U. under to 270nm wavelength；For containing 200mg alkylated cyclodextrin composition/mL solution aqueous solution,
It is 0.9A.U. or lower under 245nm to 270nm wavelength；For containing 300mg alkylated cyclodextrin composition/mL solution water
Solution is 0.9A.U. or lower at 245nm to 270nm wavelength；For molten containing 400mg alkylated cyclodextrin composition/mL
The aqueous solution of liquid is 0.9A.U. or lower at 245nm to 270nm wavelength；For being combined containing 500mg alkylated cyclodextrin
Object/mL solution aqueous solution is 0.9A.U. or lower at 245nm to 270nm wavelength；For containing 200mg alkylation ring paste
Smart composition/mL solution aqueous solution is 0.8A.U. or lower at 245nm to 270nm wavelength；For containing 300mg alkyl
Change cyclodextrin composite/mL solution aqueous solution, is 0.8A.U. or lower at 245nm to 270nm wavelength；For containing
400mg alkylated cyclodextrin composition/mL solution aqueous solution is 0.8A.U. or lower at 245nm to 270nm wavelength；It is right
In containing 500mg alkylated cyclodextrin composition/mL solution aqueous solution, at 245nm to 270nm wavelength for 0.8A.U. or
It is lower；For containing 200mg alkylated cyclodextrin composition/mL solution aqueous solution, it is at 245nm to 270nm wavelength
0.7A.U. or lower；For containing 300mg alkylated cyclodextrin composition/mL solution aqueous solution, in 245nm to 270nm wave
It is long lower for 0.7A.U. or lower；For contain 400mg alkylated cyclodextrin composition/mL solution aqueous solution, 245nm extremely
It is 0.7A.U. or lower under 270nm wavelength；For containing 500mg alkylated cyclodextrin composition/mL solution aqueous solution,
It is 0.7A.U. or lower under 245nm to 270nm wavelength；For containing 200mg alkylated cyclodextrin composition/mL solution water
Solution is 0.6A.U. or lower at 245nm to 270nm wavelength；For molten containing 300mg alkylated cyclodextrin composition/mL
The aqueous solution of liquid is 0.6A.U. or lower at 245nm to 270nm wavelength；For being combined containing 400mg alkylated cyclodextrin
Object/mL solution aqueous solution is 0.6A.U. or lower at 245nm to 270nm wavelength；For containing 500mg alkylation ring paste
Smart composition/mL solution aqueous solution is 0.6A.U. or lower at 245nm to 270nm wavelength；For containing 200mg alkyl
Change cyclodextrin composite/mL solution aqueous solution, is 0.5A.U. or lower at 245nm to 270nm wavelength；For containing
300mg alkylated cyclodextrin composition/mL solution aqueous solution is 0.5A.U. or lower at 245nm to 270nm wavelength；It is right
In containing 400mg alkylated cyclodextrin composition/mL solution aqueous solution, at 245nm to 270nm wavelength for 0.5A.U. or
It is lower；For containing 500mg alkylated cyclodextrin composition/mL solution aqueous solution, it is at 245nm to 270nm wavelength
0.5A.U. or lower；For containing 200mg alkylated cyclodextrin composition/mL solution aqueous solution, in 245nm to 270nm wave
It is long lower for 0.4A.U. or lower；For contain 300mg alkylated cyclodextrin composition/mL solution aqueous solution, 245nm extremely
It is 0.4A.U. or lower under 270nm wavelength；For containing 400mg alkylated cyclodextrin composition/mL solution aqueous solution,
It is 0.4A.U. or lower under 245nm to 270nm wavelength；For containing 500mg alkylated cyclodextrin composition/mL solution water
Solution is 0.4 or lower at 245nm to 270nm wavelength；For the aqueous solution containing 200mg alkylated cyclodextrin composition,
It is 0.3A.U. or lower at 245nm to 270nm wavelength；For containing 300mg alkylated cyclodextrin composition/mL solution
Aqueous solution is 0.3A.U. or lower at 245nm to 270nm wavelength；For containing 400mg alkylated cyclodextrin composition/mL
The aqueous solution of solution is 0.3A.U. or lower at 245nm to 270nm wavelength；For containing 500mg alkylated cyclodextrin group
Object/mL solution aqueous solution is closed, is 0.3A.U. or lower at 245nm to 270nm wavelength；For being alkylated ring containing 200mg
Dextrin composition/mL solution aqueous solution is 0.2A.U. or lower at 245nm to 270nm wavelength；For containing 300mg alkane
Base cyclodextrin composite/mL solution aqueous solution is 0.2A.U. or lower at 245nm to 270nm wavelength；For containing
400mg alkylated cyclodextrin composition/mL solution aqueous solution is 0.2A.U. or lower at 245nm to 270nm wavelength；Or
Person, for being at 245nm to 270nm wavelength containing 500mg alkylated cyclodextrin composition/mL solution aqueous solution
0.2A.U. or lower.
The cuvette that can be used 1cm journey long is surveyed under 320 to 350nm wavelength using UV/ Vis Spectrophotometry
Measure presence of the colour coupler in alkylated cyclodextrin composition.In some embodiments, the suction of alkylated cyclodextrin composition
It is following for receiving: for containing 200mg alkylated cyclodextrin composition/mL solution aqueous solution, at 320nm to 350nm wavelength
For less than 1A.U.；For containing 300mg alkylated cyclodextrin composition/mL solution aqueous solution, in 320nm to 350nm wavelength
Lower is less than 1A.U.；For containing 400mg alkylated cyclodextrin composition/mL solution aqueous solution, in 320nm to 350nm wave
It is long lower for less than 1A.U.；For containing 500mg alkylated cyclodextrin composition/mL solution aqueous solution, in 320nm to 350nm
For less than 1A.U. under wavelength；For contain 200mg alkylated cyclodextrin composition/mL solution aqueous solution, 320nm extremely
It is 0.9A.U. or lower under 350nm wavelength；For containing 300mg alkylated cyclodextrin composition/mL solution aqueous solution,
It is 0.9A.U. or lower under 320nm to 350nm wavelength；For containing 400mg alkylated cyclodextrin composition/mL solution water
Solution is 0.9A.U. or lower at 320nm to 350nm wavelength；For molten containing 500mg alkylated cyclodextrin composition/mL
The aqueous solution of liquid is 0.9A.U. or lower at 320nm to 350nm wavelength；For being combined containing 200mg alkylated cyclodextrin
Object/mL solution aqueous solution is 0.8A.U. or lower at 320nm to 350nm wavelength；For containing 300mg alkylation ring paste
Smart composition/mL solution aqueous solution is 0.8A.U. or lower at 320nm to 350nm wavelength；For containing 400mg alkyl
Change cyclodextrin composite/mL solution aqueous solution, is 0.8A.U. or lower at 320nm to 350nm wavelength；For containing
500mg alkylated cyclodextrin composition/mL solution aqueous solution is 0.8A.U. or lower at 320nm to 350nm wavelength；It is right
In containing 200mg alkylated cyclodextrin composition/mL solution aqueous solution, at 320nm to 350nm wavelength for 0.7A.U. or
It is lower；For containing 300mg alkylated cyclodextrin composition/mL solution aqueous solution, it is at 320nm to 350nm wavelength
0.7A.U. or lower；For containing 400mg alkylated cyclodextrin composition/mL solution aqueous solution, in 320nm to 350nm wave
It is long lower for 0.7A.U. or lower；For contain 500mg alkylated cyclodextrin composition/mL solution aqueous solution, 320nm extremely
It is 0.7A.U. or lower under 350nm wavelength；For containing 200mg alkylated cyclodextrin composition/mL solution aqueous solution,
It is 0.6A.U. or lower under 320nm to 350nm wavelength；For containing 300mg alkylated cyclodextrin composition/mL solution water
Solution is 0.6A.U. or lower at 320nm to 350nm wavelength；For molten containing 400mg alkylated cyclodextrin composition/mL
The aqueous solution of liquid is 0.6A.U. or lower at 320nm to 350nm wavelength；For being combined containing 500mg alkylated cyclodextrin
Object/mL solution aqueous solution is 0.6A.U. or lower at 320nm to 350nm wavelength；For containing 200mg alkylation ring paste
Smart composition/mL solution aqueous solution is 0.5A.U. or lower at 320nm to 350nm wavelength；For containing 300mg alkyl
Change cyclodextrin composite/mL solution aqueous solution, is 0.5A.U. or lower at 320nm to 350nm wavelength；For containing
400mg alkylated cyclodextrin composition/mL solution aqueous solution is 0.5A.U. or lower at 320nm to 350nm wavelength；It is right
In containing 500mg alkylated cyclodextrin composition/mL solution aqueous solution, at 320nm to 350nm wavelength for 0.5A.U. or
It is lower；For containing 200mg alkylated cyclodextrin composition/mL solution aqueous solution, it is at 320nm to 350nm wavelength
0.4A.U. or lower；For containing 300mg alkylated cyclodextrin composition/mL solution aqueous solution, in 320nm to 350nm wave
It is long lower for 0.4A.U. or lower；For contain 400mg alkylated cyclodextrin composition/mL solution aqueous solution, 320nm extremely
It is 0.4A.U. or lower under 350nm wavelength；For containing 500mg alkylated cyclodextrin composition/mL solution aqueous solution,
It is 0.4A.U. or lower under 320nm to 350nm wavelength；For the aqueous solution containing 200mg alkylated cyclodextrin composition,
It is 0.3A.U. or lower under 320nm to 350nm wavelength；For containing 300mg alkylated cyclodextrin composition/mL solution water
Solution is 0.3A.U. or lower at 320nm to 350nm wavelength；For molten containing 400mg alkylated cyclodextrin composition/mL
The aqueous solution of liquid is 0.3A.U. or lower at 320nm to 350nm wavelength；For being combined containing 500mg alkylated cyclodextrin
Object/mL solution aqueous solution is 0.3A.U. or lower at 320nm to 350nm wavelength；For containing 200mg alkylation ring paste
Smart composition/mL solution aqueous solution is 0.2A.U. or lower at 320nm to 350nm wavelength；For containing 300mg alkyl
Change cyclodextrin composite/mL solution aqueous solution, is 0.2A.U. or lower at 320nm to 350nm wavelength；For containing
400mg alkylated cyclodextrin composition/mL solution aqueous solution is 0.2A.U. or lower at 320nm to 350nm wavelength；Or
Person, for being at 320nm to 350nm wavelength containing 500mg alkylated cyclodextrin composition/mL solution aqueous solution
0.2A.U. or lower.
It is not bound by any particular theory, drug degradation agent, substance or part may include one or more low molecular weight objects
Matter (for example, the substance of molecular weight less than 1,000Da), such as, but not limited in the reactive mixture with by-product and/or decomposition
The substance that Product Form generates.Therefore, drug degradation substance include but is not limited to glycoside moiety, open loop cyclodextrin substance, also
Raw sugar, glucose degradation products are (for example, 3,4- dideoxy glucosone -3- alkene, the catabolite containing carbonyl such as 2- furfural, 5-
Methylol -2- furfural etc.), and combinations thereof.
In some embodiments, alkylated cyclodextrin composition include less than 1%wt., less than 0.5%wt., be less than
0.2%wt., less than 0.1%wt., less than the alkali halide salts of 0.08%wt. or less than 0.05%wt..
In some embodiments, alkylated cyclodextrin composition include less than 1%wt., less than 0.5%wt., be less than
0.25%wt., less than 0.1%wt., less than the alkylating agent through hydrolyzing of 0.08%wt. or less than 0.05%wt..
In some embodiments, alkylated cyclodextrin composition include less than 500ppm, less than 100ppm, be less than
50ppm, less than 20ppm, less than 10ppm, less than 5ppm, less than 2ppm, less than 1ppm, less than 500ppb's or less than 250ppb
Alkylating agent.
In some embodiments, alkylated cyclodextrin composition include less than 0.5%wt., less than 0.2%wt., be less than
The underivatized cyclodextrin of 0.1%wt. or less than 0.08%wt..
" complexing " expression " become with ... inclusion compound or clathrate complex a part ", that is, the therapeutic agent of " complexing " is
A part of inclusion compound or clathrate complex with alkylated cyclodextrin.Term " major part " refers to 50% or higher, with weight
Meter or in mol.Therefore, preparation of the invention may include activating agent, the activating agent and alkyl more than about 50 weight %
Change cyclodextrin.The actual percentage of the activating agent of complexing can be made according to the complexing for characterizing specific cyclodextrin and particular active agent
Complexation equilibrium binding constant and change.The invention also includes wherein activating agents not with cyclodextrin or in which only fraction
The embodiment of activating agent and alkylated cyclodextrin complexing.It should be noted that alkylated cyclodextrin can be with positively charged compound shape
At one or more ionic bonds.No matter whether positively charged compound passes through inclusion complexing and cyclodextrin,
This ion association occurs.
As shown in fig. 6, there is such as beta-cyclodextrin and 4- hydroxybutane -1- sulphur after the ultrafiltration of SBE-CD crude product
The impurity of sour (4-HBSA).After the second column using activated carbon, beta-cyclodextrin is reduced and 4- hydroxybutane -1- sulfonic acid is miscellaneous
The amount of matter.However, as shown in fig. 6, there is a large amount of chloride in the product after two columns.
In the purification process using activated carbon, although having reduced drug degradation agent, in alkylated cyclodextrin product
In there are a large amount of chlorides.This large amount of chloride in alkylated cyclodextrin product may with active agent response and cause
Activating agent degradation.Therefore, it is necessary to the chloride level in alkylated cyclodextrin product be reduced, especially when activating agent is to chloride
When sensitive.
Determine whether activating agent sensitive to chloride, can by those of ordinary skill in the art using known technology Lai really
It is fixed.
As shown in fig. 7, after ultrafiltration, the residual level of chloride is reduced to about 0.Using two carbon columns into one
After step purifying, chloride is added back SBE-CD solution.
During active carbon sublimated, water is made to flow through carbon column, until conductivity is perseverance before adding SBE-CD solution
Fixed level.Following table is provided to water measured by carbon column and gained conductivity.It such as can be seen that from the table, even
By 70,000 liters of water for still being sent out in final SBE-CD solution in the batch of cleaning active carbon before adding SBE-CD solution
Existing chloride impurity.
Show to pass through activity in SBE-CD solution to the wider inspection of the processing before and during active carbon cycle
Occurs maximum chloride addition in the first few minutes of the circulation of carbon bed.As shown in figure 8, two SBE-CD quotient after ultrafiltration
The chloride impurity level of industry batch is approximately 0, and is dramatically increased in initial 5 minutes after activated carbon treatment, and
And the level declines after 10 minutes and 20 minutes.
As shown in figure 9, the conductivity at the end of level for being transferred to the chloride of SBE-CD solution is cleaned with water
Between exist be directly linked.In Fig. 9, the conductivity in the first carbon column and the second carbon column is measured.It was found that passing
Conductance level is horizontal related to the residual chloride in final SBE-CD solid, such as passes through the ZIC for residual chloride content
Measured by pHILIC method.Therefore, the conductivity measurement result obtained at the end of cleaning process and final SBE-CD product
In residual chloride it is horizontal related.
Those skilled in the art can be used, and commonly any method measures the chloride water of alkylated cyclodextrin composition
It is flat.In some embodiments, chloride level is measured using charged aerosol detection (CAD).
In some embodiments, the chloride level measured in alkylated cyclodextrin composition with weight ratio (w/w)
For 1% or lower, 0.9% or lower, 0.8% or lower, 0.7% or lower, 0.6% or lower, 0.5% or lower, 0.4%
Or it is lower, 0.3% or lower, 0.2% or lower, 0.1% or lower, 0.09% or lower, 0.08% or lower, 0.07% or
It is lower, 0.06% or lower, 0.05% or lower, 0.04% or lower, 0.03% or lower, 0.02% or lower or
0.01% or lower.In some embodiments, in alkylated cyclodextrin composition chloride level be 1% to 0.01%,
0.9% to 0.01%, 0.8% to 0.01%, 0.7% to 0.01%, 0.6% to 0.01%, 0.5% to 0.01%, 0.4% to
0.01%, 0.3% to 0.01%, 0.2% to 0.01%, 0.1% to 0.01%, 0.09% to 0.01%, 0.08% to
0.01%, 0.07% to 0.01%, 0.06% to 0.01%, 0.05% to 0.01%, 0.04% to 0.01% or 0.03% to
0.01%.
Can be used those skilled in the art commonly any method come measure activated carbon water cleaning eluent conductivity.?
In some embodiments, conductivity is measured using conductivity meter (conductivity meter).In some embodiments,
Conductivity is measured using the chromatography of ions.
In some embodiments, it is measured before adding partially purified alkylated cyclodextrin solution not phosphatic
The conductivity of the water cleaning eluent of activated carbon.In some embodiments, molten in the partially purified alkylated cyclodextrin of addition
Before liquid, activated carbon water clean eluent conductivity be less than 35 μ S, less than 34 μ S, less than 33 μ S, less than 32 μ S, less than 31
μ S, less than 30 μ S, less than 29 μ S, less than 28 μ S, less than 27 μ S, less than 26 μ S, less than 25 μ S, less than 24 μ S, less than 23 μ S, small
In 22 μ S, less than 21 μ S, less than 20 μ S, less than 19 μ S, less than 18 μ S, less than 17 μ S, less than 16 μ S, less than 15 μ S, less than 14 μ
S, less than 13 μ S, less than 12 μ S, less than 11 μ S, less than 10 μ S, less than 9 μ S, less than 8 μ S, less than 7 μ S, less than 6 μ S, less than 5 μ
S, less than 4 μ S, less than 3 μ S, less than 2 μ S or less than 1 μ S.In some embodiments, partially purified alkylation ring is being added
Before dextrin solution, activated carbon water clean eluent conductivity be 10 μ S to 15 μ S, 5 μ S to 15 μ S, 5 μ S to 10 μ S, 4 μ S extremely
10 μ S, 3 μ S are to 10 μ S or 4 μ S to 8 μ S.
In some embodiments, before adding partially purified alkylated cyclodextrin solution, activated carbon is cleaned 1,
2,3,4,5,6,7,8,9,10,11,12,13,14 or 15 times.In some embodiments, partially purified alkylation is being added
Before cyclodextrin solution, by activated carbon cleaning 1 time or more time, 2 times or more time, 3 times or more time, 4 times or more time, 5
Secondary or more time, 6 times or more time, 7 times or more time, 8 times or more time, 9 times or more time or 10 times or more time.
Even when washing with water the activated carbon in column, activated carbon may also not moistened fully.In cleaning operation, no
It can control the channeling by carbon bed.It should firmly believe and more thoroughly wash carbon before recycling alkylated cyclodextrin solution, it can be from
All further additions of residual chloride are reduced or removed in alkylated cyclodextrin composition product.
In some embodiments, to the dedicated reservoir system with blender and screen system (screen system)
Middle addition activated carbon.Activated carbon is loaded, then cleans the determining period with determining stirring rate with the water of several parts.It is clear in water
After washing, water layer is removed from dedicated storage tank, and carries out additional water cleaning.After additional water cleaning, measurement activity
The conductivity of carbon, and when conductivity is lower than predeterminated level, carbon suspension in water and is pumped into carbon case (carbon
Housings in).Then, activated carbon can be used for adding alkylated cyclodextrin solution.The predeterminated level of conductivity can be for example small
In 35 μ S, less than 34 μ S, less than 33 μ S, less than 32 μ S, less than 31 μ S, less than 30 μ S, less than 29 μ S, less than 28 μ S, less than 27 μ
S, less than 26 μ S, less than 25 μ S, less than 24 μ S, less than 23 μ S, less than 22 μ S, less than 21 μ S, less than 20 μ S, less than 19 μ S, small
In 18 μ S, less than 17 μ S, less than 16 μ S, less than 15 μ S, less than 14 μ S, less than 13 μ S, less than 12 μ S, less than 11 μ S, less than 10 μ
S, less than 9 μ S, less than 8 μ S, less than 7 μ S, less than 6 μ S, less than 5 μ S, less than 4 μ S, less than 3 μ S, less than 2 μ S or less than 1 μ S.
It can be stirred with revolutions per minute (rpm) to measure.In some embodiments, stirring rate can be for such as 5rpm extremely
300rpm.For example, stirring rate can for 5rpm, 10rpm, 20rpm, 30rpm, 40rpm, 50rpm, 60rpm, 70rpm, 80rpm,
90rpm or 100rpm.Mixing time can be 1 minute to 5 days.Mixing time can be such as 5 minutes, 10 minutes, 20 minutes, 30 points
Clock, 40 minutes, 50 minutes, 60 minutes, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, it is 10 small
When, 11 hours, 12 hours, 24 hours, 2 days, 3 days or 4 days.In some embodiments, mixing time be 5 minutes to 1 hour,
5 minutes to 2 hours, 5 minutes to 3 hours, 5 minutes to 4 hours, 5 minutes to 5 hours, 10 minutes to 1 hour, it is 10 minutes to 2 small
When, 10 minutes to 3 hours, 10 minutes to 4 hours, 20 minutes to 1 hour, 20 minutes to 2 hours, 20 minutes to 3 hours, 20 points
Clock was to 4 hours, 30 minutes to 1 hour, 30 minutes to 2 hours, 30 minutes to 3 hours or 30 minutes to 4 hours.
In some embodiments, reservoir system is maintained under room temperature (25 DEG C) in water cleaning process.In some realities
It applies in scheme, reservoir system can be heated in water cleaning process.In some embodiments, temperature can be such as 30 DEG C to 100
℃.For example, cooling temperature can be 30 DEG C, 40 DEG C, 50 DEG C, 60 DEG C, 70 DEG C, 80 DEG C, 90 DEG C or 100 DEG C.Heating time can be 1 point
Clock was to 5 days.Heating time may be, for example, 5 minutes to 4 days, 5 minutes to 60 minutes, 10 minutes to 50 minutes, 20 minutes to 40 points
Clock, 30 minutes to 60 minutes, 2 hours to 24 hours, 3 hours to 12 hours, 4 hours to 10 hours, 5 hours to 9 hours, it is 6 small
Up to 8 hours, 2 days to 4 days or 3 days to 4 days.In some embodiments, heating time be 5 minutes to 1 hour, 5 minutes extremely
2 hours, 5 minutes to 3 hours, 5 minutes to 4 hours, 5 minutes to 5 hours, 10 minutes to 1 hour, 10 minutes to 2 hours, 10 points
Clock to 3 hours, 10 minutes to 4 hours, 20 minutes to 1 hour, 20 minutes to 2 hours, 20 minutes to 3 hours, it is 20 minutes to 4 small
When, 30 minutes to 1 hour, 30 minutes to 2 hours, 30 minutes to 3 hours or 30 minutes to 4 hours.
In some embodiments, the cleaning active carbon in carbon case, until having reached determining conductivity.Then,
Activated carbon can be used for adding alkylated cyclodextrin solution.
In some embodiments, activated carbon is cleaned to constant conductivity, then adds the alkyl of known quantity
Change cyclodextrin solution and make it through activated carbon, the activated carbon is lost before adding other alkylated cyclodextrin solution
It abandons.
The alkylated cyclodextrin (isolated form and/or purifying or partially purified form) obtained when the method is completed
Ultimate yield can change.Based on cyclodextrin raw material, the ultimate yield of alkylated cyclodextrin can for 10% to 95%, 15% to
90%, 20% to 85%, 30% to 85%, 35% to 85%, 40% to 85%, 45% to 80%, 50% to 80%, 55% to
80%, 60% to 80%, 50% to 90%, 55% to 90%, 60% to 90%, 70% to 90%, 80% to 90%, 60% to
98%, 70% to 98%, 80% to 98% or 90% to 98%.In some embodiments, cyclodextrin raw material, alkyl are based on
The ultimate yield for changing cyclodextrin is 80% or higher, 85% or higher, 90% or higher or 95% or higher.
The purposes of alkylated cyclodextrin composition
At other on the way, alkylated cyclodextrin composition of the invention can be used for dissolving and/or stablizing a variety of different materials
Expect and is used to prepare the preparation for specific application.Alkylated cyclodextrin composition of the invention can provide other compositions and combine
Increased solubility and/or increased chemistry, heat chemistry, hydrolysis and/or photochemical stability in object.For example, alkylation ring
Dextrin composition can be used for making in an aqueous medium surfactant stabilized.Alkylated cyclodextrin composition can also be used to increase activity
The solubility of agent in an aqueous medium.
Alkylated cyclodextrin composition of the invention includes one or more activating agents.Include in the present compositions
One or more activating agents can have extensive water solubility, bioavilability and hydrophily.Present invention is especially suited for work
Property agent include water-insoluble, poorly water soluble, water-soluble, water-soluble, the complete water-soluble, hydrophobicity of water-slight soluble, moderate and/
Or hydrophilic therapeutic agent.It will be recognized by one of ordinary skill in the art that existing one or more work in the present compositions
Property agent at each occurrence independently selected from any of activating agent and be selected from those disclosed herein.One or more work
Property agent and alkylated cyclodextrin form complex compound or form ion association with alkylated cyclodextrin and be not necessary.
Activating agent generally includes the physiology of a kind of effect that animals and humans are generated with whole body or part or a variety of effects
Or pharmaceutically active substances.Activating agent further include pesticide, herbicide, insecticide, antioxidant, plant growth promoter, bactericidal agent,
Catalyst, chemical reagent, food, nutrients, cosmetics, vitamin, without bacteria inhibitor (sterility inhibitor), raw
It educates the effective activating agent of promotor, microorganism, flavoring agent, sweetener, detergent, pharmacy and other is used for pharmacy application, animal doctor
Using, horticultural applications, daily use, food applications, culinary application, agriculture application, cosmetic applications, industrial application, clean applications,
Such compound of candy application and seasoning application.Activator can with its neutrality, ion, salt, alkalinity, acidity, natural, synthesis,
Diastereo-isomerism, isomerism, enantiomer-pure, racemic, hydrate, chelate, derivative, analog or other common shapes
Formula exists.
Typical pharmacy effective active agent includes nutrients and nutritional agents, hematology medicament, endocrine and metabolism medicament, the heart
It is blood vessel medicament, kidney and apparatus urogenitalis medicament, respiratory system medicament, central nervous system agents, stomach and intestine medicament, antimycotic
Agent, anti-infective medicament, biology and immunological reagent, dermatology medicament, ophthalmology medicament, anti-tumor agents and diagnosticum.Show
Example property nutrients and nutritional agents include such as minerals, microelement, amino acid, anti-fatty liver medicament, enzyme and chelating agent.It is exemplary
Hematology medicament includes hematinic, anti-platelet agents, anticoagulant, cumarin and indandione derivative, flocculating agent, dissolution
Thrombus medicament, anti-sickle cell form medicament, hemorheology medicament, antihemophilic medicament, hemostat, plasma expander and chlorine
Change ferroheme.Exemplary endocrine and metabolism medicament includes sex hormone, uterus activating agent, diphosphonate, anti-diabetic medicament, rises
Blood glucose medicament, corticosteroid, adrenocorticotro, parathryoid hormone, thyroid gland drug, growth hormone, pituitary
Posterior lobe hormone, octreotide acetate, Imiglucerase, salmon calcitonin, phenylbutyrate sodium, anhydrous betaine, cysteamine weight winestone hydrogen
Hydrochlorate, sodium benzoate and sodium, bromocriptine methanesulfonate, Cabergoline, medicament and antidote for gout.It is suitable
Antifungal agent for alkylated cyclodextrin composition of the invention include but is not limited to posaconazole, voriconazole, clotrimazole,
Ketoconazole, former times chaff azoles, Sertaconazole, tetconazole, Fluconazole, Itraconazole and Miconazole difficult to understand.It is suitable for the invention alkane
The antipsychotic agent of base cyclodextrin composite include but is not limited to Clozapine, prochlorperazine, haloperidol, Methotrexate,
Thiothixene, Risperidone, trifluoperazine hydrochloride, chlorpromazine, Aripiprazole, loxapine, loxapine, Olanzapine, fumaric acid quinoline
Sulphur is flat, Risperidone and Ziprasidone.
Exemplary cardiovascalar agent include cereboactive drug agent, anti-arrhythmia medicament, calcium channel blockers, vasodilator,
Antiadrenergic/retardance sympathetic nerve medicine, renin-angiotensin system antagonist, hypotensor composition, for thermophilic
The medicament of chromium cytoma, the medicament for hypertension emergency, lipidemia medicament, lipidemia compound artifact, for shock
Vasopressor, potassium-removing resin, natrium adetate, cardioplegic solution, medicament and curing agent for patient's arterial duct.
Exemplary kidney and apparatus urogenitalis medicament include interstitial cystitis medicament, sodium cellulose phosphate, Alibra agent, vinegar azanol
Sour (aha), apparatus urogenitalis flushing liquor, cystine disrupting agent (cystine-depleting agent), urine basifier, uric acid
Agent, anticholinergic agents, urine cholinergic drug, polymeric phosphate adhesive, vagina preparation and diuretics.Exemplary breathing system
System medicament include bronchodilator, leukotriene receptor antagonists, leukotriene formed inhibitor, respiratory system inhalant product,
Nasal decongestant, respiratory system enzyme, Curosurf, antihistamine, non-narcotic pectoral and expectorant.Example sexual centre mind
Through system medicament include CNS stimulant, anesthesia agonist antalgesic, anesthesia agonists-antagonists antalgesic, central analgesia medicine,
Paracetamol, salicylate, non_narcotic analgesics, nonsteroid anti-inflammatory drugs agent, the medicament for migraine, antemetic/
Combating vertigo medicament, antianxiety medicament, antidepressants, anti-neuropathy medicament, anticholinesterase, non-barbiturate sedative
With somnifacient, over the counter sleep aid, barbiturate Hypnotics and sedatives, general anesthetic, injectable local anesthetic, anti-
Convulsant, muscle relaxant, anti-Parkinson medicament, adenosine phosphate, cholinergic muscular irritation agent, two sulphur are grand, smoke Inhibitors, benefit
Shandong azoles, derivatives of hyaluronic acids and botulin toxin.Exemplary stomach and intestine medicament includes helicobacter pylori medicament, 2 antagonism of histamine H
Agent, proton pump inhibitor, ulcerlmin, prostaglandin, antacids, stomach anticholinergic agents/anti-spasm drug, mesalazine,
Olsalazine sodium, balsalazide disodium, salicylazosulfapyridine, celecoxib, infliximab, Tijiaseluo maleate, cathartic,
Antidiarrheal agent, anti-flatulence agent, lipase inhibitor, GI stimulant, digestive ferment, gastric acid agent, hydrocholeretics, cholelith increase
Menstruum, mouth and throat's product, systemic deodorant and anorectal preparation.Exemplary anti-infective medicament include penicillin,
Cephalosporin and associated antibiotic, carbapenem, monobactam, chloramphenicol, quinolone, fluoquinolone, tetracycline, in big ring
Esters, spectinomycin, streptogramin, vancomycin, oxalodinone, lincosamides, oral and parenteral ammonia
Base glucoside, Clistin-M Vial, polymyxins b sulfate, bacitracin, flagyl, sulfonamides, nitro furan
Mutter, methenamine, antifol, antifungal agent, antimalarial agents, anti-binding medicament, amebicide, antiviral drugs,
Antiretroviral agent agent, antileprotic, antiprotozoal agent, antihelmintic and the anti-infective medicament of cdc.Exemplary bio and
Immunological reagent includes immunoglobulin, monoclonal antibody formulation, antivenin, the medicament, abnormal anti-for active immunity
Answer former extract, immuning agent and antirheumatic medicament.Exemplary skin disease medicament includes external application antihistamine formulations, the anti-sense of external application
Contaminate medicine, anti-inflammatory agents, antipsoriatic agent, seborrhea product, Arnica, astringent, detergent, capsaicine, destructive medicine
Agent, desiccant, enzyme preparation, external application immunomodulator, keratolytic agent, liver derivative complex compound, external application local anesthetic, rice
Promise that, Eflornithine hydrochloride, photochemotherapeutic agent, pigment preparation, external application poison ivy product, external application Pyrimidine antagonists,
Vancide ZP, retinoids, rexinoid, scabicide/pediculicide, Wound-healing agent, softening agent, protective agent, opacifier,
Ointment and lotion base, rubbing agent and liniment, dressing and granule and physiology irrigating solution.Exemplary ophthalmic medicament includes using
In the medicament of glaucoma, mast cell stabilizers, ophthalmology preservative, ophthalmology phototherapy agent, eye lubricant, artificial tears, ophthalmology
Hypertonicity preparation and contact lense product.Exemplary anti-tumor agents include alkylating agent, antimetabolite, antimitotic drug, table ghost
Mortar toxin, antibiotic, hormone, enzyme, radiopharmaceutical, platinum coordination complex, amerantrone, substituted urea, methyl hydrazine derivative, imidazoles
And tetrazine derivatives, cell-protecting, DNA topoisomerase inhibitors, biological answer-reply instrumentality, retinoids,
Rexinoid, monoclonal antibody, proteintyrosine kinase inhibitor, porfimer, mitotane (o, p '-ddd) and three oxidations
Two arsenic.Exemplary diagnostics preparation includes in-vivo diagnostic adminicle, in-vivo diagnostic biological agent and contrast agent.
Exemplary active agents further include the compound sensitive to chloride level.Exemplary chloride Sensitive active agent packet
Include proteasome inhibitor, for example, bortezomib, disulfiram, epigallocatechin-3-gallate,
Salinosporamide A and Carfilzomib (carfilzomib).
Activating agent listed above is not considered as exhaustion, and is only many embodiments that the scope of the invention is thought
Illustration.Many other activating agents can be administered together with preparation of the invention.
Preparation of the invention can be used for delivering two or more different activating agents.It can provide in preparation of the invention
The specific combination of activating agent.Some combinations of activating agent include: the first drug for 1) treating classification from first and come from identical
Treatment classification the second different drugs；2) from first treatment classification the first drug and from different treatment classifications
The second different drugs；3) the first drug with first kind bioactivity and the difference with roughly the same bioactivity
The second drug；Not with the first drug 4) with first kind bioactivity and with different Second Type bioactivity
The second same drug.This document describes the example combinations of activating agent.
It include that activating agent in preparation of the invention can exist in the form of its pharmaceutically acceptable salt.Such as this paper institute
With, " pharmaceutically acceptable salt " refers to the derivative of disclosed compound, wherein by optionally by activating agent and acid and/or
Alkali reacts to form ionic bonding to modify it.The example of pharmaceutically acceptable salt includes by for example avirulent
The conventional non-toxic salts or quaternary ammonium salt for the compound that inorganic or organic acid is formed.Suitable non-toxic salts include from inorganic
Acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfonic acid, sulfamic acid, phosphoric acid, nitric acid and other acid known to persons of ordinary skill in the art
Those of salt；By organic acid such as amino acid, acetic acid, propionic acid, succinic acid, hydroxyacetic acid, stearic acid, lactic acid, malic acid, winestone
Acid, citric acid, ascorbic acid, flutter acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, to amino
Benzene sulfonic acid, Aspirin, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethionic acid, oxalic acid, isethionic acid and this field
The salt of the preparation of other organic acids known to those of ordinary skill.Being suitable for the invention pharmaceutically acceptable salt can be used comprising alkali
The activating agent of property or acidic-group is prepared by conventional chemical processes.Suitable addition salts can be found in Remington ' s
Pharmaceutical Sciences (the 17th edition, Mack Publishing Co., Easton, PA, 1985), correlation are open
Content all quotes addition herein.
The invention further relates to for making surfactant stabilized method, the method includes providing comprising alkylation ring paste
The alkylated cyclodextrin composition of essence, the phosphate less than 500ppm and the chloride less than 0.5%, wherein the alkylation ring
Being absorbed as of dextrin composition is less than 1A.U., as in the long cuvette of 1cm journey as described in containing 300mg alkylated cyclodextrin
What composition/mL solution aqueous solution was measured at 245nm to 270nm wavelength by UV/ Vis Spectrophotometry；
And it combines the alkylated cyclodextrin composition with activating agent.In some embodiments, the absorption less than 1A.U.
It is attributed to drug degradation agent.
The invention further relates to for making surfactant stabilized method, the method includes providing comprising alkylation ring paste
The alkylated cyclodextrin composition of essence, the phosphate less than 500ppm and the chloride less than 0.5%, wherein the alkylation ring
Being absorbed as of dextrin composition is less than 1A.U., as in the long cuvette of 1cm journey as described in containing 300mg alkylated cyclodextrin
What composition/mL solution aqueous solution was measured at 245nm to 270nm wavelength by UV/ Vis Spectrophotometry；
And it combines the alkylated cyclodextrin composition with activating agent.In some embodiments, the absorption less than 1A.U.
It is attributed to colour coupler.
It can carry out making surfactant stabilized method, wherein combining comprising one or more activating agents with alkylated cyclodextrin
The composition of object (comprising alkylated cyclodextrin and less than the phosphate of 500ppm) is with dry solution (dry solution), wet molten
Liquid, inhalable composition, parenteral composition, solid solution, solid mixture, particle, gel and ordinary skill people
The form of other known surfactant compositions of member exists.
In some embodiments, make surfactant stabilized method comprising one or more activating agents and alkylation ring
The composition of dextrin composition (comprising alkylated cyclodextrin and less than the phosphate of 500ppm) 80 DEG C at a temperature of keep 120
After the period of minute, 2% or less, 1.5% or less, 1% or less or 0.5% or less drug degradation agent are provided
Or colour coupler.
In some embodiments, make surfactant stabilized method comprising one or more activating agents and alkylation ring
The composition of dextrin composition (comprising alkylated cyclodextrin and less than the phosphate of 500ppm) 80 DEG C at a temperature of keep 120
Minute period after, provide 2% or less, 1.9% or less, 1.8% or less, 1.7% or less, 1.6% or less,
1.5% or less, 1.4% or less, 1.3% or less, 1.2% or less, 1.1% or less, 1% or less, 0.9% or
Less, 0.8% or less, 0.7% or less, 0.6% or less, 0.5% or less, 0.4% or less, 0.3% or less,
0.2% or less or 0.1% or less chloride.
Similarly, in some embodiments, make surfactant stabilized method comprising one or more activating agents with
Temperature of the composition of alkylated cyclodextrin composition (comprising alkylated cyclodextrin and less than the phosphate of 500ppm) at 80 DEG C
After the lower period for being kept for 120 minutes, 98% or more, 98.5% or more, 99% or more or 99.5% or more is provided
Activating agent activating agent measurement result.
In some embodiments, the antihunt means provide the alkylated cyclodextrin comprising alkylated cyclodextrin and combine
Object, the phosphate level of the alkylated cyclodextrin be less than 400ppm, be less than 300ppm, be less than 200ppm, be less than 125ppm,
Less than 100ppm, it is less than 75ppm or is less than 50ppm.
In some embodiments, the antihunt means provide the alkylated cyclodextrin comprising alkylated cyclodextrin and combine
Object, wherein the alkylated cyclodextrin composition is absorbed as 0.5A.U. or lower, to containing such as in the long cuvette of 1cm journey
There is 300mg alkylated cyclodextrin composition/mL solution aqueous solution at 245nm to 270nm wavelength by UV/ visible light light-splitting
What photometry was measured.In some embodiments, the 0.5A.U. or lower, which absorbs, is attributed to drug degradation agent.
In general, alkylated cyclodextrin is to be enough to have surfactant stabilized amount.Sufficient amount can be 0.1:1 to 10:
1, molar ratio (alkylated cyclodextrin: activating agent) of the 0.5:1 to 10:1,0.8:1 to 10:1 or 1:1 to 5:1.
Cyclodextrin in composition need not be in conjunction with other substances such as activating agent present in the preparation containing the cyclodextrin.
However, if cyclodextrin in conjunction with another substance, can be formed, hydrogen bond and/or Van der Waals phase because of inclusion complexing, ion pair
Interaction and form such key.
Anionic derivatized cyclodextrin can (acid-ionizable) ionizable with acid substance complexing or combine.As herein
Any compound used, that the ionizable substance of term acid is used to mean to become to ionize in the presence of acid or be ionized.
The ionizable substance of acid includes at least one acid for becoming to ionize when being exposed to acid or when being placed in acid medium can
The functional group of ionization.The ionizable functional group of exemplary acids includes primary amine, secondary amine, tertiary amine, quaternary ammonium, aromatic amine, unsaturated amine, primary
Other groups known to mercaptan, secondary mercaptan, sulfonium, hydroxyl, enol and chemical field those of ordinary skill.
The ionizable substance of acid combines the combination of generation to pass through inclusion complexing relatively and forms generation by non-covalent ionic
In conjunction with degree can be used for example1H-NMR、13The method of C-NMR or circular dichroism and by the ionizable substance of analysis acid and
The phase solubility data of anionic derivatized cyclodextrin carrys out spectroscopic assay.Those of ordinary skill in the art are able to use these routines
Method estimates the amounts of all kinds of combinations occurred in solution, to determine that the combination between substance mainly passes through non-covalent ionic knot
It closes and occurs still mainly to form generation by clathrate complex.It combines in non-covalent ionic and is more accounted for than clathrate complex formation
In the case where advantage, though phase solubility data shows there is significant combination between substance in this case, but by NMR or
The amount that clathrate complex measured by circular dichroism is formed can be reduced；Moreover, under those circumstances, being determined by phase solubility data
The ionizable substance of acid intrinsic solubility would generally be higher than it is expected horizontal.
As used herein, term " non-covalent ionic " refers to the key formed between anionic species and cationic substance.
The key is non-covalent, so that described two substances are formed together salt or ion pair.Anionic derivatized cyclodextrin provides institute
The anionic species of ion pair are stated, and the ionizable substance of acid provides the cationic substance of the ion pair.Due to anion
Derivatized cyclodextrin is multivalence, thus substance that alkylated cyclodextrin can be ionizable with one or more acid or other sun from
Sub- substance forms ion pair.
Liquid preparation of the invention can be converted into the solid pharmaceutical preparation for redissolution.The solid composite redissolved of the invention
Include activating agent, derivatized cyclodextrin and at least one other drugs excipient being optionally present.The composition that can be redissolved is available
Waterborne liquid is redissolved to form the liquid preparation being saved.The composition may include solid derivatized cyclodextrin and contain active
(there are the clathrate complex of bottom line extremely for the mixture of the solid of agent and at least one Solid pharmaceutical excipients being optionally present
There is no clathrate complex) so that most of activating agent is not complexed with derivatized cyclodextrin before redissolution.Alternatively, described group
Closing object may include the solid mixture of derivatized cyclodextrin and activating agent, wherein most of activating agent and derivative before redissolution
Change cyclodextrin.The solid composite that can be redissolved also may include derivatized cyclodextrin and activating agent, wherein essentially all work
Property agent or at least most of activating agent and derivatized cyclodextrin be complexed.
The solid composite that can be redissolved can be prepared according to any in following methods.Liquid of the invention is prepared first
Then preparation passes through freeze-drying (freeze-drying), spray drying, atomizing freeze drying, anti-solvent (antisolvent) precipitating, nothing
Bacterium spray drying, using supercritical fluid or close to known to the various methods of supercritical fluid or those of ordinary skill in the art
Other methods formed solid, thus preparation for redissolution solid.
The liquid-carrier for including in preparation of the invention may include water liquid carrier (such as water), aqueous alcohol, aqueous
Organic solvent, non-aqueous liquid vehicles, and combinations thereof.
Preparation of the invention may include one or more drug excipients, such as conventional preservatives, defoaming agent, anti-oxidant
Agent, buffer, acidulant, basifier, swelling agent, colorant, complexing promotor, cryoprotector, electrolyte, glucose, cream
It is agent, oil, plasticizer, solubilizer, stabilizer, tension regulator, flavoring agent, sweetener, adsorbent, antiplastering aid, adhesive, dilute
It is general to release agent, direct compressible excipients, disintegrating agent, glidant, lubricant, opacifier, polishing agent, complexing agent, aromatic, this field
Known other excipient in preparation of logical technical staff, and combinations thereof.
As used herein, term " adsorbent " means that other molecules can be made by physically or chemically (chemisorption) mode
It is retained in the substance on its surface.Such compound includes that (illustrating and unrestricted) powdered charcoal and active carbon and this field are common
Other substances known to technical staff.
As used herein, term " basifier " means for providing the compound of alkaline medium for product stability.This
Class compound includes (illustrating and unrestricted) ammonia solution, ammonium carbonate, diethanol amine, monoethanolamine, potassium hydroxide, Boratex, carbon
Sour sodium, sodium bicarbonate, sodium hydroxide, triethanolamine, diethanol amine, organic amine base, basic amino acid and triethanolamine, Yi Jiben
Other substances known to the those of ordinary skill of field.
As used herein, term " acidulant " means for providing the compound of acid medium for product stability.This
Class compound includes (illustrate and unrestricted) acetic acid, acidic amino acid, citric acid, fumaric acid and other alpha-hydroxy acids, hydrochloric acid, anti-bad
Hematic acid, phosphoric acid, sulfuric acid, tartaric acid and nitric acid and other substances known to persons of ordinary skill in the art.
As used herein, term " antiplastering aid " means to prevent solid dosage form formulation ingredient from adhering to tabletting during the preparation process
The punching of machine and the substance of punch die.Such compound includes (illustrating and unrestricted) magnesium stearate, talcum, calcium stearate, behenyl
Acid glyceride, polyethylene glycol, hydrogenated vegetable oil, mineral oil, stearic acid and other objects known to persons of ordinary skill in the art
Matter.
As used herein, term " adhesive " means the object for causing the powder particle in solid dosage form formulation to bond
Matter.Such compound includes (illustrating and unrestricted) Arabic gum, alginic acid, sodium carboxymethylcellulose, poly- (ethenyl pyrrolidone
Ketone), sompressible sugar, ethyl cellulose, gelatin, liquid glucose, methylcellulose, povidone and pregelatinized starch, Yi Jiben
Other substances known to the those of ordinary skill of field.
It when needed, also may include adhesive in the dosage form.Exemplary adhesive includes Arabic gum, bassora gum, bright
Glue, starch, cellulosic material such as methylcellulose and sodium carboxymethylcellulose, alginic acid and its salt, polyethylene glycol, guar gum,
Polysaccharide, bentonite, sugar, inverted sugar, poloxamer (PLURONICTMF68、PLURONICTMF127), collagen, albumin, gelatin,
Cellulosic materials, their combination and other adhesives known to persons of ordinary skill in the art in non-aqueous solvent.Its
His adhesive include for example polypropylene glycol, polyoxyethylene-polyproplyene copolymer, polyvinyl ester, polyethylene sorbitan ester,
Polyethylene oxide, their combination and other substances known to persons of ordinary skill in the art.
As used herein, conventional preservatives be at least reduced after pollution biological load amount increase speed but keep life
Object load is stable or reduces the compound of biological load amount.Such compound includes (illustrating and unrestricted) benzalkonium chloride, benzyl
Rope oronain, benzoic acid, benzyl alcohol, cetylpyridinium chloride, methaform, phenol, benzyl carbinol, phenylmercuric nitrate, phenylmercuric acetate, sulphur
Willow mercury, metacresol, nutmeg γ-picoline chloride, Potassium Benzoate, potassium sorbate, sodium benzoate, sodium propionate, sorbic acid, musk deer
Vanilla phenol, methylparaben, ethylparaben, propylben or butyl hydroxybenzoate and those of ordinary skill in the art are
Other substances known.It should be understood that some preservatives can interact with alkylated cyclodextrin, the effect of preservative is thus reduced
Power.However, passing through the concentration of the selection and preservative and alkylated cyclodextrin that adjust preservative, it is possible to find fully make alkyl
Change cyclodextrin corrosion-resistant preparation.
As used herein, term " diluent " or " filler " mean serving as filler in the system of liquid or solid dosage form
The inert substance of desired volume, flowing property and compression property is generated in agent.Such compound includes (illustrating and unrestricted)
It is liquid-carrier (such as water, alcohol, solvent etc.), calcium monohydrogen phosphate, kaolin, lactose, dextrose, magnesium carbonate, sucrose, mannitol, micro-
Crystalline cellulose, powdered cellulose, winnofil, D-sorbite and starch and it is known to persons of ordinary skill in the art its
His substance.
As used herein, term " direct compressible excipients " means the compound in the solid dosage forms for compression.It is such
Compound includes (illustrating and unrestricted) calcium monohydrogen phosphate and other substances known to persons of ordinary skill in the art.
As used herein, term " antioxidant " means to inhibit to aoxidize and is accordingly used in preventing by caused by oxidation process
The rotten substance of preparation.Such compound includes (illustrate and unrestricted) acetone, inclined potassium bisulfite, potassium sulfite, anti-bad
Hematic acid, ascorbyl palmitate, citric acid, Butylated Hydroxyanisole, Butylated Hydroxytoluene, hypophosphorous acid, monothioglycerol, gallic acid third
Ester, sodium ascorbate, sodium citrate, vulcanized sodium, sodium sulfite, sodium hydrogensulfite, sodium formaldehyde sulfoxylate, thioacetic acid,
EDTA, pentaacetic acid, sodium metabisulfite and other substances known to persons of ordinary skill in the art.
As used herein, term " buffer " means the chemical combination for being used to resist pH variation after dilution or addition acid or alkali
Object.Such compound includes (illustrating and unrestricted) acetic acid, sodium acetate, adipic acid, benzoic acid, sodium benzoate, boric acid, boric acid
Sodium, citric acid, glycine, maleic acid, sodium dihydrogen phosphate, dibastic sodium phosphate, 4- (2- hydroxyethyl) -1- piperazine ethanesulfonic acid, lactic acid,
Tartaric acid, potassium metaphosphate, potassium phosphate, acetic acid hydrogen sodium, sodium bicarbonate, three (methylol) aminomethanes, sodium tartrate, anhydrous lemon
Sour sodium and trisodium citrate dihydrate and other substances known to persons of ordinary skill in the art.
Complexing promotor can be added into preparation of the invention.When there are substance of this kind, cyclodextrin/activating agent can be changed
The ratio between.Complexing promotor is the one or more compounds for promoting the complexing of activating agent and cyclodextrin.Suitable complexing promotor
Water-soluble polymer, hydroxy acid including one or more pharmaceutical inerts and commonly used in promoting specific work through corrosion-resistant preparation
Other organic compounds of property agent and the complexing of cyclodextrin.
Hydrophilic polymer can be used as that promotor, solubilizer and/or water activity reduction agent is complexed, anti-comprising CD system to improve
The performance of the preparation of rotten agent.Loftsson have been disclosed it is a large amount of be suitable for combining with cyclodextrin (underivatized or derivatization) make
To enhance the performance of cyclodextrin and/or the polymer of property.Suitable polymer is disclosed in Pharmazie 56:746
(2001)；Int.J.Pharm.212:29(2001)；Cyclodextrin:From Basic Research to Market,
10th Int'l Cyclodextrin Symposium,Ann Arbor,MI,US,May 21-24,p.10-15(2000)；PCT
Int'l Pub.No.WO 99/42111；Pharmazie 53:733(1998)；Pharm.Technol.Eur.9:26(1997)；
J.Pharm.Sci.85:1017(1996)；0th 579 No. 435 European patent application；Proc.of the 9th Int'l
Symposium on Cyclodextrins,Santiago de Comostela,ES,May 31-June3,1998,pp.261-
264(1999)；S.T.P.Pharma Sciences9:237(1999)；Amer.Chem.Soc.Symposium Series 737
(Polysaccharide Applications):24-45(1999)；Pharma.Res.15:1696(1998)；Drug
Dev.Ind.Pharm.24:365(1998)；Int.J.Pharm.163:115(1998)；Book of Abstracts,216th
Amer.Chem.Soc.Nat'l Meeting,Boston,Aug.23-27 CELL-016(1998)；J.Controlled
Release44:95(1997)；Pharm.Res.(1997)14(11),S203；Invest.Ophthalmol.Vis.Sci.37:
1199(1996)；Proc.of the 23rd Int'l Symposium on Controlled Release of
Bioactive Materials 453-454(1996)；Drug Dev.Ind.Pharm.22:401(1996)；Proc.of the
8th Int'l Symposium on Cyclodextrins,Budapest,HU,Mar.31-Apr.2,1996,pp.373-376
(1996)；Pharma.Sci.2:277(1996)；Eur.J.Pharm.Sci.4S:S144(1996)；3rd Eur.Congress
of Pharma.Sci.Edinburgh,Scotland,UK September 15-17,1996；Pharmazie 51:39
(1996)；Eur.J.Pharm.Sci.4S:S143(1996)；5,472,954th and No. 5,324,718 United States Patent (USP)；
Int.J.Pharm.126:73(1995)；Abstracts of Papers of the Amer.Chem.Soc.209:33-CELL
(1995)；Eur.J.Pharm.Sci.2:297(1994)；Pharm.Res.11:S225(1994)；Int.J.Pharm.104:
181(1994)；And in Int.J.Pharm.110:169 (1994), entire contents integrally quote addition herein.
Other suitable polymer are the well known excipient for being usually used in field of pharmaceutical preparations, and are included in for example
Remington's Pharmaceutical Sciences, the 18th edition, pp.291-294, A.R.Gennaro (editor),
Mack Publishing Co.,Easton,PA(1990)；A.Martin et al., Physical Pharmacy.Physical
Chemical Principles in Pharmaceutical Sciences, the 3rd edition, pp.592-638 (Lea&Febinger,
Philadelphia,PA(1983)；A.T.Florence et al.,Physicochemical Principles of
Pharmacy, second edition, pp.281-334, in MacMillan Press, London, UK (1988), entire contents are integrally helped
Draw addition herein.Other suitable polymer include that water-soluble natural polymer, water-soluble semi synthetic polymer are (such as water-soluble
Cellulose derivative) and water-soluble synthetic polymer.Natural polymer includes polysaccharide such as synanthrin, pectin, phycocolloid derivative (example
Such as mosanom) and agar and polypeptide such as casein and gelatin.Semi synthetic polymer includes cellulose derivative, such as methyl
Cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, their compound ether such as hydroxypropyl methyl cellulose and other mixing
Ether such as hydroxyethyl ethylcellulose, Hydroxypropyl ethyl cellulose, hydroxypropyl methylcellulose phthalate and carboxymethyl
Cellulose and its salt (especially sodium carboxymethylcellulose).Synthetic polymer includes polyoxyethylene deriv (polyethylene glycol) and gathers
Various copolymer (the examples of ethenyl derivatives (polyvinyl alcohol, polyvinylpyrrolidone and polystyrenesulfonate) and acrylic acid
Such as carbomer).Meeting water solubility, pharmaceutical acceptability and pharmacology passivity not named here, other are natural, semi-synthetic
It is also included in the scope of the present invention with synthetic polymer.
As used herein, aromatic is a kind of substance for generating the relative volatility of detectable fragrance, smell or fragrance
Or the combination of many kinds of substance.Exemplary aromatic agent includes by United States Food and Drag Administration (U.S.Food and Drug
Administration) it is generally recognized as safe those.
As used herein, term " glidant " means the mobility for promoting solid matter in solid dosage form formulation
Substance.Such compound includes (illustrating and unrestricted) colloidal silicon dioxide, cornstarch, talcum, calcium silicates, magnesium silicate, glue
Body silicon, calcium phosphate, silicone-hydrogel and other substances known to persons of ordinary skill in the art.
As used herein, term " lubricant " means for reducing the frictional force in compression process in solid dosage form formulation
Substance.Such compound includes (illustrate and unrestricted) calcium stearate, magnesium stearate, polyethylene glycol, talcum, mineral oil, hard
Resin acid and zinc stearate and other substances known to persons of ordinary skill in the art.
As used herein, term " opacifier " means for making to be coated opaque compound.Opacifier can be used alone
Or it is used with colorant combination.Such compound includes (illustrating and unrestricted) titanium dioxide, the common skill of talcum and this field
Other substances known to art personnel.
As used herein, term " polishing agent " means the compound for assigning the attractive gloss of solid dosage forms.This
Class compound includes (illustrating and unrestricted) Brazil wax, Chinese wax and other objects known to persons of ordinary skill in the art
Matter.
As used herein, term " disintegrating agent " means to be used in solid dosage forms to promote solid matter to split into more easily quilt
The compound of the smaller particle dispersed or dissolved.Exemplary disintegrating agent includes that (illustrating and unrestricted) starch such as corn forms sediment
Powder, potato starch, their pregelatinized starch and modified starch；Sweetener；Clay；Bentonite；Microcrystalline cellulose (such as)；Calcium carboxymethylcellulose；Croscarmellose sodium；Alginic acid；Mosanom；Cellulose polacrilin potassium (example
Such as), alginates, primojel, natural gum, agar, guar gum, locust bean, karaya, pectin, yellow alpine yarrow
Glue, Crospovidone and other substances known to persons of ordinary skill in the art.
As used herein, term " stabilizer " means for making therapeutic agent for that can reduce the physics mistake of its therapeutic activity
Journey, chemical process or the stable compound of Biochemical processes.Suitable stabilizer includes (illustrating and unrestricted) albumin, saliva
Liquid acid, kreatinin, glycine and other amino acid, niacinamide, acetyl-l-tryptophan sodium (sodium
Acetyltryptophonate), zinc oxide, sucrose, glucose, lactose, D-sorbite, mannitol, glycerol, polyethylene glycol,
Sodium Caprylate and saccharin sodium and other substances known to persons of ordinary skill in the art.
As used herein, term " tension regulator " means one or more chemical combination of the tension for adjusting liquid preparation
Object.Suitable tension regulator includes glycerol, lactose, mannitol, dextrose, sodium chloride, sodium sulphate, D-sorbite, seaweed
Sugar and other materials known to persons of ordinary skill in the art.In some embodiments, the tension of the liquid preparation connects
The tension of nearby bleeding liquid or blood plasma.
As used herein, term " defoaming agent " means the foam for preventing from being formed on liquid preparation surface or reduces the foam
Amount one or more compounds.Suitable defoaming agent includes dimethicone, dimethicone, Octoxinol and ability
Other substances known to the those of ordinary skill of domain.
Term " swelling agent " used herein means for the volume of increase solid product during freeze-drying and/or helps
In the compound of the property of control preparation.Such compound includes (illustrating and unrestricted) glucan, trehalose, sucrose, poly- second
Vinyl pyrrolidone, lactose, inositol, D-sorbite, dimethyl sulfoxide, glycerol, albumin, calcium lactobionate and this field
Other compounds known to those of ordinary skill.
As used herein, term " cryoprotector " means for protection activity therapeutic agent from the physics in freeze-drying process
Or the compound of chemical degradation effect.Such compound includes (illustrating and unrestricted) dimethyl sulfoxide, glycerol, trehalose, third
Glycol, polyethylene glycol and other compounds known to persons of ordinary skill in the art.
As used herein, term " emulsifier (emulsifier) " or " emulsifier (emulsifying agent) " mean
The compound added to stablize the purpose of the interior phase drop in foreign minister into one or more phase components of lotion.Suchization
Closing object includes (illustrate rather than limit) lecithin, polyoxyethylene polyoxypropylene ether, polyoxyethylene-sorbitan list laurel
Acid esters, polysorbate, sorbitan ester, stearyl alcohol, tyloxapol, bassora gum, xanthan gum, Arabic gum, agar, algae
Acid, mosanom, bentonite, carbomer, sodium carboxymethylcellulose, cholesterol, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose,
Octoxinol, oleyl alcohol, polyvinyl alcohol, povidone, propylene glycol monostearate, lauryl sulfate ester sodium and this field are common
Other compounds known to technical staff.
Solubilizer can be added into composition of the invention.Solubilizer is the solubility for enhancing activating agent in liquid preparation
One or more compounds.When there are such reagent, the ratio between cyclodextrin/activating agent can be changed.Suitable solubilizer packet
Include one or more organic solvents, cleaning agent, soap, surfactant and commonly used in parenteral administration to enhance particular drug
Other organic compounds of the solubility of agent.
Suitable organic solvent include for example ethyl alcohol, glycerol, polyethylene glycol, propylene glycol, poloxamer (poloxomer),
And other substances known to persons of ordinary skill in the art.
Preparation comprising alkylated cyclodextrin composition of the invention may include oil (for example, fixed oil, peanut oil, sesame
Sesame oil, cottonseed oil, corn oil, olive oil etc.), fatty acid (for example, oleic acid, stearic acid, isostearic acid etc.), aliphatic ester (example
Such as, ethyl oleate, isopropyl myristate etc.), fatty glyceride, acetylated fatty acid glyceride, and combinations thereof.Comprising this
The preparation of the alkylated cyclodextrin composition of invention also may include alcohol (for example, ethyl alcohol, isopropanol, hexadecanol, glycerol, the third two
Alcohol etc.), glycerol ketals (for example, 2,2- dimethyl -1,3-dioxolane -4- methanol etc.), ether is (for example, poly(ethylene glycol) 450
Deng), petroleum hydrocarbon (for example, mineral oil, vaseline etc.), water, surfactant, suspending agent, emulsifier, and combinations thereof.
It should be appreciated that the compound for field of pharmaceutical preparations usually plays multiple functions or purpose.Therefore, if herein
The compound referred to referred only to primary or was used to define more than one term herein, then its purpose or function should not be explained
To be only limitted to mentioned purpose or function.
Preparation comprising alkylated cyclodextrin composition of the invention also may include one or more biogenic salts, sodium chloride,
Potassium chloride or other one or more electrolyte.
Since some activating agents are by oxidative degradation, liquid preparation of the invention can be substantially free of oxygen.Example
Such as, by with inert gas (for example, nitrogen, argon gas, carbon dioxide etc.) purge the container containing liquid preparation headspace,
Or by bubbling inert gas by liquid preparation, can be made the headspace it is not oxygenous, substantially free of oxygen or oxygen
Gas is reduced.For long term storage, the liquid preparation of the activating agent comprising influencing vulnerable to oxidative degradation can be stored in not oxygenous
Or in the environment of oxygen reduction.Oxygen is removed from preparation can improve the preservation that preparation resists aerobic microbiological；And into preparation
Oxygen, which is added, can improve the preservation for resisting anaerobe.
Phrase " pharmaceutically acceptable ", which is used herein to mean that in the range of reasonable medical judgment, to be suitable for and people
The tissue of class and animal contact without excessive toxicity, stimulation, allergic reaction or with it is reasonable be benefited/Hazard ratio it is comparable its
Those of his problem or complication compound, material, composition and/or dosage form.
As used herein, term " patient " or " individual " be for indicating warm-blooded animal such as mammal, such as cat, dog, small
Mouse, cavy, horse, ox, sheep, non-human and the mankind.
Preparation of the invention can include a effective amount of activating agent.Term " effective quantity " expression is adequate to bring about needs or desired
The amount or quantity of the activating agent of reaction, or in other words, the amount of appreciable biological respinse is adequate to bring about when being administered to individual.
Composition of the invention may be present in the preparation of following dosage form, such as can redissolve solid, tablet, capsule, ball
Agent, pastille, patch, permeability apparatus, stylus (stick), suppository, implantation material, glue agent (gum), effervescence combination, injection,
Eye or nose solution or inhalable powder or solution.
It include the liquid preparation of one or more activating agents and alkylated cyclodextrin composition the present invention also provides preparation
Method, wherein the alkylated cyclodextrin composition includes alkylated cyclodextrin and the phosphate less than 500ppm.The first side
Method includes: to form the first aqueous solution comprising alkylated cyclodextrin composition；Formed includes the second of one or more activating agents
Solution or suspension；And first solution and the second solution are mixed to form liquid preparation.Similar second method
Including one or more activating agents are directly added into the first solution without forming the second solution.The third method include directly to
Alkylated cyclodextrin composition is added in solution/suspension containing one or more activating agents.Fourth method includes to powder
The solution comprising one or more activating agents is added in last shape or microgranular alkylated cyclodextrin composition.Fifth method packet
It includes and one or more activating agents is directly added into powdered or microgranular alkylated cyclodextrin composition, and to the second solution
It is middle that resulting mixture is added.6th kind of method includes generating liquid preparation by any of the above method, then passes through freeze-drying, spray
Mist is dry, sterile spray drying, atomizing freeze drying, antisolvent precipitation, using supercritical fluid or close to supercritical fluid
Method or other methods known to persons of ordinary skill in the art are come the powder that isolates solid matter to prepare for redissolution.
The specific embodiment for preparing the method for liquid preparation includes such embodiment: 1) wherein the method is also wrapped
Include the filter medium aseptic filtration preparation for the use of aperture being 0.1 μm or bigger；It 2) wherein will by irradiation or high pressure sterilization
The liquid preparation sterilizing；3) wherein the method also includes isolating solid from the solution；4) wherein the solution is used
Nitrogen or argon gas or other inertia pharmaceutically acceptable gas purging so that it is most of be dissolved in the solution and/or with institute
The oxygen for stating solution surface contact is removed.
The present invention also provides comprising one or more activating agents, alkylated cyclodextrin composition and be optionally present at least one
The solid composite medicament of kind other drugs excipient redissolved.When the composition waterborne liquid being redissolved to be formed through anti-
When rotten liquid preparation, can by injection, by infusion, locally, be administered by sucking or by taking orally to individual.
The some embodiments for the solid composite medicament that can be redissolved include such embodiment: 1) the wherein drug
Composition is comprising alkylated cyclodextrin composition and contains one or more activating agents and at least one solid medicine being optionally present
The mixture of the solid of object excipient, so that most of activating agent is not complexed with alkylated cyclodextrin in redissolution；With/
Or 2) wherein the composition include alkylated cyclodextrin composition and one or more activating agents solid mixture, wherein
Redissolving the foregoing description, largely one or more activating agents and alkylated cyclodextrin are complexed.
Composition of the invention can be used for pharmaceutical dosage form, pharmaceutical composition or the combination of other substance of this kind.These alkylations
Cyclodextrin composite also acts as (but being not limited to) analytical reagent, foods and cosmetics adjuvant and/or additive, and is used as ring
Border cleanser.
In view of foregoing description and following embodiment, those of ordinary skill in the art can be real in the case where not excessive experiment
Trample claimed invention.With reference to the certain operations described below for being used to prepare molecule of the invention, composition and preparation
Following embodiment will be better appreciated by foregoing teachings.All references of these embodiments are used to illustrate purpose.Implement below
Example should not be construed as exhaustion, and only illustrate some in many embodiments of the invention.
Embodiment
Embodiment 1
Measure activating agent solubility
The comparative evaluation of solubilization of a variety of Sulfoalkyl ether cyclodextrin compositions to pharmaceutically active agents is determined as follows.With
Pure water prepares the 0.04M stoste of each selected cyclodextrin.By visually inspect or using Instrument measuring solution clarity.
It is visually inspected by naked eye, clear solution is at least transparent.Each pharmaceutically active agents for testing in duplicate and 2mL or
The combination of 4mL SAE-CD aqueous solution.
Weighing pharmaceutically active agents make its amount be more than its expected solubility, and are placed onThe nut of liner
In the bottle of lid.Activating agent exists with the amount of at least 3mg/mL.Then, it is filled with suitable cyclodextrin solution (2mL or 4mL) every
One bottle.Bottle is vortexed and is ultrasonically treated to assist fluid to moisten solid.Then, bottle laboratory is placed on to shake
For balancing on device (lab quake) or roll shaft mixer.Periodical visual inspection checks bottle, to ensure that solid is sufficiently humidified so as to
And it is contacted with fluid.Then the fluid in periodic sampling bottle is to measure the concentration of pharmaceutically active agents present in solution.It is logical
Sample was often measured with 24 hours intervals.
To bottle sample to measure activating agent solubility, this be by from bottle be decanted 1mL solution and subsequently optionally from
The heart carries out.Then the supernatant being filtered to remove using 0.22 μm of syringe type filter, and be diluted to mobile phase
Debita spissitudo in standard curve.Then sample is analyzed to measure the concentration of the medicaments derivative of dissolution by HPLC.
Embodiment 2
Measure water content
The water content for evaluating alkylated cyclodextrin is operated below.Use Brinkman Karl-Fischer Coulomb meter
(Brinkman Instruments Co., IL), is measured in duplicate with every part of 250mg.To the library Karl-Fischer
Logical sequence meter adds the solid cyclodextrin of known weight, and measures the total amount of water in sample.The total amount for the water that will be present is converted into solid
Thus body percentage obtains the percentage of water content of sample.
Embodiment 3
Capillary electrophoresis analysis
Operation is for passing through capillary electrophoresis analysis SAE-CD derivative composition below.It is coupled with UV absorption photometric detector
Beckman P/ACE2210 capillary electrophoresis system (Beckman Instruments, Inc., Fullereton, CA) be used for
Analyze the solution of SBE- β-CD and SBE- γ-CD derivative.Using fused silica capillary (have 50 μm of interior diameters,
57cm total length and 50cm effective length) and pH adjusted electrophoretic buffer be 30mM benzoic acid and 100mM TRIS (three hydroxyls
Methyl-amino methanol), it is separated at 25 DEG C.
Capillary is handled with following cleaning sequence before per injection: water, 0.01 N NaOH and electrophoretic buffer.
Detector is set in 214nm.Voltage is 30kV.Sample is introduced by pressure injection: 0.5psi lower 20 seconds.
Embodiment 4
α-the CD with monomodal distribution curve can be prepared according to embodiment 5 or herein cited any literature method to spread out
Biological composition, but β-CD or γ-CD is substituted using α-CD.Using the exemplary SBE- α-CD of following operation preparation, wherein using SBE
Alpha-cyclodextrin in derivatization alkaline aqueous medium is to form SBE- α-CD.α-CD is dissolved in NaOH aqueous solution, is heated to 70
DEG C, and stir, until being completely dissolved.Once dissolution is completed, reaction temperature is increased to 70 DEG C to 75 DEG C.Then, at least 30
1,4- butane sultone is added in the period of minute.PH is monitored in initial 4 hours, and it is at least another to continue reaction at 70 DEG C
Outer 16 hours.It is diluted reaction mixture cooling and with water (the about one third of total reaction volume).Solution is further used
Carbon (0.07 gram of carbon/gram cyclodextrin) processing is neutralized to pH6-6.5 with HCl, and passes through 0.45 μm of filter filtering.It uses
650MWCO film is by ultrafiltration come purification solution.Ultrafiltration endpoint is measured by Capillary Electrophoresis and osmolarity, in capillary electricity
Filtrate is not presented or is substantially not present 4- hydroxybutane -1- sulfonic acid and/or bis- (4- sulphur butyl) ether disodiums in swimming, in osmolarity
Middle infiltration sample is substantially not present or there is no ions.Solution is set to filter by 0.22 μm of filter and neutralize (pH6-6.5).It will
Acquired solution is condensed into about 50% solution under at 50 DEG C to 60 DEG C and less than 30mmHg vacuum and rotary evaporation.By solution
Freeze-drying is to generate SBE- α-CD white solid.
Embodiment 5
SBE6.6- β-CD synthesis
SBE is synthesized according to following operation6.6- β-CD composition, wherein in SBE precursor-derivedization alkaline aqueous medium
Beta-cyclodextrin is to form SBE6.6-β-CD.For 12.5%w/w solution, by 433kg water load 61.8kg sodium hydroxide come
Prepare sodium hydrate aqueous solution.Reactor content is heated to 40 DEG C to 50 DEG C, then starts to add 270kg β-CD, last
30-60 minutes.Reaction temperature is adjusted to 65 DEG C to 95 DEG C, then adds 259kg1,4- butane sultone lasts 30 to 60 points
Clock.Within next 6 hours, the pH of solution is kept above 9 using sodium hydrate aqueous solution.After reacting, to anti-
Additional 13.5kg sodium hydroxide should be loaded (with 20% solution form).Content is maintained at 70 DEG C to 80 DEG C, until Isosorbide-5-Nitrae-
The residual level of butane sultone is sufficiently low.Content is cooled to less than 30 DEG C, and with aqueous hydrochloric acid solution by reaction solution tune
It saves to 6.5-7.5.The SAE-CD of process generation 350-450kg.
Embodiment 6
SBE6.6- β-CD diafiltration and ultrafiltration
The SBE of embodiment 5 is purified by following operation6.6-β-CD.With 800kg water diluting reaction solution.Solution is turned
It moves and is further diluted with 500kg water.Using the automatic ultrafiltration system of Millipore Helicon, using at least 750ft2
Membrane area 1000MWCO spiral winding regenerated cellulose film, and liquor capacity (± 1%) is kept constant, to start infiltration
Filter, until returning to object (returnate) sample contains 25ppm or less sodium chloride.It is concentrated by ultrafiltration solution, until realizing
Suitable solution quality.
Embodiment 7
SBE of the invention6.6The processing of-β-CD carbon
After the diafiltration and ultrafiltration of embodiment 6, by following operation come carbon sublimated SBE6.6-β-CD.With 32kg (β-ring
The about 11-12%wt. (11.8-12%wt.) of dextrin initial amount)DC32 granule activated carbon loads column,
And it is thoroughly cleaned with water, until cleaning sample has constant conductivity.SBE6.6The ratio between-β-CD and activated carbon can be about
8.4:1 to 8.5:1 (about 8.44:1).After cleaning, makes reaction solution transmission (recycling) by the carbon, continue at least 2 hours, from
And complete the first process cycle.
With 32kg (the about 11-12%wt. of beta-cyclodextrin initial amount)DC32 granule activated carbon fills
The second column is carried, and is thoroughly cleaned with water, until cleaning sample has constant conductivity.After cleaning, transmit reaction solution
By the carbon, continue at least 2 hours, to complete the second processing period.
Embodiment 8
SBE6.6- β-CD concentration and isolation
The SBE by carbon treatment prepared in embodiment 7 is concentrated and isolated using following operation6.6- β-CD solution: make
SBE6.6- β-CD solution is filtered by 0.65 μm and 0.22 μm of filter, then -0.6 bar to -0.7 bar of decompression and 65 DEG C extremely
It at a temperature of 72 DEG C, is concentrated under the stirring of 70rpm to 100rpm, until realizing the SBE of solution6.6- β-CD concentration is
50%w/w.Concentrate solution is cooled to lower than 60 DEG C, 0.65 μm and 0.22 μm of filter filtering are then passed through.Then, it uses
170 DEG C of inlet temperatures, fluidised spray-dryer (" the FSD ") system of 20 bars of initial pressures and setting value are respectively 125 DEG C, 105
DEG C and 100 DEG C of room 1-3, filtered solution is spray-dried.
Embodiment 9
In D2In Bruker in OPass through on 400 or 500 instruments1H-NMR、13C-NMR, COSY-NMR and
HMQC measures cyclodextrin substitute mode
The measurement of substitute mode is carried out according to the method for the embodiment 6 of WO 2005/042584, relevant disclosure is helped
Draw addition herein.
Embodiment 10
SBE6.6- β-CD compares carbon processing
By following operation come the exemplary SBE of carbon sublimated6.6- β-CD: with 32kg (the beta-cyclodextrin initial amount of embodiment 5
About 11-12%wt. (11.8-12%wt.))DC32 granule activated carbon loads column, and thorough with water
Cleaning, until cleaning sample has constant conductivity.After cleaning, reaction solution is made to transport through the carbon, it is small to continue at least 2
When.
Embodiment 11
SBE6.6- β-CD impurity analysis I
It is concentrated and is isolated by method described in embodiment 8 and is primary with activated carbon treatment according to embodiment 10 and 7 respectively
Or SBE twice6.6- β-CD sample, is then analyzed by UV/ Vis Spectrophotometry.By will be suitable
SBE6.6- β-CD is dissolved in water (for example, through the modified 0.1g to 6g SBE of water content6.6- β-CD is dissolved in 10mL water) come
The solution comprising 1% to 60%w/w derivatized cyclodextrin is provided, to be analyzed.
The cyclodextrin analyzed on Perkin Elmer Lambda 35UV/ visible spectrophotometer by carbon treatment is molten
Liquid is scanned from 190nm to 400nm with the speed of 240nm/min, and slit width is 1.0nm.Before analysis, make sample
Blank is become to water.It provides in graphical form in fig. 1 and 2 respectively Bu Tong dense after once with activated carbon treatment twice
The SBE of degree6.6The UV/ visible absorption spectrum of-β-CD solution, described Fig. 1 and Fig. 2 provide by UV method analyze primary or
SBE after carbon processing twice6.6The diagram of-β-CD batch.It, should be statistics indicate that ought be only with activated carbon to SBE with reference to Fig. 16.6-β-
When CD solution is handled one time, there is the impurity absorbed in the visible light region UV/ of spectrum there are higher concentration.With reference to Fig. 2,
This is statistics indicate that the processing of the second carbon reduces the horizontal of UV/ visible absorption impurity by least 5 times or more.
Embodiment 12
SBE6.6- β-CD impurity analysis II
Using following operation by UV/ Vis Spectrophotometry come analysis examples SBE6.6- β-CD sample: logical
Crossing will be through the modified 54.1 grams of SBE of water content6.6- β-CD is dissolved in caustic liquor of 12.5 grams of sodium hydroxides in 100mL water
In, to prepare 50%w/w SBE6.6- β-CD solution.In Perkin Elmer Lambda 35UV/ visible spectrophotometer
Upper analysis initial soln is scanned from 190nm to 400nm with the speed of 240nm/min, and slit width is 1.0nm.It is analyzing
Before, sample is made to become sky to water.Solution is placed in 60 DEG C of furnaces, at most 168 hours.24 hours, 72 hours, it is 96 small
When and 168 hours analytical solution samples.
Fig. 3 is provided to SBE6.6- β-CD composition heat and causticity stress result diagram.It, should with reference to Fig. 3
Statistics indicate that forming significant absorption at 245nm to 270nm, and the absorption is with heat and causticity in 24 hours
The exposed duration and increase.Up to the absorption maximum value under 168 hours (7 days), 245nm to 270nm wavelength has increased
To magnitude identical with having the absorption of maximum value at about 230nm.It is furthermore noted that 320nm to 350nm wavelength under absorption also with
Exposure duration and increase.This statistics indicate that at 245nm to 270nm wavelength have absorb drug degradation impurity and
There is the colour coupler absorbed concentration increasing with the time in the case where being exposed to heat and/or severe conditions under 320nm to 350nm wavelength
Add.
Embodiment 13
Measure colour coupler
Activated carbon single treatment will be undergone or handle the SBE of (respectively according to embodiment 10 and 7) twice6.6- β-CD composition
With the antimycotic API of triazole (posaconazole, in oral aqueous suspension form purchased from Schering-Plough,)
It prepares together.It is following that formulation operations are provided.
Using lot number 17CX01.HQ00044,17CX01.HQ00037,17CX01.HQ00035,17CX01.HQ00033 and
The SBE of 17CX01.HQ000296.6- β-CD prepares the antimycotic API of triazole (5mg/mL) and SBE6.6- β-CD composition
The aqueous sample of (100mM, pH3).All solution examples are filtered by 0.22 μm of PVDF filter, and are divided in the vial.
Using PERKIN ELMER Lambda 35UV/ visible spectrophotometer (with the speed of 240nm/min from 190nm scan to
400nm, and slit width is 1.0nm) on 1cm Hunter absorption cell come the UV/ visible light that measures a part of initial soln
It absorbs, and using Hunter Labs common software (4.10 version) in Hunter LabsOn colorimeter
It is analyzed.Before measuring, sample is made to become blank to water.Then, the sample of remainder is put into 60 DEG C of furnaces, is continued
7 days, color change then was analyzed using same operation.Data are shown in the following table.
SBE6.6- β-CD initial soln: UV/ visible light analysis
SBE6.6The analysis of-β-CD solution colour
L=brightness；It is 100 for perfect white, and is 0 for black；
A=is measuring red for timing, and grey is measured when for 0, and green is measured when being negative；
B=is measuring yellow for timing, and grey is measured when for 0, and blue is measured when being negative；
Total variances √ (the Δ L of DE=and standard2+Δa2+Δb2)
Triazole API/SBE6.6The analysis of-β-CD solution colour
L=brightness；It is 100 for perfect white, and is 0 for black.
A=is measuring red for timing, and grey is measured when for 0, and green is measured when being negative；
B=is measuring yellow for timing, and grey is measured when for 0, and blue is measured when being negative；
Total variances √ (the Δ L of DE=and standard2+Δa2+Δb2)。
UV analysis confirms, when cyclodextrin composite being handled twice with activated carbon, is present in initial SBE6.6- β-CD combination
UV active impurity in object is more significantly lower.SBE6.6The Hunter color analysis of-β-CD composition shows using activated carbon twice
It handles and those of processing SBE6.6The DE value of-β-CD batch is lower.Therefore, the SBE with activated carbon treatment twice6.6- β-CD group
The colour coupler that lower impurity level results in object is closed to reduce.
Embodiment 14
SBE6.6- β-CD DS successively carries out heat treatment and carbon processing
The effect of derivatized cyclodextrin composition of the invention is heated in following research.By what is prepared according to embodiment 5
SBE6.6- β-CD composition dissolves in aqueous solution, and is analyzed using UV/ Vis Spectrophotometry.Specifically
Ground, by by 70 grams of SBE6.6- β-CD batch 17CX01.HQ00044 (correcting through water content) is dissolved in 230mL water, to make
Standby 30%w/w beta-cyclodextrin solution.It is analyzed on Perkin Elmer Lambda 35UV/ visible spectrophotometer initial molten
Liquid is scanned from 190nm to 400nm with the speed of 240nm/min, and slit width is 1.0nm.Before analysis, make sample
Blank is become to water.Solution is heated to 70 DEG C under stiring, continues 48 hours.Solution is cooled to environment temperature, and is separated.
It adds to each separated solution through pre-cleaningDC32 granule activated carbon.By SBE6.6- β-CD solution
Then stirring 3 hours uses 0.22 μm of PVDF filter filtration of active charcoal.It can using Perkin Elmer Lambda 35UV/
Light-exposed spectrophotometric analysis solution, is scanned from 190nm to 400nm, and slit width is with the speed of 240nm/min
1.0nm.Before analysis, sample is made to become blank to water.
Fig. 4 describes data in graphical form.With reference to Fig. 4, (++++) before the heat treatment is provided, it is small in heat treatment 48
When after at once (■ ■ ■ ■) and be exposed to useful load be 0.24%w/w (), 10%w/w
(--- ---), 25%w/w (◆ ◆ ◆ ◆) and 50%w/w () (according to SBE6.6- β-CD concentration) activated carbon it
Afterwards, the UV/ visible absorption of solution.Should statistics indicate that, by SBE6.6- β-CD solution is exposed to heat 48 hours, leads to 245nm extremely
Absorption maximum value under 270nm wavelength dramatically increases (about 95%).However, reducing the wave-length coverage with activated carbon treatment
It absorbs.Therefore, at 245nm to 270nm wavelength there is the drug degradation impurity absorbed to increase with heating, but can passes through
Carbon processing is to remove.
Embodiment 15
SBE6.6- β-CD DS and API stability
It is checked by UV/ Vis Spectrophotometry and HPLC analysis and is handled to handle with single or twice carbon
The SBE of different batches containing antipsychotics API (Aripiprazole)6.6The comparative evaluation of-β-CD.Provided hereinafter be used for
Evaluate SBE6.6The general operation of-β-CD/API preparation stability.
Preparation is 7.5mg/mL and SBE comprising API (Aripiprazole) concentration6.6- β-CD concentration is the API sample of 150mg/mL
The aqueous solution of product.Tartaric acid is added to water, until dissolution, then adds SBE to tartaric acid solution6.6-β-CD.Then, molten to this
Liquid adds API, and dissolves in addition in about 10 minutes.It stirs the mixture for 1 hour, heats, then by sterile
Filter filtering.Use the SBE of following batch6.6- β-CD carries out the process, and some of which experience uses the single of activated carbon
Processing, and other experience use the processing (SBE twice of activated carbon6.6- β-CD lot number 17CX01.HQ00021,
17CX01.HQ00025、17CX01.HQ00029、17CX01.HQ00035、17CX01.HQ00036、17CX01.HQ00037、
17CX01.HQ00038、17CX01.HQ00039、17CX01.HQ00040、17CX01.HQ00041、17CX01.HQ00042、
17CX01.HQ00043 and 17CX01.HQ00044).Solution example is placed in 50 DEG C of equalization chamber, at most 9 weeks.At 4 weeks
When remove sample, removed sample again at 9 weeks, and carry out HPLC analysis with measure API degradation degree.
Using following operation, aqueous sample is analyzed by UV/ Vis Spectrophotometry.By will be above-mentioned
SBE6.6- β-CD batch (correcting through water content) is dissolved in water to prepare 30%w/w beta-cyclodextrin solution.Use Perkin
Elmer Lambda 35UV/ visible spectrophotometer, the analytical solution in 1cm absorption cell, with the speed of 240nm/min from
190nm is scanned to 400nm, and slit width is 1.0nm.Before analysis, sample is made to become blank to water.Following table includes coming
From the data of the research.
SBE6.6- β-CD batch is summarized and UV content
SAE-CD&API impurity analysis
Should statistics indicate that, when API with only undergo single activated carbon treatment SBE6.6It is described when-β-CD batch is prepared together
API undergoes significant higher degradation.Include SBE6.6The API preparation of-β-CD lot number 17CX01.HQ00025 has highest UV-
Active impurity level (absorption maximum=0.44A.U.) and API 1.42% total degradation is gone through in 9 Zhou Houjing.Experience is active twice
The SBE of carbon processing6.6- β-CD batch is measured as lower in UV- active impurity level and two aspect of API palliating degradation degree.50
DEG C storage 9 weeks during occur API degradation degree it is related to the concentration of UV active impurity present in preparation.For example, comprising
SBE6.6The API preparation (it includes absorption maximum=0.05A.U. UV active impurities) of-β-CD lot number 17CX01.HQ00044 exists
Experience is only 0.35% total degradation after 9 weeks at 50 DEG C.
Fig. 5 provides SBE6.6The initial UV/ visible absorption of-β-CD batch at 245nm to 270nm wavelength at 4 weeks
The diagram of relationship between the API palliating degradation degree of measurement in 9 weeks.It, should be statistics indicate that at 4 weeks with reference to Fig. 5With 9 weeksThe degree of API degradation is with being present in SBE6.6The drug degradation of absorption UV/ visible light in-β-CD composition
The concentration of impurity and increase.
Embodiment 16
Impurity is measured by processing
Using Shimadzu Prominence 20A HPLC instrument andPHILIC column (150 × 4.6mm, 5 μm,
200A,PEEK Merck SeQuantTMSN 1479), using Corona (ESA Bioscience) charged aerosol detector,
Separation, identification and quantify after Reaction Separation purifies (embodiment 5), after ultrafiltration (embodiment 6), it is (real in the second carbon column
Apply example 7) after, the SBE after concentration (embodiment 8) and as final product6.6- β-CD sample.Use 100mM formic acid
Ammonium (pH is adjusted to 4.6), methanol, 2- propyl alcohol and acetonitrile 15/5/20/65 (A) solution and 30mM ammonium formate (pH is adjusted to
4.6), the solution of methanol, 2- propyl alcohol and acetonitrile 65/5/20/10 (B) carries out gradient mobile phase method.With the concentration of about 40mg/mL
It is prepared in HPLC grades of acetonitrile/watersSample solution, and under impurity prescribed limit, relative to known concentration
4- hydroxybutane -1- sulfonic acid, bis- (4- sulphur butyl) ether disodiums, chloride, sodium ion, phosphate, silica and β-ring paste
The reference solution that has prepared of the essence in acetonitrile/water is analyzed.Study on the efficiency has shown that this method is specific, impurity
It is linear, accurate and stable in prescribed limit.Gradient used is shown in the following table.
| Time (min) | %B |
| 0 | 20 |
| 15 | 35 |
| 28 | 90 |
| 32 | 90 |
| 36 | 15 |
| 38 | 20 |
| 45 | 20 |
As shown in fig. 6, in SBE6.6After the ultrafiltration of-β-CD crude product, there is such as beta-cyclodextrin and 4- hydroxybutane-
The impurity of 1- sulfonic acid (4-HBSA).After the second column of active carbon, decreased beta-cyclodextrin and 4- hydroxybutane -1-
The amount of sulfonic acid impurity.However, as shown in fig. 6, there is a large amount of chloride in the product after two columns.
Embodiment 17
Measure chloride concentration
It is analyzed using Corona (ESA Bioscience) charged aerosol detector and purifies (embodiment in Reaction Separation
5) after, after ultrafiltration (embodiment 6), after the second carbon column (embodiment 7), after concentration (embodiment 8), Yi Jizuo
For the SBE of final product6.6- β-CD sample, to measure chloride concentration.
As shown in fig. 7, after ultrafiltration, the residual level of chloride is reduced to about 0.Using two carbon columns into one
After step purifying, chloride is added back SBE6.6In-β-CD solution.
Embodiment 18
Measure chloride concentration
It is analyzed using Corona (ESA Bioscience) charged aerosol detector and purifies (embodiment in Reaction Separation
5) after, after ultrafiltration (embodiment 6), after being added to the first carbon column 5 minutes, 10 minutes and 20 minutes and
5 minutes, the 10 minutes and 20 minutes SBE after being added to the second carbon column6.6- β-CD sample, so that it is dense to measure chloride
Degree.
As shown in figure 8, two SBE after ultrafiltration6.6The chloride impurity level of-β-CD commercial lot is approximately 0, and
And it is dramatically increased in initial 5 minutes after activated carbon treatment, and the level declines after 10 minutes and 20 minutes.
Embodiment 19
Use the active carbon sublimated of dedicated reservoir system
Activated carbon is added to the dedicated reservoir system with blender and screen system.Activated carbon can be loaded, is then used
The water of several parts period determining with determining stirring rate cleaning.After water cleaning, water layer can be removed from dedicated storage tank, and
And it is cleaned with additional water.After additional water cleaning, the conductivity of the water of elution can be used the chromatography of ions (4.0 ×
250mm USP packet L50 similarly has mobile phase of the 4mM sodium bicarbonate in methanol/water (1:9), flow velocity 1mL/
Min, sample volume is 20 μ L, and runing time is 10min) it measures, it, can will and when conductivity is lower than predeterminated level
Carbon suspension in water, and is pumped into carbon case.Then, activated carbon can be used for adding alkylated cyclodextrin solution.
Embodiment 20
Use the active carbon sublimated SBE with predetermined conductivity6.6-β-CD
With 32kg (the about 11-12%wt. (11.8-12%wt.) of beta-cyclodextrin initial amount)DC32
Granular activated charcoal is thoroughly cleaned to load column with water, until cleaning sample has the conductivity less than 10 μ S, it is as follows
Shown in table.Using the chromatography of ions (4.0 × 250mm USP packet L50 or similarly have 4mM sodium bicarbonate in methanol/water
Mobile phase in (1:9), flow velocity 1mL/min, sample volume is 20 μ L, and runing time is 10min) measurement conductivity.
SBE6.6The ratio between-β-CD and activated carbon can be about 8.4:1 to 8.5:1 (about 8.44:1).Once cleaning, makes to react molten
Liquid transmits (recycling) by the carbon, continues at least 2 hours, to complete the first process cycle.
With 32kg (the about 11-12%wt. of beta-cyclodextrin initial amount)DC32 granule activated carbon fills
The second column is carried, and is thoroughly cleaned with water, until there is cleaning sample the conductivity less than 10 μ S (to use the chromatography of ions
(4.0 × 250mm USP packet L50 similarly has mobile phase of the 4mM sodium bicarbonate in methanol/water (1:9), and flow velocity is
1mL/min, sample volume is 20 μ L, and runing time is 10min) measured by), as shown in the table.After cleaning, make to react
Solution transports through the carbon, continues at least 2 hours, to complete the second processing period.
After the second processing period, analyzed using Corona (ESA Bioscience) charged aerosol detector
SBE6.6- β-CD is to measure chloride concentration.
As shown in the table, all samples have 0.07% or lower chloride content, and 6/9 sample have it is small
In 0.05% chloride content (detection of the chromatography of ions limits).For using prior method shown in Fig. 10, (it is being obtained for this
Less than in terms of 0.10% chloride level only with 65% success rate (44/68 sample)) measurement be a kind of improvement.
For sample shown in Fig. 10, by the prior method in activated carbon treatment period twice, (it is obtaining the chlorination less than 0.1% for this
The horizontal aspect of object only has 48% success rate (20/42 sample)) it is also significant improvement.
Embodiment 21
Activated carbon is purified to constant conductivity
32kg (the about 11-12%wt. (11.8-12%wt.) of alkylated cyclodextrin initial amount) can be used
DC32 granule activated carbon is thoroughly cleaned to load column with water, until cleaning sample has constant conductivity.It is clear in water
After washing, alkylated cyclodextrin solvent portions can be added in case, and transport through carbon, persistently the determining period, then be lost
It abandons.Other alkylated cyclodextrin solution can be added into the case, and make it through carbon, continue at least 2 hours, to complete the
One process cycle.
32kg (the about 11-12%wt. (11.8-12%wt.) of alkylated cyclodextrin initial amount) can be used
DC32 granule activated carbon is thoroughly cleaned to load the second column with water, until cleaning sample has constant conductivity.?
After water cleaning, alkylated cyclodextrin solvent portions can be added in case, and by carbon, persistently the determining period, then lost
It abandons.Other alkylated cyclodextrin solution can be added into the case, and make it through carbon, continue at least 2 hours, to complete the
One process cycle.
Conclusion
These embodiments illustrate possible embodiment of the invention.Although described above is a variety of embodiment party of the invention
Case, it should be understood that it only presents by way of example rather than limits.Those skilled in the relevant arts are it is readily apparent that without departing substantially from this
A variety of variations of form and details can be carried out in the case where the spirit and scope of invention.Therefore, range of the invention and range
It should not be limited, and should be defined according only to the following claims and their equivalents by any of above exemplary implementation scheme.
It will also be appreciated that detailed portion (rather than part of summarizing and make a summary) is intended for explaining claim.It summarizes and plucks
It can partially illustrate one or more of the invention as expected from inventor (but and not all) exemplary implementation scheme, therefore its
It is not intended to limit the invention in any way and the attached claims.
Various aspects, embodiment and option as described herein can be combined in a manner of any variation and all changes.
All references recited herein (including journal of writings or abstract, disclosed or corresponding U.S. or foreign patent
Application, publication or foreign patent or any other document) it is respectively whole quote addition herein, be included in literature cited
All data, table, figure and the text presented.
Claims (60)
1. the method for alkylated cyclodextrin composition of the preparation comprising alkylated cyclodextrin, which comprises
(a) cyclodextrin and alkylating agent are mixed to form comprising alkylated cyclodextrin, one or more undesirable components and one
The reaction environment of kind or a variety of drug degradation impurity；
(b) one or more separation are carried out to remove one or more undesirable components from the reaction environment, thus
The partially purified solution comprising the alkylated cyclodextrin and one or more drug degradation impurity is formed, wherein described
One or more separation are ultrafiltration, diafiltration, centrifugation, extraction, solvent deposition or dialysis；
(c) it is partially purified solution described in the not phosphatic activated carbon treatment of 10 μ S or lower with residual conduction rate and produces
The raw alkylated cyclodextrin；And
(d) chloride level of the alkylated cyclodextrin composition is measured；
Wherein the chloride level is 0.07% (w/w) or lower.
2. the method as described in claim 1, wherein the alkylated cyclodextrin composition also includes the phosphoric acid less than 500ppm
Salt.
3. the method as described in claim 1, wherein the alkylated cyclodextrin composition also includes the phosphoric acid less than 300ppm
Salt.
4. the method as described in claim 1, wherein the alkylated cyclodextrin composition also includes the phosphoric acid less than 200ppm
Salt.
5. the method as described in claim 1, wherein the alkylated cyclodextrin composition also includes the phosphoric acid less than 125ppm
Salt.
6. the method as described in claim 1, wherein the residual conduction rate in (c) is 9 μ S or lower.
7. the method as described in claim 1, wherein the residual conduction rate in (c) is 8 μ S or lower.
8. the method as described in claim 1, wherein the alkylated cyclodextrin composition also includes 0.05% (w/w) or less
Chloride.
9. the method as described in claim 1, wherein as detected using the charged aerosol of the detection limit with the chromatography of ions
It is measured, the alkylated cyclodextrin composition is free of the chloride of detectable level.
10. the method as described in claim 1, wherein the average substitution degree of the alkylated cyclodextrin composition is 2 to 9.
11. the method as described in claim 1, wherein the average substitution degree of the alkylated cyclodextrin composition be 4.5 to
7.5。
12. the method as described in claim 1, wherein the average substitution degree of the alkylated cyclodextrin composition is 6 to 7.5.
13. the method as described in claim 1, wherein the alkylated cyclodextrin composition is absorbed as such as existing less than 1A.U.
In the long cuvette of 1cm journey containing alkylated cyclodextrin composition/mL solution aqueous solution described in 300mg 245nm extremely
It is measured under 270nm wavelength by UV/ Vis Spectrophotometry.
14. the method as described in claim 1, wherein the alkylated cyclodextrin composition is absorbed as less than 0.5A.U., such as
In the long cuvette of 1cm journey containing alkylated cyclodextrin composition/mL solution aqueous solution described in 300mg 245nm extremely
It is measured under 270nm wavelength by UV/ Vis Spectrophotometry.
15. method as claimed in claim 13, wherein described absorb is attributed to drug degradation agent.
16. method as claimed in claim 13, wherein the absorption is in the long cuvette of 1cm journey to containing 500mg institute
Alkylated cyclodextrin composition/mL solution aqueous solution is stated at 245nm to 270nm wavelength by UV/ visible light light-splitting luminosity
What measuring method was measured.
17. the method as described in claim 1, wherein the alkylated cyclodextrin composition is absorbed as such as existing less than 1A.U.
In the long cuvette of 1cm journey containing alkylated cyclodextrin composition/mL solution aqueous solution described in 300mg 320nm extremely
It is measured under 350nm wavelength by UV/ Vis Spectrophotometry.
18. the method as described in claim 1, wherein the alkylated cyclodextrin composition is absorbed as less than 0.5A.U., such as
In the long cuvette of 1cm journey containing alkylated cyclodextrin composition/mL solution aqueous solution described in 300mg 320nm extremely
It is measured under 350nm wavelength by UV/ Vis Spectrophotometry.
19. method as claimed in claim 17, wherein described absorb is attributed to colour coupler.
20. method as claimed in claim 17, wherein the absorption is in the long cuvette of 1cm journey to containing 500mg institute
Alkylated cyclodextrin composition/mL solution aqueous solution is stated at 320nm to 350nm wavelength by UV/ visible light light-splitting luminosity
What measuring method was measured.
21. the method as described in claim 1, wherein the not phosphatic activated carbon is cleaned with solvent, until elution
Solvent has reached the residual conduction rate in (c).
22. the method as described in claim 1, wherein the not phosphatic activated carbon is washed with water, until the water of elution
Have reached the residual conduction rate in (c).
23. the method as described in claim 1, wherein the alkylated cyclodextrin is the sulfoalkyl ether cyclodextrin of formula (II):
Wherein p is 4,5 or 6, and R1At each occurrence independently selected from-OH or-O- (C2-C6Alkylidene)-SO3 -- T, wherein
For T at each occurrence independently selected from pharmaceutically acceptable cation, condition is at least one R1It is-OH and at least one R1It is
O-(C2-C6Alkylidene)-SO3 --T。
24. method as claimed in claim 23, wherein R1At each occurrence independently selected from-OH or-O- (C4Alkylidene)-
SO3 -- T, and-T is Na at each occurrence+。
25. the method as described in claim 1 further includes by the alkylated cyclodextrin composition and one or more figurations
Agent combination.
26. the method as described in claim 1 further includes combining the alkylated cyclodextrin composition with activating agent.
27. method as claimed in claim 26, wherein the activating agent is selected from bortezomib, disulfiram, epigallocatechin gallate
The chloride Sensitive active agent of theine -3- gallate, salinosporamide A and Carfilzomib.
28. method as claimed in claim 27, wherein the chloride Sensitive active agent is Carfilzomib.
29. product is being prepared by the method as described in any one of claim 1 to 28.
30. alkylated cyclodextrin composition, it includes:
The alkylated cyclodextrin that average substitution degree is 2 to 9；
Phosphate less than 500ppm；And
0.07% (w/w) or less chloride；
Wherein the alkylated cyclodextrin composition is absorbed as being less than 1A.U., such as to containing in the cuvette that 1cm journey is grown
The composition of alkylated cyclodextrin described in 300mg/mL solution aqueous solution passes through UV/ visible light point at 245nm to 270nm wavelength
Light photometry is measured.
31. alkylated cyclodextrin composition as claimed in claim 30, wherein the alkylated cyclodextrin composition includes
0.05% (w/w) or less chloride.
32. alkylated cyclodextrin composition as claimed in claim 30, wherein as limited using the detection with the chromatography of ions
Charged aerosol measured, the alkylated cyclodextrin composition is free of the chloride of detectable level.
33. alkylated cyclodextrin composition as claimed in claim 30, it includes the phosphate for being less than 300ppm.
34. alkylated cyclodextrin composition as claimed in claim 30, it includes the phosphate for being less than 200ppm.
35. alkylated cyclodextrin composition as claimed in claim 30, it includes the phosphate for being less than 125ppm.
36. alkylated cyclodextrin composition as claimed in claim 30, wherein the absorption of the alkylated cyclodextrin composition
For 0.5A.U. or lower, in the long cuvette of 1cm journey containing alkylated cyclodextrin composition/mL solution as described in 300mg
Aqueous solution measured at 245nm to 270nm wavelength by UV/ Vis Spectrophotometry.
37. alkylated cyclodextrin composition as claimed in claim 30, wherein the absorption of the alkylated cyclodextrin composition
For 0.2A.U. or lower, in the long cuvette of 1cm journey containing alkylated cyclodextrin composition/mL solution as described in 300mg
Aqueous solution measured at 245nm to 270nm wavelength by UV/ Vis Spectrophotometry.
38. alkylated cyclodextrin composition as claimed in claim 30, wherein described absorb is attributed to drug degradation agent.
39. alkylated cyclodextrin composition as claimed in claim 30, wherein the absorption of the alkylated cyclodextrin composition
For 0.5A.U. or lower, in the long cuvette of 1cm journey containing alkylated cyclodextrin composition/mL solution as described in 500mg
Aqueous solution measured at 245nm to 270nm wavelength by UV/ Vis Spectrophotometry.
40. alkylated cyclodextrin composition as claimed in claim 30, wherein the average substitution degree is 6 to 7.5.
41. alkylated cyclodextrin composition as claimed in claim 30, wherein the alkylated cyclodextrin is the sulphur of formula (II)
Alkyl ether cyclodextrin:
Wherein p is 4,5 or 6, and R1At each occurrence independently selected from-OH or-O- (C2-C6Alkylidene)-SO3 -- T, wherein
For T at each occurrence independently selected from pharmaceutically acceptable cation, condition is at least one R1It is-OH and at least one R1It is
O-(C2-C6Alkylidene)-SO3 --T。
42. alkylated cyclodextrin composition as claimed in claim 41, wherein R1At each occurrence independently selected from-OH or-
O-(C4Alkylidene)-SO3 -- T, and-T is Na at each occurrence+。
43. alkylated cyclodextrin composition as claimed in claim 30, wherein the alkylated cyclodextrin is sulphur butyl ether ring
Dextrin.
44. alkylated cyclodextrin composition, it includes:
The alkylated cyclodextrin that average substitution degree is 2 to 9；
Phosphate less than 500ppm；And
0.07% (w/w) or less chloride；
Wherein the alkylated cyclodextrin composition is absorbed as being less than 1A.U., such as to containing in the cuvette that 1cm journey is grown
The composition of alkylated cyclodextrin described in 300mg/mL solution aqueous solution passes through UV/ visible light point at 320nm to 350nm wavelength
Light photometry is measured.
45. alkylated cyclodextrin composition as claimed in claim 44, wherein the alkylated cyclodextrin composition includes
0.05% (w/w) or less chloride.
46. alkylated cyclodextrin composition as claimed in claim 44, wherein as limited using the detection with the chromatography of ions
Charged aerosol measured, the alkylated cyclodextrin composition is free of the chloride of detectable level.
47. alkylated cyclodextrin composition as claimed in claim 44, it includes the phosphate for being less than 300ppm.
48. alkylated cyclodextrin composition as claimed in claim 44, it includes the phosphate for being less than 200ppm.
49. alkylated cyclodextrin composition as claimed in claim 44, it includes the phosphate for being less than 125ppm.
50. alkylated cyclodextrin composition as claimed in claim 44, wherein the absorption of the alkylated cyclodextrin composition
For 0.5A.U. or lower, in the long cuvette of 1cm journey containing alkylated cyclodextrin composition/mL solution as described in 300mg
Aqueous solution measured at 320nm to 350nm wavelength by UV/ Vis Spectrophotometry.
51. alkylated cyclodextrin composition as claimed in claim 44, wherein the absorption of the alkylated cyclodextrin composition
For 0.2A.U. or lower, in the long cuvette of 1cm journey containing alkylated cyclodextrin composition/mL solution as described in 300mg
Aqueous solution measured at 245nm to 270nm wavelength by UV/ Vis Spectrophotometry.
52. alkylated cyclodextrin composition as claimed in claim 44, wherein described absorb is attributed to colour coupler.
53. alkylated cyclodextrin composition as claimed in claim 44, wherein the absorption of the alkylated cyclodextrin composition
For 0.5A.U. or lower, in the long cuvette of 1cm journey containing alkylated cyclodextrin composition/mL solution as described in 500mg
Aqueous solution measured at 320nm to 350nm wavelength by UV/ Vis Spectrophotometry.
54. alkylated cyclodextrin composition as claimed in claim 44, wherein the average substitution degree is 6 to 7.5.
55. alkylated cyclodextrin composition as claimed in claim 44, wherein the alkylated cyclodextrin is the sulphur of formula (II)
Alkyl ether cyclodextrin:
Wherein p is 4,5 or 6, and R1At each occurrence independently selected from-OH or-O- (C2-C6Alkylidene)-SO3 -- T, wherein
For T at each occurrence independently selected from pharmaceutically acceptable cation, condition is at least one R1It is-OH and at least one R1It is
O-(C2-C6Alkylidene)-SO3 --T。
56. alkylated cyclodextrin composition as claimed in claim 55, wherein R1At each occurrence independently selected from-OH or-
O-(C4Alkylidene)-SO3 -- T, and-T is Na at each occurrence+。
57. alkylated cyclodextrin composition as claimed in claim 44, wherein the alkylated cyclodextrin is sulphur butyl ether ring
Dextrin.
58. pharmaceutical composition, it includes as described in any one of claim 30 to 57 alkylated cyclodextrin composition and
Active agents.
59. pharmaceutical composition as claimed in claim 58, wherein the active agents are selected from bortezomib, disulfiram, table
The chloride Sensitive active agent of nutgall catechin -3- gallate, salinosporamide A and Carfilzomib.
60. pharmaceutical composition as claimed in claim 59, wherein the chloride Sensitive active agent is Carfilzomib.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261604504P | 2012-02-28 | 2012-02-28 | |
| US61/604,504 | 2012-02-28 | ||
| CN201380022316.4A CN104704007A (en) | 2012-02-28 | 2013-02-27 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| PCT/US2013/028094 WO2013130666A1 (en) | 2012-02-28 | 2013-02-27 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380022316.4A Division CN104704007A (en) | 2012-02-28 | 2013-02-27 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110066351A true CN110066351A (en) | 2019-07-30 |
| CN110066351B CN110066351B (en) | 2022-06-14 |
Family
ID=49083249
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380022316.4A Pending CN104704007A (en) | 2012-02-28 | 2013-02-27 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| CN201910279005.5A Active CN110066351B (en) | 2012-02-28 | 2013-02-27 | Alkylated cyclodextrin compositions and methods of making and using the same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380022316.4A Pending CN104704007A (en) | 2012-02-28 | 2013-02-27 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9493582B2 (en) |
| EP (1) | EP2748205A4 (en) |
| JP (3) | JP2015508846A (en) |
| KR (3) | KR20160033795A (en) |
| CN (2) | CN104704007A (en) |
| AU (2) | AU2013226073B2 (en) |
| CA (1) | CA2865950C (en) |
| HK (1) | HK1211311A1 (en) |
| MX (1) | MX353603B (en) |
| RU (2) | RU2747757C2 (en) |
| WO (1) | WO2013130666A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115166115A (en) * | 2022-07-20 | 2022-10-11 | 宁波工程学院 | Sample pretreatment method for detecting various mercury morphological contents in fish meat and detection method |
| CN115505052A (en) * | 2022-08-23 | 2022-12-23 | 安徽普利药业有限公司 | Preparation method of beta-cyclodextrin derivative |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| MX2011004225A (en) | 2008-10-21 | 2011-06-21 | Onyx Therapeutics Inc | Combination therapy with peptide epoxyketones. |
| US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
| PT2814849T (en) | 2012-02-15 | 2020-03-04 | Cydex Pharmaceuticals Inc | Manufacturing process for cyclodextrin derivatives |
| JP2015508846A (en) | 2012-02-28 | 2015-03-23 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | Alkylated cyclodextrin compositions and methods for their preparation and use |
| EP2662094B1 (en) | 2012-05-08 | 2024-04-17 | Onyx Therapeutics, Inc. | Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors |
| WO2014066274A1 (en) * | 2012-10-22 | 2014-05-01 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| MX363386B (en) | 2013-10-03 | 2019-03-20 | Dow Pharmaceutical Sciences | Stabilized efinaconazole compositions. |
| KR102612453B1 (en) | 2013-11-22 | 2023-12-08 | 다우 파마슈티컬 사이언시즈, 인코포레이티드 | Anti-infective methods, compositions, and devices |
| CN103694376B (en) * | 2014-01-10 | 2016-04-13 | 凯莱英医药集团（天津）股份有限公司 | A kind of method preparing sulfobutyl ether-beta-cyclodextrin |
| HUE063851T2 (en) | 2014-08-22 | 2024-02-28 | Cydex Pharmaceuticals Inc | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same |
| WO2016098904A1 (en) * | 2014-12-19 | 2016-06-23 | 国立大学法人 長崎大学 | Novel bisphosphonic acid derivative and application for same |
| CN105016334A (en) * | 2015-08-22 | 2015-11-04 | 钱景 | Method for reducing graphene oxide through alkylated cyclodextrin |
| FR3042501B1 (en) * | 2015-10-16 | 2017-11-03 | Roquette Freres | NOVEL METHYLATED CYCLODEXTRINS AND PROCESSES FOR THEIR PREPARATION |
| JP2019512538A (en) | 2016-02-18 | 2019-05-16 | メリンタ セラピューティクス、 インコーポレイテッドＭｅｌｉｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Oritavancin formulation |
| CN116869983A (en) * | 2016-09-16 | 2023-10-13 | 锡德克斯药物公司 | Formulations comprising acetaminophen and sulfoalkyl ether cyclodextrin |
| CA3075714A1 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| US11147754B2 (en) | 2017-09-20 | 2021-10-19 | Kao Corporation | Powder composition comprising hair direct dyes |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| EP3766475A1 (en) | 2019-07-15 | 2021-01-20 | OP-Hygiene IP GmbH | Wipes |
| WO2021101842A1 (en) * | 2019-11-18 | 2021-05-27 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| DE102019133243A1 (en) * | 2019-12-05 | 2021-06-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Process for the production of spray-freeze-dried particles and correspondingly produced particles |
| JP2023544122A (en) * | 2020-09-24 | 2023-10-20 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | Alkylated cyclodextrin compositions and methods of preparation and use thereof |
| CN113275306B (en) * | 2021-04-19 | 2022-09-23 | 龙岩市华研活性炭科技有限公司 | Dynamic rotational flow active carbon pickling machine |
| US11649299B2 (en) | 2021-06-10 | 2023-05-16 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd. | Purification of sulfobutylated cyclodextrins with specific ion exchange resins |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5831081A (en) * | 1995-02-16 | 1998-11-03 | Consortium Fur Elektrochemische Industrie Gmbh | Process for the purification of water-soluble cyclodextrin derivatives |
| US6153746A (en) * | 1997-07-01 | 2000-11-28 | Pfizer Inc. | Process for making a cyclodextrin |
| WO2009018069A2 (en) * | 2007-07-30 | 2009-02-05 | Cydex Pharmaceuticals, Inc | Mixtures of cyclodextrin derivatives |
| CN101959508A (en) * | 2008-04-28 | 2011-01-26 | 锡德克斯药物公司 | Sulfoalkyl ether cyclodextrin compositions |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US472706A (en) | 1892-04-12 | Elias m | ||
| US2744938A (en) | 1952-07-24 | 1956-05-08 | Universal Oil Prod Co | Removal of color impurities from organic compounds |
| US3033900A (en) | 1958-03-25 | 1962-05-08 | Pfanstiehl Lab Inc | Method of preparing calcium glucoheptonate |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| JPS5953038B2 (en) | 1979-04-07 | 1984-12-22 | メルシャン株式会社 | Manufacturing method of cyclodextrin |
| NL8104410A (en) | 1981-09-24 | 1983-04-18 | Proefstation Voor Aardappelver | PROCESS FOR PREPARING CYCLODEXTRINE. |
| JPS5862152A (en) | 1981-10-08 | 1983-04-13 | Microbial Chem Res Found | N-(4-(3-aminopropyl)aminobutyl)-2-(omega-guanidino-fatty acid amido)-2-hydroxyethanamide, its derivative and their preparation |
| DE3477929D1 (en) | 1983-12-17 | 1989-06-01 | Hoechst Ag | Beta-cyclodextrin and process for its preparation |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| JPS61169149A (en) | 1985-01-22 | 1986-07-30 | Nippon Mining Co Ltd | Continuous casting method |
| US4597946A (en) | 1985-04-30 | 1986-07-01 | Uop Inc. | Vertical tube reactor with serial downward flow through a plurality of sets of particulate containing tubes |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US4920214A (en) | 1986-04-16 | 1990-04-24 | American Maize-Products Company | Process for producing modified cyclodextrins |
| US4738923A (en) | 1986-05-20 | 1988-04-19 | American Maize-Products Company | Process for producing and separating cyclodextrins |
| ES2062988T3 (en) | 1986-12-19 | 1995-01-01 | Sankyo Co | NEW OLIGOPEPTIDES INHIBITORS OF RENINE, ITS PREPARATION AND USE. |
| US5760015A (en) | 1988-01-19 | 1998-06-02 | The Trustees Of The University Of Pennsylvania | Cyclodextrin compounds and methods of making and use thereof |
| US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
| US5019562A (en) | 1988-01-19 | 1991-05-28 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Growth inhibiting agent and the use thereof |
| US5658894A (en) | 1989-04-23 | 1997-08-19 | The Trustees Of The University Of Pennsylvania | Compositions for inhibiting restenosis |
| US5183809A (en) | 1990-02-15 | 1993-02-02 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Cyclodextrin polymers and cyclodextrins immobilized on a solid surface |
| US4904306A (en) | 1988-07-22 | 1990-02-27 | American Maize-Products Company | Separation and purification of gamma cyclodextrin |
| DK0465535T3 (en) | 1989-04-03 | 1999-03-01 | Janssen Pharmaceutica Nv | Regioselective substitutions in cyclodextrins |
| US5173481A (en) | 1989-04-03 | 1992-12-22 | The United States Of America As Represented By The Department Of Health And Human Services | Preparation of specifically substituted cyclodextrins |
| US5257985A (en) | 1989-12-04 | 1993-11-02 | Richard Puhl | Multi-chamber intravenous bag apparatus |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (en) | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5241059A (en) | 1990-05-21 | 1993-08-31 | Toppan Printing Co., Ltd. | Cyclodextrin derivatives |
| JP2905573B2 (en) | 1990-06-28 | 1999-06-14 | 日本食品化工株式会社 | Purified hydroxyalkylated cyclodextrin and process for producing the same |
| FR2668163B1 (en) | 1990-10-18 | 1993-01-15 | Orsan | PROCESS FOR THE MANUFACTURE OF BETA-CYCLODEXTRIN. |
| JPH051102A (en) | 1991-05-29 | 1993-01-08 | Toppan Printing Co Ltd | Cyclodextrin derivative |
| CN1072185A (en) | 1991-11-13 | 1993-05-19 | 美国玉米产品公司 | The method for preparing haze-free cyclodextrins |
| US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| EP0589578B1 (en) | 1992-09-24 | 1998-12-23 | Terumo Kabushiki Kaisha | Sulfonated compounds of beta-cyclodextrin polymer and inhibitory drug for vascular wall hyperplasia containing the same |
| FR2705963B1 (en) | 1993-06-03 | 1995-07-13 | Commissariat Energie Atomique | Sulfonated derivatives of cyclomalto-oligosaccharides, process for their preparation and support for active substances containing these derivatives. |
| US5393880A (en) | 1993-06-17 | 1995-02-28 | American Maize-Products Company | Cyclodextrin refining process |
| DE4333598A1 (en) | 1993-10-01 | 1995-04-06 | Consortium Elektrochem Ind | Process for the preparation of alkylated cyclodextrin derivatives, methylated cyclodextrin derivatives which can be prepared by the process and the use of the products |
| US5479254A (en) | 1993-10-22 | 1995-12-26 | Woskov; Paul P. | Continuous, real time microwave plasma element sensor |
| US5661151A (en) | 1993-12-21 | 1997-08-26 | Schering Corporation | Tetrahydrofuran antifungals |
| DE4401618A1 (en) | 1994-01-20 | 1995-07-27 | Consortium Elektrochem Ind | New or known amino-functional cyclodextrin deriv. prepn. |
| US5658390A (en) | 1994-06-29 | 1997-08-19 | American Maize-Products Company | Purification of beta cyclodextrin |
| DE4428654A1 (en) | 1994-08-12 | 1996-02-15 | Consortium Elektrochem Ind | Water soluble cyclodextrin derivatives with lipophilic substituents and process for their preparation |
| US5550222A (en) | 1994-12-14 | 1996-08-27 | American Maize-Products Company | Process for producing gamma-cyclodextrin |
| DE4446891A1 (en) | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stable aqueous budesonide solution |
| US5569756A (en) | 1995-03-21 | 1996-10-29 | American Maize-Products Company | Purification of chemically modified cyclodextrins |
| FR2735136B1 (en) | 1995-06-08 | 1997-08-14 | Roquette Freres | PULVERULENT COMPOSITION OF HYDROXYPROPYL-BETACYCLODEXTRIN AND ITS PREPARATION PROCESS. |
| US5935941A (en) | 1997-10-24 | 1999-08-10 | Pitha; Josef | Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6033573A (en) | 1997-05-29 | 2000-03-07 | The United States Of America As Represented By The Secretary Of Agriculture | Activated nutshell carbons from agricultural waste |
| JP4439596B2 (en) | 1997-06-13 | 2010-03-24 | サイデクス ファーマシューティカルズ、 インク． | Pharmaceutical composition containing polar drug or polar prodrug having long shelf life, and method for producing the same |
| US6316613B1 (en) | 1997-07-25 | 2001-11-13 | Beckman Coulter, Inc. | Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis |
| CA2301746C (en) | 1997-08-26 | 2011-02-15 | Board Of Regents, The University Of Texas System | Chelators in combination with biocides: treatment of microbially induced biofilm and corrosion |
| WO1999009997A1 (en) | 1997-08-26 | 1999-03-04 | Board Of Regents, The University Of Texas System | Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections |
| US6391862B1 (en) | 1997-10-14 | 2002-05-21 | The Texas A&M University System | Chiral resolving agents for enantioseparations |
| AU1598399A (en) | 1997-12-01 | 1999-06-16 | Schering Corporation | Injectable antifungal formulations |
| AU759280C (en) | 1998-02-23 | 2004-01-22 | Cyclops, Ehf | High-energy cyclodextrin complexes |
| TW394749B (en) | 1998-03-05 | 2000-06-21 | Deng Jian Lang | Method of manufacturing active carbon by using carbon black |
| AT410321B (en) | 1998-08-11 | 2003-03-25 | Tulln Zuckerforschung Gmbh | METHOD FOR PRODUCING CYCLODEXTRIN |
| US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
| DE19930553A1 (en) | 1999-07-02 | 2001-01-11 | Wacker Chemie Gmbh | Process for the preparation of alkylated cyclodextrin derivatives |
| TWI242015B (en) | 1999-11-29 | 2005-10-21 | Akzo Nobel Nv | 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| US6479467B1 (en) | 1999-12-16 | 2002-11-12 | Eastman Chemical Company | Cyclodextrin ethers |
| FR2808691B1 (en) | 2000-05-12 | 2005-06-24 | Coletica | CYCLODEXTRINS SUBSTITUTED PREFERENTIALLY ON THEIR PRIMARY SURFACE BY ACID OR AMINE FUNCTIONS |
| JP2005503446A (en) | 2001-01-11 | 2005-02-03 | イーストマン ケミカル カンパニー | Cyclodextrin sulfonate, guest inclusion complex, production method thereof and related substances |
| WO2002074200A1 (en) | 2001-03-20 | 2002-09-26 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| AU2003275329B2 (en) | 2002-09-13 | 2008-04-03 | Cydex Pharmaceuticals, Inc. | Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin |
| CN101039682A (en) | 2003-10-31 | 2007-09-19 | 堪萨斯大学 | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20070020298A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
| US20070020196A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
| CN101098678A (en) | 2004-04-23 | 2008-01-02 | 锡德克斯公司 | Dpi formulation containing sulfoalkyl ether cyclodextrin |
| CN1980574A (en) | 2004-05-06 | 2007-06-13 | 锡德克斯公司 | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin |
| US7559241B2 (en) | 2004-05-27 | 2009-07-14 | Sulphco, Inc. | High-throughput continuous-flow ultrasound reactor |
| US20060009469A1 (en) | 2004-05-28 | 2006-01-12 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmacutical compositions of posaconazole |
| US7582758B2 (en) | 2004-06-08 | 2009-09-01 | Metabasis Therapeutics, Inc. | Lewis acid mediated synthesis of cyclic esters |
| CA2589921C (en) | 2004-12-07 | 2016-01-26 | Proteolix, Inc. | Composition comprising a cyclodextrin and a proteasome inhibitor |
| US20060128653A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| WO2007047253A2 (en) | 2005-10-11 | 2007-04-26 | Eastman Chemical Company | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| EP2581078B1 (en) * | 2005-10-26 | 2014-12-10 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| CN100503647C (en) | 2005-11-02 | 2009-06-24 | 南京师范大学 | Hydroxypropyl- sulfobutyl-beta- cyclodextrin and its preparation method, analytical method and pharmaceutical uses |
| EP2061458B1 (en) | 2006-09-15 | 2014-12-10 | Regents of the University of Minnesota | Topiramate compositions and methods for their use |
| US20090239942A1 (en) | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| DK2152078T3 (en) | 2007-04-27 | 2021-02-08 | Cydex Pharmaceuticals Inc | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYLETHERCYCLODEXTRINE AND USE PROCEDURES |
| EP1992334A1 (en) | 2007-05-08 | 2008-11-19 | Docpharma NV/SA | Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation |
| US7834612B2 (en) * | 2007-07-26 | 2010-11-16 | Altronix Corporation | Method and apparatus for regulating voltage in a remote device |
| EP2018866A1 (en) | 2007-07-27 | 2009-01-28 | Sandoz AG | Pharmaceutical compositions containing voriconazole |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| KR20170040374A (en) * | 2007-10-04 | 2017-04-12 | 오닉스 세라퓨틱스, 인크. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| CA2720851A1 (en) | 2008-04-15 | 2009-10-22 | Schering Corporation | Oral pharmaceutical compositions in a molecular solid dispersion |
| US10463677B2 (en) | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
| DK3100728T3 (en) | 2009-05-13 | 2020-02-17 | Cydex Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITIONS COMPREHENSIVE PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS FOR PREPARING AND USING SAME |
| CN102458114A (en) | 2009-05-29 | 2012-05-16 | 锡德克斯药物公司 | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
| US8492538B1 (en) | 2009-06-04 | 2013-07-23 | Jose R. Matos | Cyclodextrin derivative salts |
| CN102040675B (en) | 2010-12-22 | 2012-10-03 | 石药集团中诺药业（石家庄）有限公司 | Method for preparing hydroxypropyl-beta-cyclodextrin |
| PT2814849T (en) | 2012-02-15 | 2020-03-04 | Cydex Pharmaceuticals Inc | Manufacturing process for cyclodextrin derivatives |
| JP2015508846A (en) * | 2012-02-28 | 2015-03-23 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | Alkylated cyclodextrin compositions and methods for their preparation and use |
| WO2014066274A1 (en) | 2012-10-22 | 2014-05-01 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| HUE063851T2 (en) | 2014-08-22 | 2024-02-28 | Cydex Pharmaceuticals Inc | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same |
| CN104892797B (en) | 2015-05-28 | 2017-03-22 | 天津大学 | Synthesis method of sulfobutyl ether-beta-cyclodextrin with specific average substitution degree |
| CN104974275A (en) | 2015-07-30 | 2015-10-14 | 淄博千汇生物科技有限公司 | Synthetic method of sulfoalkyl ether cyclodextrin derivative |
-
2013
- 2013-02-27 JP JP2014560000A patent/JP2015508846A/en active Pending
- 2013-02-27 KR KR1020167006808A patent/KR20160033795A/en active Application Filing
- 2013-02-27 CA CA2865950A patent/CA2865950C/en active Active
- 2013-02-27 EP EP13755899.5A patent/EP2748205A4/en active Pending
- 2013-02-27 WO PCT/US2013/028094 patent/WO2013130666A1/en active Application Filing
- 2013-02-27 MX MX2014010323A patent/MX353603B/en active IP Right Grant
- 2013-02-27 KR KR1020207025580A patent/KR20200106100A/en not_active Application Discontinuation
- 2013-02-27 KR KR1020147027335A patent/KR101633479B1/en active IP Right Grant
- 2013-02-27 AU AU2013226073A patent/AU2013226073B2/en active Active
- 2013-02-27 US US14/381,568 patent/US9493582B2/en active Active
- 2013-02-27 RU RU2016140391A patent/RU2747757C2/en active
- 2013-02-27 RU RU2014136206A patent/RU2615385C2/en active
- 2013-02-27 CN CN201380022316.4A patent/CN104704007A/en active Pending
- 2013-02-27 CN CN201910279005.5A patent/CN110066351B/en active Active
-
2015
- 2015-12-08 HK HK15112091.6A patent/HK1211311A1/en unknown
-
2016
- 2016-04-22 JP JP2016085851A patent/JP6517725B2/en active Active
- 2016-08-04 AU AU2016210707A patent/AU2016210707B2/en active Active
- 2016-11-14 US US15/351,272 patent/US10323103B2/en active Active
-
2018
- 2018-01-05 JP JP2018000617A patent/JP2018048350A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5831081A (en) * | 1995-02-16 | 1998-11-03 | Consortium Fur Elektrochemische Industrie Gmbh | Process for the purification of water-soluble cyclodextrin derivatives |
| US6153746A (en) * | 1997-07-01 | 2000-11-28 | Pfizer Inc. | Process for making a cyclodextrin |
| WO2009018069A2 (en) * | 2007-07-30 | 2009-02-05 | Cydex Pharmaceuticals, Inc | Mixtures of cyclodextrin derivatives |
| CN101959508A (en) * | 2008-04-28 | 2011-01-26 | 锡德克斯药物公司 | Sulfoalkyl ether cyclodextrin compositions |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115166115A (en) * | 2022-07-20 | 2022-10-11 | 宁波工程学院 | Sample pretreatment method for detecting various mercury morphological contents in fish meat and detection method |
| CN115505052A (en) * | 2022-08-23 | 2022-12-23 | 安徽普利药业有限公司 | Preparation method of beta-cyclodextrin derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2865950C (en) | 2016-12-20 |
| JP6517725B2 (en) | 2019-05-22 |
| RU2014136206A (en) | 2016-04-20 |
| CN110066351B (en) | 2022-06-14 |
| RU2615385C2 (en) | 2017-04-04 |
| AU2013226073A1 (en) | 2014-10-02 |
| EP2748205A4 (en) | 2014-07-30 |
| KR20160033795A (en) | 2016-03-28 |
| WO2013130666A1 (en) | 2013-09-06 |
| KR20150004797A (en) | 2015-01-13 |
| AU2016210707B2 (en) | 2018-03-08 |
| US20150045311A1 (en) | 2015-02-12 |
| KR101633479B1 (en) | 2016-07-08 |
| RU2747757C2 (en) | 2021-05-13 |
| US10323103B2 (en) | 2019-06-18 |
| US9493582B2 (en) | 2016-11-15 |
| JP2018048350A (en) | 2018-03-29 |
| MX353603B (en) | 2018-01-19 |
| KR20200106100A (en) | 2020-09-10 |
| CA2865950A1 (en) | 2013-09-06 |
| AU2016210707A1 (en) | 2016-08-25 |
| MX2014010323A (en) | 2014-12-08 |
| JP2015508846A (en) | 2015-03-23 |
| CN104704007A (en) | 2015-06-10 |
| JP2016166368A (en) | 2016-09-15 |
| RU2016140391A3 (en) | 2020-02-21 |
| US20170158781A1 (en) | 2017-06-08 |
| EP2748205A1 (en) | 2014-07-02 |
| AU2013226073B2 (en) | 2016-05-05 |
| RU2016140391A (en) | 2018-12-14 |
| HK1211311A1 (en) | 2016-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110066351A (en) | Alkylated cyclodextrin composition and its preparation and application | |
| CN105073785B (en) | Alkylated cyclodextrin composition and its preparation and application | |
| JP6444548B2 (en) | Sulfoalkyl ether cyclodextrin composition | |
| US20230002513A1 (en) | Alkylated cyclodextrin compositions and processes for preparing and using the same | |
| JP2023544122A (en) | Alkylated cyclodextrin compositions and methods of preparation and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |